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ABSTRACT 
 
Arenaviruses are enveloped negative-strand RNA viruses that cause significant 
human disease. Despite decades of research, it is still unclear how these viruses establish a 
lifelong, asymptomatic infection in their rodent hosts while infection of humans often results 
in severe disease. Unable to enter a state of bona fide latency, the transcription and replication 
of the viral genomic RNA is likely highly regulated in time and subcellular space. Moreover, 
we hypothesize that the viral nucleoprotein (NP), responsible for the encapsidation of the viral 
RNA and the most highly expressed viral gene product, plays a key role in the regulation of 
the viral gene expression program. Further, exploring host-virus interactions may elucidate the 
basic aspects of arenavirus biology and how they cause such severe disease in humans. To 
explore these questions in greater detail, this dissertation has pursued three main avenues.  
 
First, to better understand lymphocytic choriomeningitis mammarenavirus (LCMV) 
genome replication and transcription at the single-cell level, we established a high-throughput, 
single-molecule (sm)FISH image acquisition and analysis pipeline and followed viral RNA 
species from viral entry through the late stages of persistent infection in vitro. This work 
provided support for a cyclical model of persistence where individual cells are initially 
transiently infected, clear active infection, and become re-infected from neighboring reservoir 
cells within the population. 
 
Second, we used FISH to visualize viral genomic RNA to describe the subcellular 
sites where LCMV RNAs localize during infection. We observed that, viral RNA concentrates 
in large subcellular structures located near the cellular microtubule organizing center and 
colocalizes with the early endosomal marker Rab5c and the viral glycoprotein in a proportion 
of infected cells. We propose that the virus is using the surface of a cellular membrane bound 
organelle as a site for the pre-assembly of viral components including genomic RNA and viral 
glycoprotein prior to their transport to the plasma membrane where new particles will bud. 
 
Last, we used mass spectrometry to identify human proteins that interact with the NPs 
of LCMV and Junín mammareanavirus (JUNV) strain Candid #1. We provided a detailed map 
of the host machinery engaged by arenavirus NPs, and in particular, showed that NP associates 
with the double-stranded RNA (dsRNA)-activated protein kinase (PKR), a well-characterized 
antiviral protein that inhibits cap-dependent protein translation initiation via phosphorylation 
of eIF2α. We demonstrated that JUNV antagonizes the antiviral activity of PKR completely, 
effectively abrogating the antiviral activity of this surveillance pathway. 
 
In sum, the work composing this dissertation has given us fresh insight into how 
arenaviruses establish and maintain persistence; the nature of the subcellular site where viral 
genomic RNA is transcribed, replicated, and assembled with other viral components; and a 
global view of the cellular machinery hijacked by the viral nucleoprotein. This work improves 
our basic understanding of the arenavirus life cycle and may suggest novel antiviral therapeutic 
targets that could be exploited in the future. 
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CHAPTER 1: COMPREHENSIVE LITERATURE REVIEW 
1.1. Introduction 
Arenaviruses are important human pathogens. There are no FDA approved 
vaccines to prevent human infections by arenaviruses. In addition, there are limited 
effective antiviral therapeutics available for the treatment of infected individuals. Gaps in 
our understanding of the fundamental stages of the arenavirus life cycle in the human host 
is a major contributing factor to the lack of effective preventive and treatment options. 
During my time in the Botten laboratory, my dissertation research has focused on 
elucidating critical, yet incompletely understood, aspects of the viral life cycle. My work 
has sought to improve our understanding of viral gene transcription and genomic 
replication. Taking advantage of new technologies permitting the visualization of RNA 
molecules with high sensitivity and specificity by fluorescence microscopy, it is possible 
for the first time to probe the dynamics of these events within individual infected cells and 
to explore previously intractable questions such as the nature of the viral gene expression 
program during persistence. Further, this approach makes it possible to examine the 
subcellular locations where these events occur to gain an appreciation for how the virus 
may be utilizing particular cellular structures to promote its replication. Last, we know that 
the viral nucleoprotein gene is the first viral gene expressed following infection and is the 
most highly expressed viral gene product in infected cells. Its canonical role during 
infection is the encapsidation of the viral genomic RNA. However, little is known 
regarding what additional accessory roles the viral NP may play and how these may be 
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mediated through protein-protein interactions with host cellular proteins. We have 
employed a proteomics approach to elucidate the protein-protein interaction network of the 
arenavirus nucleoprotein. This work has given us new insight into how NP plays an 
important role in manipulating the host cell environment to maintain conditions favorable 
for viral replication. What follows is a comprehensive literature review providing the 
necessary concepts to appreciate the intellectual contribution of the work constituting the 
three manuscripts produced during the course of this dissertation project. 
1.2. Arenaviruses 
1.2.1. History of the Arenaviridae 
In 1929, Viets and Watts described a cluster of six patients presenting with an 
unusual form of meningitis. The cerebrospinal fluid of these patients contained abundant 
lymphocytes but no detectable bacteria. Further, the absence of other symptoms 
corresponding to other known causes of meningitis led the physicians to suggest a new 
disease of unknown etiology, which they initially referred to as aseptic (lymphocytic) 
meningitis (Viets and Watts, 1929a, b). Between 1934 and 1936 the viral etiology of this 
lymphocytic meningitis syndrome was independently established by Armstrong et al., 
Traub, McNair and Rivers, and Findlay et al. (Armstrong and Dickens, 1935; Armstrong 
and Lillie, 1934; Armstrong and Wooley, 1935; Findlay et al., 1936; Rivers and McNair 
Scott, 1935; Rivers and Scott, 1936; Traub, 1935). In 1934, Armstrong and Lillie described 
a viral agent that was able to provoke a disease closely resembling that described by Viets 
and Watts just five years previously by performing intracranial injections of infected brain 
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matter into naïve Rhesus macaques (Armstrong and Lillie, 1934). Other groups showed 
that cerebrospinal fluid or brain tissue from infected humans or animals was able to cause 
a similar aseptic meningitis following intracranial injection into mice and guinea pigs  
(Rivers and McNair Scott, 1935; Rivers and Scott, 1936; Scott and Rivers, 1936; Traub, 
1935). Additional support for this being the causative agent for the aseptic lymphocytic 
meningitis seen in humans came with the observation that serum from aseptic lymphocytic 
meningitis survivors provided a high degree of protection to both Rhesus macaques, mice, 
and guinea pigs infected with isolated strains of virus (Armstrong and Dickens, 1935; 
Armstrong and Wooley, 1935; Rivers and Scott, 1936; Scott and Rivers, 1936). 
Additionally, animals surviving infection with one strain displayed immunity when 
subsequently reinoculated with additional strains isolated from other sources (Rivers and 
Scott, 1936). The viral nature of the causative agent of the disease was demonstrated 
through the ability of the infectious agent to pass through a filter with an average pore size 
of 150 µm and the inability to see bacteria, fungal, or protozoal cells via histology of 
infected tissue or failure to cultivate bacteria in rich growth media (Rivers and Scott, 1936). 
The virus determined to be the cause of this disease, and independently isolated by multiple 
researchers in both North America and Europe, came to be named lymphocytic 
choriomeningitis virus (LCMV), due to the large lymphocyte infiltration observed by 
histology in both the meninges and the choroid plexus in infected tissue, a pattern that was 
uniquely associated with infection with this viral agent (Armstrong and Dickens, 1935; 
Armstrong and Wooley, 1935; Findlay et al., 1936). 
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The study of LCMV continued during the following decades, but it was not until 
the mid-1960’s that it became apparent that LCMV shared similar characteristics with other 
more recently described viruses including Lassa (LASV), Junín (JUNV), Machupo 
(MACV), and Tacaribe (TCRV) viruses. In 1970, an official classification for these viruses 
was proposed and the name for this virus family “arenovirus” was proposed (Lehmann-
Grube, 1971; Rowe et al., 1970). The latin root arenosus (meaning sandy) was chosen to 
describe this newly classified family due to the hallmark grainy appearance of these viral 
particles in negative stained electron micrographs.  These electron dense granules in viral 
particles were subsequently demonstrated to be host ribosomes (Farber and Rawls, 1975; 
Lehmann-Grube, 1971; Leung and Rawls, 1977; Rowe et al., 1970). Additional unifying 
features of this viral family consisted of their lipid envelope, serological relatedness, 
pleomorphic virion form, release of viral particles from infected cells by budding, and 
contained RNA (Lehmann-Grube, 1971; Rowe et al., 1970). In 1970, the International 
Committee for the Taxonomy of Viruses (ICTV) approved the official classification of this 
group of viruses, and the initially chosen name “arenovirus” was changed slightly to 
“arenavirus” to avoid confusion with the already recognized taxon “adenovirus” (Murphy, 
1975; Wildy, 1971). 
Recently, several new arenavirus-like viruses were discovered in snakes 
(Bodewes et al., 2014; Stenglein et al., 2012). This discovery prompted the ICTV to change 
the previously recognized genus “Arenavirus” to “Mammarenavirus”. Further, within the 
family Arenaviridae a new genus called “Reptarenavirus” was created containing the 
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newly described snake viruses (ICTV, 2014a). In the newly revised official nomenclature, 
previously recognized names were altered such that lymphocytic choriomeningitis virus 
was renamed lymphocytic choriomeningitis mammarenavirus (ICTV, 2014b). 
1.2.2.  Arenavirus infections in humans 
During the decades following their initial discovery, we have come to understand 
much about the disease pathology caused by these viruses and the molecular events 
underlying each stage of their life cycles. The arenavirus family is broadly divided into the 
Old World and New World groups. The classification of viruses into one group or the other 
is determined by genetic relatedness of viral genomes, geographic distribution, and 
serology (Buchmeier et al., 2013; Burri et al., 2012; Charrel et al., 2003; Emonet et al., 
2006) (Table 1.1 and Figure 1.1 and 1.2). 
The arenaviruses are zoonotic viruses, meaning that, in nature, they are 
maintained in animal reservoirs and human spillover is incidental (Buchmeier et al., 2013; 
Charrel and de Lamballerie, 2010; Vela, 2012). For most members of the genus 
Mammarenavirus, the viruses exploit rodent reservoirs. Only TCRV has been isolated from 
bats (Buchmeier et al., 2013). The endemic geographical range where arenavirus infections 
have been observed overlap with the geographical distribution of the known species of 
rodent reservoir utilized by each specific arenavirus (Charrel et al., 2008). 
Transmission of arenavirus from infected rodents to humans is thought to occur 
primarily through inhalation, ingestion, or contact of skin wounds or abrasions with 
infected rodent excreta (Buchmeier et al., 2013; Charrel et al., 2008; Grant et al., 2012). 
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Several well documented cases of nosocomial acquired infections by health care providers 
have also been reported (Russier et al., 2012). LCMV can be transmitted vertically from 
mother to the developing fetus and is a significant teratogenic threat (Bonthius, 2009). 
Moreover, several cases of LCMV acquired through the transplantation of infected organs 
have recently been reported with nearly uniform rates of lethality (Fischer et al., 2006; 
Macneil et al., 2012). In immunocompetent individuals, LCMV infection is often 
subclinical and inapparent but can manifest as severe aseptic meningitis (Bonthius, 2012). 
Further evidence of the danger of LCMV is the high rates at which people are exposed to 
its reservoir, the house mouse Mus musculus. A serological study performed in 
Birmingham, Alabama, USA showed that greater than 4% of individuals were seropositive 
for LCMV antigen indicating prior exposure to this human pathogen (Stephensen et al., 
1992). 
Lassa virus is the greatest public health threat of any member of the arenavirus 
family. It is endemic in Western Africa where it infects up to 300,000 people annually (Yun 
and Walker, 2012). The ease of international airline travel has increased the risk that cases 
could spread worldwide. Lassa virus is maintained in Mastomys sp. rats, which are 
peridomestic and routinely come into close contact with people living in rural areas in its 
endemic region (Russier et al., 2012). Lassa virus infection can cause severe disease in 
humans, and can cause a hemorrhagic fever syndrome in serious cases (Russier et al., 2012; 
Yun and Walker, 2012). There are currently no vaccines to prevent Lassa virus infections 
despite a significant need (Charrel et al., 2011). The only antiviral therapeutic option is 
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ribavirin.  However, the need for early administration and the risk of significant side effects 
limit its efficacy (Bausch et al., 2010; Vela, 2012).  
One of several South American arenaviruses known to cause hemorrhagic fever, 
Junín virus is the etiologic agent of Argentine hemorrhagic fever (Grant et al., 2012). 
Maintained in Calomys sp. rodents, which prefer to live in close proximity to agriculture, 
farmers are the primary group at risk for infection with JUNV (Charrel and de Lamballerie, 
2003). An attenuated strain of JUNV (strain Candid #1) was developed as a joint effort 
between the US Army Medical Research Institute of Infectious Diseases and the Argentine 
Ministry of Health and Social Action. This strain has been delivered as a live-attenuated 
vaccine to at risk populations in Argentina, and has shown efficacy in preventing new 
infections of vaccinated individuals. Despite efficacy, there is concern that the mutant virus 
could revert to wild type and thus does not have US Food and Drug Agency approval 
(Ambrosio et al., 2011). 
1.2.3. The arenavirus life cycle 
Members of the genus Mammarenavirus are enveloped with a host-derived lipid 
bilayer (Figure 1.3) (Buchmeier et al., 2013). The viral envelope glycoprotein is embedded 
in the virion membrane. The viral glycoprotein precursor (GPC) is proteolytically 
processed in the secretory pathway into three subunits: GP1, GP2, and a stable signal 
peptide, which is unusually long and remains associated with the viral glyocoprotein post-
processing (Figure 1.3) (Buchmeier et al., 2013; Burri et al., 2012; Rojek and Kunz, 2008; 
Rojek et al., 2008). Three GP1, GP2, and SSP units associate to form homotrimers (Burri 
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et al., 2012). The viral Z protein is the bona fide viral matrix protein needed for viral 
budding (Figure 1.3) (Urata and Yasuda, 2012; Wolff et al., 2013b). Within the viral 
particle, the viral ribonucleoprotein (RNP) consists of the viral single-stranded RNA 
genome (which is encoded on two distinct segments), the viral nucleoprotein (NP), which 
encapsidates the genomic RNA, and the viral encoded RNA-dependent RNA polymerase 
(L) (Figure 1.3) (Buchmeier et al., 2013). The last component of arenavirus particles are 
packaged host ribosomes, whose presence in viral particles confers the family’s 
characteristic grainy appearance in electron micrographs though their functional 
importance, if any, is still unknown (Buchmeier et al., 2013; Leung and Rawls, 1977). 
Though differences do exist between members of the Old and the New World 
arenaviruses, the basic steps of the viral life cycle are shared among all members of the 
family (Figure 1.4). The first phase of an arenavirus infection is entry of the arenavirus 
particle into a naïve host cell (Burri et al., 2012; Rojek and Kunz, 2008; Rojek et al., 2008). 
The attachment to the host cell is mediated by the GP1 subunit of the envelope 
glycoprotein, which binds to the cell surface receptor. The Old World arenaviruses and 
Clade C of the New World arenaviruses use alpha-dystroglycan and Clade B of the New 
World arenaviruses use transferrin receptor (TfR1) as the cell surface receptor (Burri et al., 
2012). The binding of the viral glycoprotein to the cellular receptor triggers endocytosis of 
the attached virion (Burri et al., 2012). Entry of New World arenaviruses is clathrin-
dependent (Rojek et al., 2008). On the other hand, entry of the Old World arenaviruses is 
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clathrin, caveolin, and dynamin- independent and does not rely on Rab5 or Rab7 (Rojek 
and Kunz, 2008). 
Upon cellular uptake by endocytosis, progressive acidification of endosomes 
leads to a conformational change in the GP2 subunit of the envelope glycoprotein 
triggering a fusion event between the viral envelope and the endosomal membrane (Figure 
1.4) (Burri et al., 2012). Viral envelope fusion releases the viral RNP into the cytoplasm of 
the newly infected cell. There, the viral L polymerase begins transcribing the viral genomic 
RNA, and viral mRNAs are translated into polypeptides by host ribosomes (Figure 1.4) 
(Buchmeier et al., 2013; Meyer et al., 2002). Then, full length viral genome is replicated 
by the L polymerase (Figure 1.4) (Buchmeier et al., 2013; Meyer et al., 2002). Lastly, the 
viral genomic RNA and the viral proteins traffic to the plasma membrane where they 
assemble and bud as new infectious viral particles (Figure 1.4) (Urata and Yasuda, 2012; 
Wolff et al., 2013b). 
1.3. Transcription and Replication of Viral RNA during Acute and Persistent 
Phases of Infection 
Arenaviruses are enveloped viruses that have a single-stranded, bisegmented, 
negative-sense RNA genome. Each genomic RNA segment (named S and L) contains 2 
viral open reading frames encoded in ambisense orientation (Figure 1.5) (Buchmeier et al., 
2013). The canonical sequence of genetic events following release of arenavirus genomic 
RNA into the cytoplasm of a newly infected cell is primary transcription of the NP and L 
mRNAs from the viral S and L genomic segments, full length replication of the 
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antigenomic RNA, transcription of the GPC and Z mRNAs from the S and L antigenomic 
RNA, and finally replication of more genomic RNA (Figure 1.6) (Buchmeier et al., 2013; 
Ferron et al., 2017). 
Early work aimed at elucidating the genetic composition of these viruses 
determined that they had a bisegmented single-stranded RNA genome (Carter et al., 1973). 
The presence of cellular ribosomes in arenavirus particles initially was suggestive that 
these viruses could possess a positive-sense RNA genome, however the presence of a viral 
RNA polymerase along with RNase protection assays suggested that the viral genomic 
RNAs from purified virions was indeed of negative-sense polarity (Carter et al., 1974; 
Leung et al., 1977). Determination of the full-length sequence of the viral S segment 
genomic RNA showed the first evidence of the arenaviral ambisense coding strategy where 
the NP gene is encoded in a negative-sense polarity on the 3’ half of the viral genomic 
RNA and the GPC gene is encoded in a pseudo-positive-sense polarity on the 5’ half 
(Auperin et al., 1984a; Southern et al., 1987). At the same time it was determined that the 
two viral genes are separated by an intergenic region (IGR) that was predicted to adopt a 
hairpin secondary structure, a potential means of transcription termination (Auperin et al., 
1984a; Auperin et al., 1984b). The L segment was subsequently shown to encode the L 
protein in the same negative-sense polarity and position as the NP gene on the S segment 
(Singh et al., 1987). Z was shown to be encoded in pseudo-positive-sense polarity, 
analogous to GPC on the S segment, and is separated from the L gene by an intergenic 
region (Salvato and Shimomaye, 1989). 
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The discovery of the ambisense coding strategy employed by the arenaviruses 
suggested a mechanism by which these viruses could temporally regulate the expression of 
their various gene products (Auperin et al., 1984b; Southern et al., 1987). The use of 
sequence specific Northern blot probes made it possible to track the expression levels of 
different viral RNA species over time. Using Northern blot, it was confirmed that the 
appearance of the NP mRNA could be detected just 2 hours post infection, and this viral 
subgenomic RNA accumulated even in the absence of protein synthesis – which the authors 
inhibited with pactamycin treatment (Franze-Fernandez et al., 1987). On the other hand, 
the GPC mRNA was not detected until 4 hours post infection, and its expression was 
wholly dependent on the presence of active translation (Franze-Fernandez et al., 1987). 
These data suggested that translation of the NP and L protein were necessary for the 
production of the full length antigenomic RNA, which would serve as the template for GPC 
transcription. Significantly, this was the first demonstration of the hypothesized ability of 
the arenaviruses to temporally separate the different viral gene expression events. Further 
work suggested that S genome was expressed to a higher degree than the L genomic RNA 
(Fuller-Pace and Southern, 1988) and that viral RNAs increased in abundance over the first 
few days of infection and began to decrease after achieving those peak levels (Fuller-Pace 
and Southern, 1988; Iapalucci et al., 1994; Raju et al., 1990; Shivaprakash et al., 1988; 
Southern et al., 1987). qRT-PCR data has confirmed the trend of initial increase in RNA 
levels over the first 48 hours of infection followed by their subsequent decline (Haist et al., 
2015). 
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Arenavirus mRNAs bear 5’ 7-methylguanylate caps, which the virus presumably 
procures through a cap-snatching mechanism (Meyer and Southern, 1993; Polyak et al., 
1995a; Raju et al., 1990) potentially conferred by an endonuclease activity present in the 
viral L polymerase (Morin et al., 2010). Further, viral mRNAs are not polyadenylated 
(Auperin et al., 1984b; Leung et al., 1977). The secondary structure created by the viral 
intergenic region serves as the viral transcription termination signal, and 3’ termini of viral 
mRNAs are heterogeneous in length representing variablility in the position in which the 
viral polymerase terminates mRNA synthesis in response to secondary structural cues 
(Iapalucci et al., 1991; Lopez and Franze-Fernandez, 2007; Meyer et al., 2002; Pinschewer 
et al., 2005). It seems that sequence specificity of the IGR is not of paramount importance 
as chimeric genomic sequences containing heterologous IGR regions from distantly related 
arenaviruses are still able to serve as transcription termination signals, and recombinant 
viruses with these heterologous IGRs are viable (Iwasaki et al., 2016). 
In contrast to the viral mRNAs, the viral genomic and antigenomic RNAs are 
uncapped. At the 3’ and 5’ termini of the viral genomic segments, there are important 
untranslated regions (UTR) that play roles in the initiation of transcription and replication. 
The terminal 19 nucleotides of the 3’ UTR are highly conserved between the S and L 
segments, and the reverse complement of the 3’ UTR is present in the 5’ UTR (Auperin et 
al., 1982a; Auperin et al., 1982b; Meyer et al., 2002). It is proposed that the 3’ and 5’ UTRs 
will base pair, leading the genomic RNA to form a closed panhandle structure (Meyer et 
al., 2002). It appears that both the exact sequence and the double-stranded character of the 
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3’ and 5’ UTRs are critical for effective viral transcription and replication (Hass et al., 
2006; Perez and de la Torre, 2003). In Lassa virus it appears that the requirement for 
sequence specificity from bases 13-19 of the conserved UTR is relaxed, and mutation in 
this region is permitted so long as double-stranded character is maintained (Hass et al., 
2006).  
Another striking feature of the arenavirus genomic RNAs is the presence of one 
non-templated base, most often a G, present at the 5’ terminus (Polyak et al., 1995a). The 
viral L polymerase uses a “prime-realign” mechanism to initiate replication of the viral 
genomic RNAs leaving a one base pair overhang at the 5’ terminus (Garcin and 
Kolakofsky, 1990, 1992; Raju et al., 1990). An important functional consequence of the 
presence of this 5’ nontemplated base pair is that RIG-I, an important innate immune sensor 
of cytoplasmic 5’ triphosphate bearing RNAs with dsRNA character, was unable to 
recognize RNA duplexes with a single nucleotide overhang and, thus, not induce the 
expression of type I interferon (IFN) (Marq et al., 2010). 
A hallmark characteristic of arenavirus infections is their ability to establish 
lifelong persistent infection in rodents infected in utero or at birth (Francis et al., 1987). An 
understanding of the mechanism by which arenaviruses are able to establish persistence 
without adversely affecting their rodent hosts is important not just as a means to understand 
basic steps of the virus’ life cycle but also as a way to appreciate how and why severe 
disease often occurs in their incidental human hosts. Arenaviruses are unable to enter a 
bona fide latent state such as retroviruses like HIV-1 or herpes viruses like Epstein Barr 
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virus (Buchmeier et al., 2013; Meyer et al., 2002). Thus, persistently infected cells must 
maintain arenavirus genomic RNA over long periods of time, though how this occurs is 
still unclear, despite much study. A few principle models to explain the mechanism of 
arenavirus persistence have been proposed, and a detailed understanding of the genetics of 
persistence promises to yield a fresh outlook on this question that has long interested the 
field. 
It is possible to recapitulate key elements of persistenct infection in cell culture 
models of infection, a fact that has greatly facilitated our ability to study arenaviral 
persistence in simplified in vitro systems (Lehmann-Grube, 1967; Lehmann-Grube et al., 
1969; Meyer et al., 2002). One characteristic of cell culture models of persistent LCMV 
infection is the cyclical rise and fall of  infectious virus released into cell culture 
supernatants over time, and these cycles have a periodicity of a few days (Hotchin, 1974a; 
Hotchin et al., 1975; Lehmann-Grube, 1967; Lehmann-Grube et al., 1969; Staneck et al., 
1972). Additional features of arenavirus persistence is the continuous expression of NP and 
the downregulation of GPC surface expression (Oldstone and Buchmeier, 1982) and the 
resistance of cells to super infection with homologous virus (Ellenberg et al., 2004). 
One hypothesis seeking to explain how persistent infection is established and 
maintained suggests that within a population of arenavirus infected cells, infection of a 
single cell is transient and self-limited. Further, upon clearance of an arenaviral infection, 
that cell becomes susceptible to being re-infected by neighboring reservoir cells within the 
population (Hotchin, 1973, 1974a, b; Hotchin et al., 1975). The primary evidence 
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supporting this model comes from the observation that when large numbers of single cell 
clones are established from a population where almost all cells were infected, virus was 
only detected in the supernatant of a small percentage of established clones (~5%) 
(Hotchin, 1973, 1974a, b; Hotchin et al., 1975). Additional evidence of the importance of 
viral clearance followed by re-infection in the maintenance of persistent arenavirus 
infections comes from the observation that treatment of persistently infected cultures with 
blocking arenavirus antisera leads to a progressive decline in the percentage of cells 
expressing viral antigen as visualized by immunofluorescence microscopy (Lehmann-
Grube et al., 1969). Potential mechanisms that could be employed by arenaviruses to 
establish transient self-limiting infections in cells likely include the inhibition of the viral 
RNA dependent RNA polymerase by the viral Z protein (Cornu and de la Torre, 2001, 
2002; Jacamo et al., 2003; Kranzusch and Whelan, 2011; Lopez et al., 2001) and the 
production of defective interfering particles (Burns and Buchmeier, 1993; Huang, 1973; 
Huang and Baltimore, 1970; Oldstone, 1998; Welsh et al., 1972; Ziegler et al., 2016a; 
Ziegler et al., 2016b). 
A second hypothesis explaining arenaviral persistence suggests that the appearance 
of defective genomes during the persistent phase of arenavirus persistence leads to greatly 
reduced levels of infectious virus production (Rawls et al., 1981). The basis for this 
hypothesis is the observation that viral genomic RNAs are expressed at high levels in vivo 
in persistently infected animals (Francis and Southern, 1988b). Further it was shown that 
during persistence, truncated subgenomic RNAs appear in vitro (Francis and Southern, 
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1988a), and many of the genomic and antigenomic RNAs that appear to be full length 
actually have short (< 50 nucleotide) deletions at the 3’ and 5’ termini (Meyer and 
Southern, 1994). It was suggested that these terminally deleted genomes are replication 
competent as a specific 3’ genomic deletion and the identical corresponding 5’ antigenomic 
deletion were readily detected (Francis and Southern, 1988a; Meyer and Southern, 1994). 
However, these deletions were never observed in the 5’ termini of viral mRNA sequences, 
suggesting that these truncated genomes are not transcriptionally competent (Meyer and 
Southern, 1993, 1994). There is a small amount of evidence that in some instances viral 
RNAs appeared to have additional nontemplated bases at their termini, suggesting a 
potential path by which terminally truncated genomes could be repaired (Meyer and 
Southern, 1997). By balancing the loss and replacement of genomic and antigenomic 
termini, the virus could potentially autoregulate viral transcription and production of 
infectious virions during persistence (Francis and Southern, 1988a; Meyer and Southern, 
1993, 1994, 1997) – explaining the oscillatory behavior of viral release observed during 
persistent infection in cell culture.  
Much of the work undertaken to probe the genetic events of viral transcription 
and replication has relied on Northern blot (Auperin et al., 1984b; Fuller-Pace and 
Southern, 1988; Polyak et al., 1995a, b; Raju et al., 1990; Shivaprakash et al., 1988; 
Southern et al., 1987) and qRT-PCR (Haist et al., 2015) to examine the levels of viral RNAs 
during infection. Studies using Northern blot to track viral RNAs during the course of 
infection have the advantage of being able to distinguish each of the viral RNAs (Auperin 
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et al., 1984b; Fuller-Pace and Southern, 1988; Polyak et al., 1995a, b; Raju et al., 1990; 
Shivaprakash et al., 1988). However, the extreme variability in detection sensitivity 
between independent studies and the inability to quantitatively compare the levels of viral 
RNAs labeled by different probe sets is a significant disadvantage of Northern blot 
(Auperin et al., 1984b; Fuller-Pace and Southern, 1988; Polyak et al., 1995a, b; Raju et al., 
1990; Shivaprakash et al., 1988; Southern et al., 1987). qRT-PCR has also been 
implemented to track the dynamics of transcription and replication of viral RNAs by Haist 
et al. and has the advantage of exquisite sensitivity. However, qRT-PCR has the 
disadvantage of being unable to distinguish viral mRNAs from respective genomic or 
antigenomic RNA (Haist et al., 2015). A limitation to both approaches is that they measure 
gene expression of cell populations and are thus unsuitable to analyze the heterogeneity of 
individual cells (Auperin et al., 1984b; Fuller-Pace and Southern, 1988; Haist et al., 2015; 
Polyak et al., 1995a, b; Raju et al., 1990; Shivaprakash et al., 1988; Southern et al., 1987). 
While these methods have provided invaluable insight into the genetics of the viral life 
cycle, discerning between the two major hypotheses presented above will depend on a more 
nuanced view of the genetic events of infection in individual cells over time. 
1.4. Viral Replication Complexes 
The nucleoprotein is the major viral protein component of the viral RNPs (Ferron 
et al., 2017). LCMV NP in an infected cell localizes predominantly to punctate cytoplasmic 
structures during acute infection (Knopp et al., 2015; Ortiz-Riano et al., 2011; Young et 
al., 1987). In transfection experiments, ectopically expressed LCMV NP can adopt a 
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distribution similar to that observed during infection  (Knopp et al., 2015; Ortiz-Riano et 
al., 2011). NP in cells infected with JUNV and TCRV, can exhibit a pattern of staining 
ranging from diffusely cytoplasmic to concentration of NP in punctate cytoplasmic 
structures (Baird et al., 2012; Ellenberg et al., 2002). The observation that NP can 
concentrate in specific subcellular locations during both infection and when NP is 
ectopically expressed suggests that the virus may benefit from compartmentalizing viral 
machinery in specific subcellular sites. The identification and description of these sites as 
well as the elucidation of how the virus may be benefitting by a particular localization 
pattern are of great interest. 
It is known that many viruses take advantage of specific subcellular sites to 
facilitate their life cycles. A particularly rich literature exists describing the way viruses 
with single-stranded positive sense genomes hijack host membrane bound compartments 
to shield the transcription and replication of their genomes from cytoplasmic RIG-I like 
receptor (RLR) surveillance (Chan and Gack, 2016; den Boon and Ahlquist, 2010; den 
Boon et al., 2010; Novoa et al., 2005a). While less is known regarding how negative-strand 
viruses, like the arenaviruses, may rely on membrane bound cellular compartments, there 
are notable examples of other negative-strand viruses that rely on cellular organelles to 
promote genome replication, assembly, and/or trafficking phases of their life cycle 
including Influenza A virus and Bunyamwera virus (Amorim et al., 2011; Bruce et al., 
2010; Novoa et al., 2005a; Novoa et al., 2005b).  
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To explore the question of whether arenaviruses take advantage of particular 
subcellular sites to promote their life cycle, Baird et al. performed the first comprehensive 
study to examine the subcellular localization of sites of active transcription and replication 
of TCRV and JUNV viral genomic RNA (Baird et al., 2012). The authors found that active 
sites of genome transcription and replication (or viral replication and transcription 
complexes; RTC) were localized to punctate structures in infected cells. Moreover, viral 
RNPs co-sedimented with membrane components by density-gradient centrifugation, 
providing the first hint that the virus may be co-opting some existing organelle membrane 
during the cytoplasmic phases of its life cycle (Baird et al., 2012). Nevertheless, Baird et 
al. were unable to identify the cytoplasmic organelle hijacked by the virus, and the identity 
of these subcellular sites of TCRV replication remain obscure (Baird et al., 2012). 
1.5. The Viral Nucleoprotein 
The arenavirus nucleoprotein, sometimes referred to as the nucleocapsid protein 
(abbreviated NP or N), is the viral protein expressed at the highest levels during infection. 
NP, consisting of between 558 and 570 amino acids, has a molecular weight ranging from 
60-68 kDa depending upon the virus (Buchmeier, 2002). The viral gene encoding the NP 
protein is located on the S gene segment and is encoded in a negative-sense polarity – such 
that transcription of the genome yields a coding mRNA (Meyer et al., 2002). During the 
persistent phase of infection, while the expression of the other viral proteins becomes 
undetectable, NP levels remain high (Ellenberg et al., 2002). While NP plays multiple roles 
in the virus life cycle, classically, encapsidation of the viral genomic RNA and replicative 
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intermediate RNA (antigenomic RNA) has been considered to be NP’s fundamental role 
(Buchmeier et al., 2013). Structural biology and mutagenesis approaches have made it 
possible to map the regions important for NP’s various functions and in mediating its 
interactions with both viral and host proteins. 
The primary amino acid sequence of the NP is highly conserved across the 
arenavirus family – including a high degree of similarity between the Old World and the 
New World arenaviruses (Buchmeier, 2002; Lan et al., 2008; Qi et al., 2010). Crystal 
structures of Lassa virus NP have been solved and have shown that NP folds into two 
discrete domains – an N terminal domain roughly encompassing residues 1-338 and a C 
terminal domain encompassing residues 364-561 with a flexible linking region connecting 
the two (Qi et al., 2010). In the N terminal domain, there is a deep cavity lined with basic 
residues at the bottom of which is located a patch of hydrophobic amino acids. It was 
initially suggested that this N terminal cavity coordinated the binding to the 7-
methylguanylate cap (m7G cap) which members of the arenavirus family have been 
demonstrated to use to cap their mRNAs. The authors hypothesized that the hydrophobic 
residues deep in the cavity coordinated the m7G cap, and the basic channel coordinated the 
triphosphate bridge (Qi et al., 2010). When the authors mutated several key residues 
identified in this region, severe defects in viral transcription were observed – supporting 
their hypothesis that NP is involved in m7G cap-snatching (Qi et al., 2010). Other groups 
have questioned this proposed model (Brunotte et al., 2011; Hastie et al., 2011b). The co-
crystallization of LASV NP in complex with RNA has suggested that the N terminal cleft 
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does not bind m7G caps. Rather, the cleft is responsible for binding single stranded viral 
RNA (Brunotte et al., 2011; Hastie et al., 2011b). It was shown that the basic amino acid 
residues lining the cavity were important in mediating the electrostatic interactions between 
the NP and the phosphate backbone of the ssRNA molecule (Brunotte et al., 2011; Hastie 
et al., 2011b). 
 LASV NP crystal structures have also given insight into the role of the C terminal 
domain. Two papers independently showed extensive 3d structure similarity between the 
C terminal domain of LASV NP and the DEDD superfamily of exonucleases despite little 
primary sequence identity (Hastie et al., 2011a; Qi et al., 2010). Structures reveal a deep 
cleft at the top of the C terminal domain of LASV NP. Moreover, these catalytic residues 
were shown to occupy the same positions as in the active site of the human DEDD family 
3’-5’ exonuclease TREX1 (Hastie et al., 2011a; Qi et al., 2010). Characterization of the 
enzymatic activity of the C terminal domain showed that NP degraded RNA but not DNA 
in a 3’ to 5’ direction, and that, moreover, this exoribonuclease activity was dependent 
upon a divalent Mn2+ cation coordinated by the C terminal domain (Hastie et al., 2011b; 
Qi et al., 2010). While Qi et al. (Qi et al., 2010) showed that NP degraded both ssRNA and 
dsRNA, Hastie et al. (Hastie et al., 2011a) demonstrated a clear preference of NP for 
dsRNA.  
In addition to this initial crystallography examining the structure of LASV NP, the 
structure of TCRV, JUNV, and LCMV NP have all recently been solved and have been 
shown to possess a C terminal 3’-5’ exoribonuclease domain (Jiang et al., 2013; West et 
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al., 2014; Zhang et al., 2013). TCRV NP was further shown to possess exonuclease activity 
with specificity for dsRNA ligands, like LASV NP (Jiang et al., 2013). However, JUNV 
NP was shown to lack exonuclease activity in an in vitro dsRNA degradation assay (Zhang 
et al., 2013). It is possible that the crystallization scheme utilized by these researchers led 
to the protein adopting an inactive conformation, lacking a key Zn2+ cation shown to be 
conserved in all other crystallized arenavirus NP’s (West et al., 2014; Zhang et al., 2013). 
It is also possible JUNV does not possess the ability to degrade dsRNA substrates. 
Nevertheless, the potential diversity in NP functionality across members of the Old World 
and New World viruses is intriguing, and further work should be performed to better 
understand the divergent strategies employed by these related viruses to subvert effective 
host innate immune responses. 
Other motifs present in the NP protein include a zinc finger motif in NP’s C 
terminus (Parisi et al., 1996; Qi et al., 2010; Tortorici et al., 2001b). The zinc finger motif 
identified in the C terminus of LASV and JUNV was between amino acids 500 and 530. 
The position of the zinc finger motif in the crystal structure of the LASV NP suggests that 
it may play a role in coordinating the exoribonuclease domain (Qi et al., 2010; Tortorici et 
al., 2001b). 
Important for encapsidation of the viral RNA genome, arenavirus NP has been 
shown to form homo-oligomers. The interaction between individual NP monomers has 
been suggested to be mediated by NP’s N terminal domain (Levingston Macleod et al., 
2011; Ortiz-Riano et al., 2011, 2012). However, C terminal to N terminal interactions also 
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appear to be of importance (Brunotte et al., 2011; Hastie et al., 2011b). X-Ray 
crystallography of LASV NP reveals homotrimers formed of monomers associated in a 
ring-like structure (Brunotte et al., 2011; Hastie et al., 2011b; Qi et al., 2010). NP subunits 
are arranged in either a symmetric head-tail fashion or an asymmetric fashion in the 
trimeric ring (Brunotte et al., 2011). However, complementary EM analysis of NP trimers 
in solution shows that NP trimers exist predominantly in a symmetric state (Brunotte et al., 
2011). Crystallization has also suggested that NP monomers undergo a conformational 
change in their N terminal domain upon trimerization making the N terminal cleft 
unavailable for RNA binding (Hastie et al., 2011b). Thus, an open and a closed 
conformation of the N terminal domain of NP corresponds to monomeric and trimeric NP 
respectively. While unable to bind RNA, it is possible that homotrimeric NP has distinct 
biological roles in the viral life cycle. For example, it has been demonstrated that NP that 
is unable to trimerize is defective in its ability to promote transcription and replication in 
minigenome reporter assays but has no effect on interaction with other viral proteins or its 
ability to antagonize a type I IFN response (D'Antuono et al., 2014; Lennartz et al., 2013). 
It is possible that head to tail interactions between NP subunits bound upon the length of 
viral genomic (or antigenomic) RNA provide the structural basis for viral RNA 
encapsidation (Hastie et al., 2011b). 
LCMV NP can be phosphorylated during infection on serine and threonine 
residues (Howard and Buchmeier, 1983). It is unclear what the significance of NP 
phosphorylation may be, though it seems that phosphorylation of the LCMV NP protein 
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increases over the course of an infection (Young and Howard, 1983). It was hypothesized 
that the phosphorylation of NP may play a role in regulation of the conformational changes 
in NP promoting or inhibiting its multimerization (Brunotte et al., 2011). More recently, 
mass spectrometry of the LCMV NP demonstrated phosphorylation at three serines, one 
threonine, and one tyrosine. Further, additional serine and threonine residues that could be 
phosphorylated were identified with predictive algorithms (Knopp et al., 2015). Mutation 
of a threonine residue predicted to be phosphorylated greatly changed the subcellular 
distribution of NP in transfected cells, negatively affected translation priming, and a 
recombinant virus bearing this mutation was not viable (Knopp et al., 2015). Mutation of 
the phosphorylated tyrosine was also shown to be critical as recombinant virus with a 
mutation at this site was not viable (Knopp et al., 2015). 
While the majority of NP expressed in infected cells exhibits a molecular weight of 
60-68 kDa, it is possible to visualize a 28 kDa and 36 kDa cleavage product of NP as well 
(Harnish et al., 1981). The functional importance of these two truncated NP’s is unclear, 
but at late time points following infection (up to 20 days post infection), staining of NP in 
nuclear inclusions was observed in infected cells only when monoclonal antibodies capable 
of recognizing these short forms of NP were used (Young et al., 1987).  
The first evidence to explain a potential role for these truncated NPs came with the 
observations that JUNV NP appeared to be cleaved by caspases and that expression of 
ectopic JUNV NP could prevent the activation of the effector caspase 3, a critical event in 
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the execution of apoptosis (Wolff et al., 2013a). Thus, the short forms of NP observed 
during infection may represent a strategy employed by the virus to prevent apoptosis. 
Extensive work has been performed to characterize NP’s role in mediating 
transcription and replication of the arenavirus’ ssRNA genome. Expression of NP and the 
L protein are sufficient for the transcription and replication of a viral minigenome (Lee et 
al., 2000). A commonly accepted model for the switch from transcription to replication in 
arenaviruses was that an intergenic region (IGR), which separates the two genes in each 
viral gene segment, adopts a secondary structure hairpin loop whose formation in a 
transcribed mRNA leads to transcription termination. It was thought that as levels of NP 
increased over the course of infection, the IGR would be bound by NP upon exiting the 
polymerase thus becoming unable to adopt a hairpin, allowing the viral polymerase to 
proceed and transcribe the full length viral antigenome. This model was supported by the 
observation that when translation was blocked in cells infected with JUNV or TCRV, 
transcripts encoding the NP protein but not full length antigenome accumulated (Franze-
Fernandez et al., 1987; Tortorici et al., 2001a). 
Though appealing, this model for the regulation of viral transcription and 
replication has not been supported. Instead, it seems that as NP expression increased so did 
the levels of both viral minigenome replication and transcription (Pinschewer et al., 2003). 
Because viral mRNAs possess a 5’ m7G cap, and genomic and antigenomic RNAs do not 
(Meyer and Southern, 1993; Pinschewer et al., 2003; Tortorici et al., 2001a), it is possible 
that the “decision” to initiate either transcription or replication is made by the viral 
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polymerase at the moment of primer binding. That is, polymerase bound to a capped primer 
will prevent the encapsidation of the nascent RNA transcript and secondary structure of the 
transcribed IGR will terminate elongation. However, if the viral polymerase has bound an 
uncapped primer, encapsidation of the nascent RNA will occur, the secondary structure of 
the transcribed IGR will not be allowed to form, and the polymerase will continue until it 
reaches the end of the gene segment resulting in a full length antigenome (Pinschewer et 
al., 2003; Tortorici et al., 2001a). The authors hypothesized that increased levels of NP 
could increase the activity of the viral polymerase in a general manner, as has been 
observed for viruses in other families (Pinschewer et al., 2003). 
The NP of all members of the arenavirus family have been shown to suppress the 
induction of type I interferon (IFN) expression – with the exception of MOPV whose NP 
seems to exhibit only weak anti-IFN activity (Martinez-Sobrido et al., 2007; Martinez-
Sobrido et al., 2006; Ortiz-Riano et al., 2011; Pannetier et al., 2004). It was shown that 
expression of NP, in the absence of other viral proteins, was sufficient to prevent activation 
of the IRF3 responsive promoter (which controls expression of IFN-α/β) and nuclear 
translocation of IRF3 in response to infection with Sendai virus – a virus known to induce 
the expression of type I IFN (Martinez-Sobrido et al., 2007; Martinez-Sobrido et al., 2006). 
Mutational analysis has shown that the C terminal domain of the NP protein mediates the 
inhibition of the type I IFN response in LCMV (Martinez-Sobrido et al., 2009). 
Specifically, residues 382-386 were shown to be critical for the inhibition of the induction 
of IFN-β in LCMV and LASV (Carnec et al., 2011; Martinez-Sobrido et al., 2009). The 
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equivalent residues were shown to be present in the 3’-5’ exoribonuclease domain of LASV 
NP (Hastie et al., 2011b; Qi et al., 2010). 
The 3’-5’ exoribonuclease domain of LASV NP is capable of degrading a wide 
range of dsRNA substrates, including arenaviral RNAs and Poly I:C (Hastie et al., 2011a; 
Qi et al., 2010). Moreover, mutation of residues in the exonuclease domain resulted in 
mutant NPs unable to suppress induction of IFN-β expression (Harmon et al., 2013; Hastie 
et al., 2011a; Huang et al., 2015; Jiang et al., 2013; Qi et al., 2010). Key residues in the 
exonuclease domain including G392 and R393 of LASV (corresponding to LCMV NP 
G385 and R386) are conserved in the primary sequence of every mammarenavirus 
(Harmon et al., 2013; Jiang et al., 2013; Qi et al., 2010). Mutation of these catalytic residues 
has been shown to inhibit the growth of mutant recombinant virus in cell lines known to 
have intact type I IFN signaling pathways as well as in in vivo models of infection (Huang 
et al., 2015; Pannetier et al., 2014; Russier et al., 2014).  
RIG-I and MDA5 were both shown to be important in the detection of LCMV 
infection and the induction of IFN-β expression. It was shown that these two cytoplasmic 
sensors bound LCMV RNA. However, LCMV NP was able to suppress the induction of 
IFN- β by RIG-I and MDA5. NP, RIG-I and MDA5 were shown to physically associate 
which may be important for its inhibitory role in this signaling pathway (Zhou et al., 2010). 
Additionally, LCMV NP has been shown to interact with the kinase IKKε. This is 
significant because IKKε is a kinase important for type I IFN induction downstream of 
RIG-I. (Pythoud et al., 2012). In contrast to other arenaviruses, JUNV infection results in 
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robust induction of type I IFN expression, and this induction is dependent on RIG-I 
expression (Huang et al., 2012). Nevertheless, JUNV infection is unaffected by IFN 
treatment suggesting that it has additional mechanisms to evade a host antiviral response 
(Huang et al., 2012). Both New World and Old World NPs were shown to prevent the 
nuclear translocation of NF-κB and the activation of transcription of NF-κB responsive 
genes providing another way that arenaviruses may negatively modulate the amplitude of 
the host’s innate immune response (Rodrigo et al., 2012). 
Despite the putative role of truncated forms of NP in inhibition of apoptosis (Wolff 
et al., 2013a), in some cases, infected cells can undergo apoptosis. It appears that RIG-I 
signaling can lead to the initiation of the apoptotic pathway in JUNV infected cells 
(Kolokoltsova et al., 2014; Pythoud et al., 2015). While it was shown that LCMV 
effectively inhibits the induction of type I IFN through the activation of RIG-I, RIG-I 
induced apoptosis, a parallel, non-overlapping pathway, remained fully active in LCMV 
infected cells (Pythoud et al., 2015). In the case of JUNV infection, it is unclear to what 
extent the caspase decoy function of NP may play in modulating apoptosis, and the effect 
of viral strain, cell type, timing, and other variables remain to be explored. 
The interaction of NP with other viral proteins is important at multiple steps in 
the arenavirus life cycle. While LCMV NP was shown to localize with GP in one study, 
this result has not been reproduced in other members of the arenavirus family (Burns and 
Buchmeier, 1991; Schlie et al., 2010). NP has been shown to interact with L polymerase 
from TCRV, LASV, MOPV, and LCMV (Jacamo et al., 2003; Kerber et al., 2011). While 
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the functional relevance of the NP-L interaction has yet to be defined, it was shown that 
within the Old World arenavirus clade, the activity of the MOPV and LASV L polymerase 
could be heterologously complemented by either MOPV, LASV, or LCMV NP. However, 
the activity of the LCMV L polymerase could not be complemented by MOPV or LASV 
NP (Kerber et al., 2011). Further, it appears that this interaction may be mediated via the 
viral genomic RNA and specifically the 3’ and 5’ UTRs (Iwasaki et al., 2015). 
NP has been shown to interact with Z for all arenavirus species examined, with the 
exception of MOPV and TCRV (Casabona et al., 2009; Eichler et al., 2004; Jacamo et al., 
2003; Ortiz-Riano et al., 2011; Salvato et al., 1992; Shtanko et al., 2010; Shtanko et al., 
2011). The NP-Z interaction is purported to be important in the assembly of budding viral 
particles. While Z protein alone is sufficient to direct the budding of VLPs, the expression 
of NP along with Z can may be important for the recruitment of RNPs into budding 
particles (Casabona et al., 2009; Groseth et al., 2010; Ortiz-Riano et al., 2011; Schlie et al., 
2010). The ability to interact with Z was mapped to the C terminal domain of NP, but 
mutation to key residues resulting in the loss of IFN inhibitory activity did not affect the 
ability of NP to bind Z suggesting that these two functions of the C terminal domain of NP 
are independent of each other (Ortiz-Riano et al., 2011). 
In addition to NP’s ability to interact with other viral proteins, NP has also been 
shown to interact with cellular proteins. JUNV NP was shown to interact with hnRNP 
A1/A2. hnRNP A1/A2 are RNA binding proteins which shuttle between the nucleus and 
the cytoplasm. While knockdown of these hnRNPs resulted in a defect in viral replication, 
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the mechanism of why this interaction could be important is, as yet, unknown (Maeto et 
al., 2011). Furthermore, LCMV NP was shown to interact with the intermediate filament 
protein Keratin 1. Cells infected with LCMV were shown to have a more extensive Keratin 
network than uninfected cells and an increased concentration of desmosomes at sites of 
cell to cell contact (Labudova et al., 2009). The increased stability of the intermediate 
filament network and increased cell contacts observed in LCMV infected cells facilitated 
the efficient transmission of virus between cells. Disruption of the keratin network resulted 
in decreased cell to cell transmission of virus (Labudova et al., 2009). MOPV NP and Z 
were both shown to interact with the ALIX/AIP1, part of the cellular ESCRT pathway – a 
protein complex involved in the budding of vesicles into multivesicular bodies (MVBs) 
(Shtanko et al., 2011). It appears that AIP1 interaction bridges NP and Z and may thus play 
a role in promoting RNP recruitment into budding MOPV particles (Shtanko et al., 2011). 
Lastly, it was shown that NP may play an important role in regulating host cellular 
translation (Linero et al., 2011). Infection with JUNV as well ectopic expression of NP or 
GPC was able to prevent the formation of stress granules in response to cellular stress 
(Linero et al., 2011). Stress granules are transient non-membrane bound accumulations of 
stalled small ribosomal subunits along with their bound cap-dependent mRNA transcripts. 
Stress granules are temporary depots of non-essential transcripts and their accompanying 
translation machinery that are formed in response to a variety of cellular stresses that 
activate a member of the eIF2AK family of kinases, whose role it is to phosphorylate eIF2α 
and stall global cap-dependent translation. This permits the selective translation of stress 
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response mRNAs bearing alternate translation initiation signals such as internal ribosomal 
entry sites (IRES). Importantly, stress granules can dissolve following the resolution of the 
cellular stress and the resident mRNAs can re-enter the pool of actively translating cellular 
mRNAs (Anderson and Kedersha, 2008; Buchan and Parker, 2009; Thomas et al., 2011). 
As the stress of viral infection can initiate the formation of stress granules, many viruses 
have been shown to interfere with stress granule formation, function, and/or hijack stress 
granules to promote their own replication (Reineke and Lloyd, 2013; Valiente-Echeverria 
et al., 2012; White and Lloyd, 2012). How, then, JUNV NP (and/or GPC) may be affecting 
viral translation is a fascinating question. It is possible that JUNV NP’s ability to interact 
with the eIF4 complex to promote cap-dependent translation (Linero et al., 2013) along 
with other, as yet, undescribed mechanisms may all play important roles in maintaining 
high rates of translation in infected cells. 
The arenavirus nucleoprotein clearly performs many roles in the life cycle of the 
virus. While its classical role has been considered to be the encapsidation of the viral 
genomic and antigenomic RNA, NP’s role in interacting with other viral proteins as well 
as inhibiting a cellular IFN response are also beginning to be appreciated. Crystal strutures 
of LASV NP have provided new insight into the molecular mechanism by which NP is 
able to perform such diverse functions as binding viral RNA, degrading immunogenic viral 
RNA, and self-associate in higher order trimeric structures. It appears that the ability of NP 
to associate with the viral Z protein may also be of great importance to direct the viral 
RNPs into budding virions. While still poorly understood, NP’s ability to interact with host 
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proteins also seems to be important. There remains much work to be done in these veins to 
more fully understand the interplay between arenavirus and host in the pathogenesis of 
arenaviral infections. 
1.6. Summary 
Arenaviruses remain major public health threats in developed countries where 
populations are in constant exposure to LCMV and also worldwide where infection with 
Lassa virus and several South American viruses cause extremely dangerous hemorrhagic 
fever in infected individuals. Despite great effort, significant gaps remain in our 
understanding of the viral life cycle and in our appreciation of how the virus takes 
advantage of the host cell to its own benefit. These gaps in our understanding of arenavirus 
biology are highlighted by our limited arsenal of available preventive and antiviral 
therapeutic options. We believe that the development of new, more effective antiviral 
strategies will likely depend upon the elucidation of key aspects of basic arenavirus 
biology. 
Toward this ambitious goal, a good starting point is to better understand the 
regulation of viral gene expression and genome replication, how the virus may be 
compartmentalizing these events within specific subcellular niches, and how the major 
viral protein component of the viral RNP, the viral nucleoprotein, may be playing 
heretofore unappreciated accessory roles to promote these and other steps of the viral life 
cycle. It was our hope that the work in this dissertation would help us better understand 
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how these viruses are able to establish persistent infections and how they are able to cause 
such severe disease in humans but asymptomatic infections in their rodent reservoir.  
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1.7. Tables 
Table 1.1.  Members of the genus Mammarenavirus 
Viruses of the family Arenaviridae, their geographic distribution, reservoirs and associated human diseases. 
Adapted from Viruses, 5(2), S. Wolff, H. Ebihara, and A. Groseth, Arenavirus Budding: A Common Pathway 
with Mechanistic Differences, p. 528-549, 2013, under a Creative Commons Attribution license (CC-BY 
4.0).       (Wolff et al., 2013b) 
 
  Virus Distribution Reservoir Human Disease 
O
ld
 W
o
rl
d
 
Dandenong virus* 
Yugoslavia, Australia 
(?) 
Unknown 
Febrile illness with 
encephalopathy (transplant-
related) 
Gbagroube virus* Argentina 
Mus (Nannomys) 
setulosus 
None known 
Ippy virus 
Central African 
Republic 
Arvicanthus spp. None known 
Lassa virus Western Africa Mastomys natalensis 
Febrile illness, hemorrhagic 
fever in severe cases 
Lymphocytic 
Choriomeningitis virus 
Worldwide Mus musculus 
Febrile illness, aseptic 
meningitis in severe cases 
Lujo virus Zambia Unknown Hemorrhagic fever 
Luna virus* Zambia Mastomys natalensis None known 
Kodoko virus * Guinea 
Mus (Nannomys) 
minutoides 
None known 
Menekre virus* Côte d'Ivoire Hylomyscus spp. None known 
Merino Walk virus * South Africa Myotomis unisulcatus None known 
Mobala virus 
Central African 
Republic 
Praomys jacksoni None known 
Mopeia virus Mozambique Mastomys natalensis None known 
Morogoro virus * Tanzania Mastomys spp. None known 
N
e
w
 W
o
rl
d
 
Allpahuayo virus Peru Oecomys spp. None known 
Amapari virus Brazil 
Oryzomys gaeldi 
Neacomys guianae 
None known 
Bear Canyon virus USA 
Peromyscus 
californicus 
None known 
Big Brushy Tank virus* USA Neotoma albigula None known 
Catarina virus * USA Neotoma micropus None known 
Chapare virus Bolivia Unknown Hemorrhagic fever 
Cupixi virus Brazil Oryzomys spp. None known 
Flexal virus Brazil Oryzomys spp. Febrile illness(Lab-acquired) 
Guanarito virus Venezuela 
Zygodontomys 
brevicauda 
Hemorrhagic fever 
Junín virus Argentina Calomys musculinus Hemorrhagic fever 
Latino virus Bolivia Calomys callosus None known 
Machupo virus Bolivia Calomys callosus Hemorrhagic fever 
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Oliveros virus Argentina Bolomys spp. None known 
Paraná virus Paraguay Oryzomys buccinatus None known 
Pichinde virus Columbia Oryzomys albigularis None known 
Pinhal virus Brazil Calomys tener None known 
Pirital virus Venezuela Sigmodon alstoni None known 
Real de Catorce virus * Mexico Neotoma leucodon None known 
Sabiá virus Brazil Unknown Hemorrhagic fever 
Skinner Tank virus * USA Neotoma mexicana None known 
Tacaribe virus Trinidad Artibeus spp. (bat) 
Possible febrile illness (Lab-
acquired) 
Tamiami virus USA Sigmodon hispidus None known 
Tonto Creek virus USA Neotoma albigula None known 
Whitewater Arroyo 
virus 
USA Neotoma albigula Possible hemorrhagic fever 
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1.8. Figures 
 
 
Figure 1.1. Phylogeny of the genus Mammarenavirus  
Phylogenetic tree of arenavirus Z protein. Amino acid sequences of Z protein were used for analysis. The 
phylogenetic tree was drawn using GENETYX [1]. The scale bar indicates substitutions per site. Accession 
numbers for reference sequences are: ABY20731 (Dandenong), YP_516232 (Ippy), NP_694871.1 (LASV, 
Josiah), ABC96003 (LCMV, Armstrong), YP_002929492 (Lujo virus), YP_516228 (Mobala virus), 
ABC71136 (Mopeia virus), YP_003090216 (Morogoro virus), YP_004933732 (Luna virus), YP_001649213 
(Allpahuayo virus), AEQ59327 (Bear Canyon virus), AEQ59329 (Catarina virus), YP_001936023 (Flexal 
virus), YP_001936027 (Parana virus), YP_138535 (Pichinde virus), YP_025092 (Pirital virus), AEQ59336 
(Skinner Tank virus), YP_001911119 (Whitewater arroyo virus), YP_001649217 (Amapari virus), 
YP_001816784 (Chapare virus), YP_001649219 (Cupixi virus), NP_899220 (Guanarito virus), NP_899216 
(Junin virus, XJ-13), NP_899215 (Machupo virus), YP_089659 (Sabia virus), Q88470 (Tacaribe virus), 
YP_001911117 (Tamiami virus), YP_001936025 (Latino virus), YP_001649215 (Oliveros virus). 
Reproduced from Viruses, 4(10), S. Urata and J. Yasuda, Molecular Mechanism of Arenavirus Assembly 
and Budding, p. 2049-2079, 2012, under a Creative Commons Attribution license (CC-BY 4.0). (Urata and 
Yasuda, 2012)  
 37 
 
 
 
Figure 1.2. Geographic distribution of mammarenaviruses  
Geographic distribution of human pathogenic arenaviruses. This map summarizes the distribution of human 
pathogenic New and Old World mammarenavirus species. The year of the first description is indicated in 
brackets. Reproduced from Viruses, 4(11), S. K. Fehling, F. Lennartz, and T. Strecker, Multifunctional 
Nature of the Arenavirus RING Finger Protein Z, p. 2973-3011, 2012, under a Creative Commons Attribution 
license (CC-BY 4.0). (Fehling et al., 2012) 
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Figure 1.3. Arenavirus particle  
Arenavirus particles are enveloped by a host-derived lipid bilayer. The viral envelope glycoprotein is a 
transmembrane protein made up of three subunits: GP1, GP2, and the SSP. Mature glycoprotein form 
homotrimers in the viral envelope (not shown). The viral Z protein is the bona fide viral matrix protein and 
is responsible for budding of nascent virions. The viral ribonucleoprotein complexes (vRNP) are made up of 
the viral genomic RNA, the viral L polymerase, and the viral nucleoprotein (NP). Though their functional 
relevance is unclear, arenaviruses also package cellular ribosomes in virions.  
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Figure 1.4. Arenavirus Life cycle  
(1) The arenavirus life cycle begins with the envelope glycoprotein binding to its cell surface receptor. (2) 
Receptor binding triggers the uptake of the viral particle into an endocytic compartment. (3) Endosome 
acidification triggers a conformation change in GP2 and the fusion of the viral envelope with the endosomal 
membrane. (4) The released RNP is transcribed in the cytoplasm and viral mRNAs are translated into protein 
by host ribosomes. (5) Upon accumulation of viral protein, full length replication of the viral genomic RNA 
is permitted. (6) The individual viral protein and RNA components assemble and (7) bud as newly formed 
infectious virions from the cellular plasma membrane. 
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Figure 1.5. Arenavirus genomic organization  
The single-stranded, negative-sense RNA genome is contained on two segments. The S segment encodes the 
NP gene in a negative orientation and the GPC gene in a pseudo-positive orientation. The L segment encodes 
the L gene in a negative orientation and the Z gene in a pseudo-positive orientation. For both the S and the L 
segment the two encoded gene products are separated by an intergenic region (IGR) that adopts a hairpin 
secondary structure and serves as the transcription termination signal. There are 3’ and 5’ untranslated regions 
(UTR) that provide critical sequence information needed for L polymerase recruitment and viral gene 
transcription and genome replication. 
 
  
 41 
 
 
 
 
Figure 1.6. Arenavirus genomic RNA transcription and replication  
The events of viral genome transcription are shown. The order of all events is identical for both the S and the 
L segment. For simplicity, only the S segment is shown. (1) First, the NP gene (the gene encoded a negative 
orientation) is transcribed by the viral L polymerase. The NP mRNA can be translated by cellular ribosomes. 
Upon accumulation of viral antigen, a switch to full length genome replication (2) occurs. The full-length 
RNA molecule complementary to the viral genome is called the antigenome. It serves as both the template 
for replication of more genomic RNA and (3) the transcription of the GPC gene (now in a negative 
orientation). The GPC mRNA can be translated into protein by cellular ribosomes. 
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2.1. Abstract 
Lymphocytic choriomeningitis mammarenvirus (LCMV) is an enveloped, 
negative-strand RNA virus that causes serious disease in humans but establishes an 
asymptomatic, lifelong infection in reservoir rodents. Different models have been proposed 
to describe how arenaviruses regulate the replication and transcription of their 
bisegmented, single-stranded RNA genomes, particularly during persistent infection. 
However, these models were largely based on viral RNA profiling data derived from entire 
populations of cells. To better understand LCMV replication and transcription at the single-
cell level, we established a high-throughput, single-molecule (sm)FISH image acquisition 
and analysis pipeline and followed viral RNA species from viral entry through the late 
stages of persistent infection in vitro. We observed transcription of viral nucleoprotein and 
polymerase mRNAs from the incoming S and L segment genomic RNAs, respectively, 
within 1 hr of infection, whereas transcription of glycoprotein mRNA from the S segment 
antigenome required ~4-6 hr. This confirms the temporal separation of viral gene 
expression expected due to the ambisense coding strategy of arenaviruses and also suggests 
that antigenomic RNA contained in virions is not transcriptionally active upon entry. Viral 
replication and transcription peaked at 36 hours post-infection, followed by a progressive 
loss of viral RNAs over the next several days. During persistence, the majority of cells in 
culture showed repeating cyclical waves of viral transcription and replication followed by 
clearance of viral RNA. Thus, our data support a model of LCMV persistence whereby 
infected cells spontaneously clear infection and become reinfected by viral reservoir cells 
that remain in the population.  
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2.2. Importance 
Arenaviruses are human pathogens that can establish asymptomatic, life-long 
infections in their rodent reservoirs. Lymphocytic choriomeningitis mammarenavirus 
(LCMV) is carried in nature by the common house mouse and can be transmitted from 
mother to pup. Because pups recognize viral antigens as self, they are unable to mount 
an effective T cell response to clear infection. Yet LCMV, despite being able to infect 
most cells in the host, restricts its spread and several models have been proposed to 
explain this regulation. We developed a high throughput, single-molecule RNA FISH 
assay to profile the dynamics of LCMV genome replication and transcription in 
individual cells. Our findings provide novel insights in the timing of replication and 
transcription, the composition of virus particles and the functionality of their packaged 
viral RNA species, and suggest a revised model for how LCMV restricts its spread among 
susceptible host cells during persistent infection. 
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2.3. Introduction 
Several members of the arenavirus family are significant threats to human health. 
Lassa virus and Junín virus cause hemorrhagic fever syndromes while lymphocytic 
choriomeningitis virus (LCMV), the prototypic member of the family, is a well-known 
cause of severe birth defects and is highly lethal in immunocompromised individuals 
(Buchmeier et al., 2007; Fischer et al., 2006). A critical imperative to better understand the 
key steps of the arenavirus life cycle is made evident by the fact that there are no FDA-
approved vaccines to prevent arenavirus transmission and only a very limited repertoire of 
antivirals (Enria et al., 2008; McCormick et al., 1986). New strategies to prevent and treat 
arenavirus infections will likely hinge upon an improved understanding of key phases of 
the life cycle of these important human pathogens.  
Arenaviruses are enveloped viruses that have a single-stranded, bisegmented, 
negative-sense RNA genome. The ~3.5 kb small (S) and ~7.2 kb large (L) genomic RNA 
segments each encode two viral open reading frames in ambisense orientation (Figure 
2.1A) (Buchmeier et al., 2007). The nucleoprotein (NP) and polymerase (L) genes are 
encoded in typical negative-sense orientation on genomic RNA while the glycoprotein 
(GPC) and matrix protein (Z) genes are encoded in pseudo positive-sense orientation. The 
canonical sequence of genetic events following the release of arenavirus genomic RNA 
into the cytoplasm of a newly infected cell is (i) primary transcription of the NP and L 
mRNAs from the viral S and L genomic segments, respectively, followed by (ii) full length 
replication of the S and L segment antigenomic RNAs and subsequent transcription of the 
GPC and Z mRNAs from the S and L antigenomic RNAs, respectively, and (iii) replication 
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of additional full-length genomic RNAs from the antigenomic RNA templates (Figure 
2.1A) (Buchmeier et al., 2007; Meyer et al., 2002). 
While rodent-borne arenaviruses cause severe diseases in humans, they are thought 
to be asymptomatic in their sylvatic hosts, where they can establish a persistent, life-long 
infection (Buchmeier et al., 2007). LCMV is carried by the common house mouse and can 
be transmitted vertically from mother to pup (Buchmeier et al., 1980; Buchmeier and Zajac, 
1999; Lehmann-Grube et al., 1983). The pups are born infected but never mount an 
effective immune response to clear the virus as viral proteins are seen as self-antigens by 
the pup’s developing immune system (Buchmeier et al., 1980; Buchmeier and Zajac, 1999; 
Lehmann-Grube et al., 1983) . Paradoxically, while LCMV can infect most cells in the host 
rodent, it tightly regulates its spread and therefore does not overrun its host. Several 
hypotheses have been proposed for how LCMV restricts its spread, including through (i) 
the production of defective interfering (DI) particles (Burns and Buchmeier, 1993; Huang 
and Baltimore, 1970; Oldstone, 1998), which can enter susceptible host cells and make 
them refractory to productive infection (Huang, 1973; Welsh et al., 1972) and (ii) the 
accumulation of transcriptionally-defective genomic and antigenomic RNAs, which limit 
viral protein expression and infectious virus production (Meyer et al., 2002; Meyer and 
Southern, 1994, 1997). It has also been proposed that LCMV can establish a cyclical, 
transient pattern of infection such that susceptible cells are productively infected for a short 
time before clearing the virus and once again becoming susceptible to reinfection by 
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neighboring cells that remain productively infected (Hotchin, 1973, 1974a, b; Hotchin et 
al., 1975).  
A current gap in our knowledge of how arenaviruses restrict their dissemination is 
that we lack a detailed understanding of how the events of viral genome replication and 
transcription are regulated during the acute and persistent phases of infection. Previous 
studies examining the genetic events of arenavirus replication and transcription, including 
those described above regarding the accumulation of transcriptionally defective RNAs 
(Meyer et al., 2002; Meyer and Southern, 1994, 1997), relied on techniques such as 
Northern blot or quantititative RT-PCR. Both are powerful techniques used to examine 
RNA. Quantitative RT-PCR is exquisitely sensitive (Haist et al., 2015), and Northern blot 
is able to specifically distinguish between each of the viral RNA species (Auperin et al., 
1984b; Francis and Southern, 1988a, b; Franze-Fernandez et al., 1987; Fuller-Pace and 
Southern, 1988, 1989; Meyer and Southern, 1997; Polyak et al., 1995b; Shivaprakash et 
al., 1988; Southern et al., 1987). However, both techniques measure RNA at a population 
level and thus provide population average data. Variability in RNA expression between 
individual cells in a heterogeneous population cannot be evaluated using these approaches. 
Single-molecule RNA fluorescence in situ hybridization (smFISH) can bridge this 
technical gap to allow for detection of RNAs with single-copy sensitivity in individual cells 
by fluorescence microscopy (Raj et al., 2008). In the present study, we designed specific 
smFISH probe sets to fluorescently-label different LCMV RNA species (Figure 2.1A) and 
to quantitatively characterize their expression in single cells during the entire time course 
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of arenavirus infection. Our studies confirm the temporal separation of LCMV negative-
sense and pseudo positive-sense gene expression and reveal a striking pattern of cyclical 
loss and reappearance of viral RNA in individual cells during persistence. Our studies 
provide fresh insight into the functional genetic composition of infectious virions, the 
kinetics of transcription and replication in the hours immediately following initial 
infection, and suggest a revised model of how viral replication and transcription are 
regulated during persistence to restrict virus spread. Further, the image acquisition and 
analysis pipeline developed here is easily adaptable to other viruses. 
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2.4. Results 
2.4.1.  Visualization of LCMV RNA species in infected cells.  
To visualize LCMV RNAs in cells by fluorescence microscopy, we designed 
smFISH probe sets complementary to different viral RNA species (see overview in Figure 
2.1A). An important feature of smRNA FISH is the ability to detect single RNA molecules 
using multiple, singly-labeled oligonucleotide probes (Raj et al., 2008). The high signal-
to-noise ratio of the probe set binding to a specific target RNA yields single RNAs that 
appear as bright spots. To validate our ability to specifically label arenavirus RNAs, we 
used a cellular mRNA smFISH probe set specific for the housekeeping gene MDN1 as a 
control (Figure 2.1B) for comparison with a smFISH probe set designed to target both the 
viral S genome RNA and GPC mRNA (Figure 2.1C). MDN1 probes detect single 
cytoplasmic mRNAs as well as sites of active transcription in the nucleus, where multiple 
nascent RNAs are detected as more intense signals (Figure 2.1B). Next, we confirmed that 
the viral RNA smFISH probe set is highly specific as fluorescent signal was absent in 
uninfected cells, but bright spots were detected in LCMV-infected cells fixed at 24 hpi 
(Figure 2.1C). Moreover, similar to smFISH staining obtained with our control MDN1, 
individual smFISH spots were homogeneous in size, shape, and fluorescence intensity 
(Figure 2.1B and C) consistent with the detection of single RNAs, as shown previously 
(Raj et al., 2008; Zenklusen et al., 2008). Furthermore, in contrast to the nuclear transcribed 
MDN1 mRNAs, viral RNAs were largely excluded from the nucleus, consistent with the 
cytoplasmic viral life cycle (Figure 2.1B to C). 
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2.4.2.  smFISH probes complementary to viral mRNA species provide high signal-
to-noise staining.  
We designed multiple smFISH probe sets to have specificity for different RNA 
species produced during the course of the LCMV life cycle (Figure 2.1A). Specifically, 
these probe sets target (i) S genome only, (ii) GPC mRNA and S genome, (iii) NP mRNA 
and S antigenome, or (iv) L mRNA and L antigenome. When infected cells were stained 
with probe sets complementary to “S genome only” or “S genome and GPC mRNA” 
(referred to has “GPC mRNA/S genome” from this point forward), we noted high quality 
staining with the GPC mRNA/S genome probes as evidenced by homogeneity in spot size, 
shape, and intensity (Figure 2.2A) and high signal-to-noise ratio (Figure 2.3). The NP 
mRNA/S antigenome and L mRNA/L antigenome probe sets yielded similar high quality 
staining as evidenced by high signal-to-noise ratios (Figure 2.3). However, we noted lower 
quality staining with the “S genome only” probes as evidenced by the dimmer staining 
(Figure 2.2) and low signal-to-noise ratio (Figure 2.3). Moreover, the “S genome only” 
probes yielded greater non-specific staining in uninfected cells, potentially leading to 
detection of false-positive spurious events (Figure 2.2C) – perhaps an artifact of the long 
exposure times and high light intensity needed to detect this less sensitive probe set binding 
to its target. Similarly low signal-to-noise ratios were observed with probe sets specific for 
“S antigenome only” or “L genome only” (data not shown). It is possible that the 
encapsidation of genome and antigenome by viral nucleoprotein partially occludes smFISH 
probe hybridization with these target RNA sequences and thus leads to the lower signal-
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to-noise ratio observed with these probe sets. Therefore, use of these probe sets with cells 
containing small numbers of viral RNAs would be problematic due to the level of 
background staining observed (Figure 2.2C). However, these probe sets are effective when 
paired with cells containing abundant copies of viral genome or antigenome (Figure 2.2B 
and data not shown), which easily exceeds the quantity of background spots observed in 
mock-infected control cells (Figure 2.2C). Because the probe sets that targeted an mRNA 
plus either genome or antigenome provided the highest quality staining and sensitivity, we 
elected to use these probe sets to follow the kinetics of viral transcription and replication 
events in infected cells. 
2.4.3.  smFISH spot detection and quantification in individual LCMV-infected cells.  
A primary goal of our study was to globally describe the kinetics of transcription 
and replication of the LCMV genome from the early hours following viral entry through 
the late stages of persistence. Ideally, we would be able to infect cells at a high multiplicity 
of infection (MOI) and take snapshots of a population of synchronously infected cells at 
time points throughout the entire course of arenavirus infection. However, we were obliged 
to infect cells at a low MOI due to the characteristic high prevalence of DI particles present 
in LCMV stocks (Ziegler et al., 2016b). Because only a small proportion of cells would be 
productively infected upon viral inoculation, we needed to image a large population of cells 
at each time point tested to provide an accurate portrait of the heterogeneity present in a 
population of asynchronously infected cells. Thus, it was important for this study to both 
image and quantitatively characterize the smFISH staining of viral RNAs in a high-
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throughput fashion. To accomplish this goal, we automatically segmented the nuclei using 
DAPI and cell outlines using CellMask Green fluorescent staining with CellProfiler 
software (Kamentsky et al., 2011) (Figure 2.4A). Next, smFISH-labeled viral RNAs were 
detected using FISH-quant software (Mueller et al., 2013) (Figure 2.4B). We were able to 
image two distinct RNA smFISH probe sets labeled with spectrally-distinct fluorophores 
in individual cells. This allowed us to characterize relative viral RNA expression levels 
and compare localization of different viral RNAs (Figures 2.4B to C). We were able to 
robustly quantify viral RNAs using FISH-quant across a range of expression levels. We 
observed a linear relationship between the quantity of detected viral RNAs and the total 
fluorescence signal in the smFISH channel up to approximately 1,000 RNAs/cell, after 
which the number of detected viral RNAs reached a plateau (Figure 2.4D). This represents 
the point at which smFISH spots are so dense, that we were no longer able to accurately 
distinguish closely spaced RNAs. Examples of a cell displaying moderate levels of viral 
RNAs where identification of diffraction limited spots was robust (Figure 2.4B) and a cell 
with very high expression of viral RNAs where overcrowded spots are unable to be 
effectively spatially resolved (Figure 2.4C) are shown for reference. Thus, when viral RNA 
levels are relatively low (less than several hundred copies per cell) we have high confidence 
in the accuracy of the quantification provided by FISH-quant. However, when viral RNA 
levels are at their peak and RNAs are very dense, quantification should be considered an 
underestimate of RNA expression levels. 
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2.4.4.  Viral RNA transcription and replication following viral entry.  
We next aimed to monitor the early events of viral genomic transcription and 
replication immediately following viral entry. Cells were infected with LCMV at an MOI 
of 0.1, fixed at multiple time points, stained for NP mRNA/S antigenome, GPC mRNA/S 
genome, or L mRNA/L antigenome, and several hundred cells were imaged and analyzed 
at each time point (Table S2.1). As discussed above in relation to Figure 2.2, our probes 
sets specific for only genome or antigenome (but not an additional complementary viral 
mRNA) have low signal-to-noise ratios and sensitivity when compared to probe sets that 
also target a viral mRNA. Importantly, FISH-quant was unable to detect viral genome or 
antigenome spots in cells that had been infected with LCMV for less than 8 h (Figure 2.2 
and data not shown). However, by 8 hpi and later, genome and antigenome spots become 
detectable with these probe sets (Figure 2.2, B.R. King, S. Kellner, P.L. Eisenhauer, E.A. 
Bruce, C.M. Ziegler, D. Zenklusen, and J. Botten, submitted for publication, and data not 
shown). Therefore, in this set of experiments, smFISH spots detected with the NP mRNA/S 
antigenome, GPC mRNA/S genome, or L mRNA/L antigenome probe sets prior to 8 hpi 
are presumed to represent only the designated mRNA target in each case, whereas at 8 hpi 
and later it is possible to detect a mixture of the targeted RNAs.  
Representative images of cells infected from 0 to 6 hpi are shown (Figure 2.5A to 
B). Notably, transcription of the NP mRNA and L mRNA is detected as early as 1 hour 
following infection (Figure 2.5 and 2.6A to B) indicating primary transcription of the S 
and L genomic RNA occurs soon after entry and uncoating of arenavirus virions. The GPC 
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mRNA, on the other hand, is first detected at 6 hours following infection (Figure 2.5A and 
2.6A and C). This delayed appearance of the GPC mRNA indicates that transcriptionally 
competent S antigenomic RNA is not delivered into cells by incoming virions. Further, it 
suggests that a 4-6 hour lag is required for the production of S antigenomic RNA, which 
serves as the template for transcription of GPC mRNA (Figure 2.1A). This result is in 
agreement with previous studies that examined arenavirus mRNA synthesis via Northern 
blot (Franze-Fernandez et al., 1987; Meyer et al., 2002).  
When examining the subcellular localization of NP mRNA and GPC mRNA or NP 
mRNA and L mRNA pairs at 6 hpi or earlier, no overt colocalization between viral mRNAs 
was noted (Figure 2.5A to B). 
2.4.5.  Disproportionate transcription of S segment genes early after infection.  
For each probe set used in the experiments shown in Figures 2.5 and 2.6, the number 
of false-positive viral RNAs detected in mock-infected cells was used to establish a 
threshold to classify cells as either “positive” or “negative” for each of the tested viral RNA 
species. At 6 hpi (a time point before virus in the initially infected cells could have 
completed its life cycle and spread to adjacent, initially uninfected cells (Buchmeier et al., 
1978; Dutko and Pfau, 1978; Lehmann-Grube, 1971; Lehmann-Grube et al., 1975), we 
observed that 65-90% of cells were positive for NP mRNA and 40% were positive for GPC 
mRNA (Figure 2.6C to D). This high frequency of cells containing S segment-derived 
transcripts was surprising given the fact we initially infected cells at an MOI of 0.1, and 
thus would have expected approximately only 10% of cells to have been expressing viral 
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RNAs at this early time point. However, at this same early time point, only 8% of cells 
were positive for L segment-derived L mRNA (Figure 2.6D), which is consistent with the 
expected frequency of viral RNA-positive cells based on the initial MOI. This result may 
suggest that a high proportion of viral particles either fail to package the L genome or 
alternatively deliver a transcriptionally-defective L genome.  
2.4.6.  Viral RNA replication and transcription at peak of acute infection.  
To profile LCMV RNAs at the peak of infectious virus release during acute 
infection, cells were infected with LCMV at an MOI of 0.01, fixed at various time points 
between 12 and 96 hpi, stained for NP mRNA/S antigenome, GPC mRNA/S genome, or L 
mRNA/L antigenome, and several hundred cells were imaged and analyzed at each time 
point (Table S2.1). Levels of viral RNAs detected by each probe set rapidly increased over 
the first 24 hours of infection (Figure 2.7A to B and 2.8A to B). The proportion of cells 
positive for these viral RNAs also rapidly increased over the first 24 hours of infection 
such that almost all cells had substantial levels of all viral RNAs (Figure 2.8C to D). Peak 
viral transcription and replication occurred at 36 hours post infection (Figure 2.7A to B and 
2.8A to B). At this time point, viral smFISH signal was very dense and true levels of viral 
NP mRNA and GPC mRNA were likely underestimated due to inability of FISH-quant to 
accurately count tightly packed viral RNAs in the cytoplasm of infected cells (Figure 2.4B 
to C, 2.7A to B, and 2.8A to B). Furthermore, RNAs detected by the S segment-specific 
probe sets greatly exceeded those detected by the L segment-specific probe set (10-35 fold 
greater) between 12 and 96 hpi (Figure 2.8A to B, Table 2.1). Following peak viral 
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transcription and replication at 36 hours post-infection, levels of viral RNAs began to 
decrease (Figure 2.7A to B and 2.8A to B). The proportion of cells positive for L mRNA/L 
antigenome expression decreased steadily beginning at 48 hours post-infection (Figure 
2.8D). In contrast, all cells maintained NP mRNA/S antigenome and GPC mRNA/S 
expression over this entire time period (Figure 2.8C to D). 
2.4.7.  Cyclical patterns of genome transcription and replication during persistent 
infection.  
Lastly, we wanted to examine the transcription and replication dynamics of 
arenavirus genomic RNA during the persistent phase of infection. Cells were infected with 
LCMV at an MOI of 0.01, fixed at multiple time points between 1.5 and 41 days (d)pi, 
stained for NP mRNA/S antigenome, GPC mRNA/S genome, or L mRNA/L antigenome, 
and several hundred cells were imaged and analyzed at each time point (Table S2.1). 
Following peak RNA transcription and replication at 36 hpi, we observed the levels of NP 
mRNA/S antigenome, GPC mRNA/S genome, or L mRNA/L antigenome decrease over 
the next several days such that at 8 dpi, the majority of cells are negative for all of these 
viral RNAs (Figure 2.9A to F). However, by 13 dpi, the levels of viral RNAs detected by 
each probe set increase and the majority of cells are again positive for all viral RNAs 
(Figure 2.9C and F). Viral RNA levels again fall and many cells are no longer positive for 
viral RNA by 16 dpi. (Figure 2.9C and F). These cycles of increased levels of viral RNA 
expression and increased frequency of viral RNA expressing cells in the population repeat 
in a cyclical fashion multiple times over the first 41 days following infection (Figure 2.9). 
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In summary, the sequential loss and reappearance of viral gene expression observed here 
suggest a potential genetic signature of populations of cells persistently infected with 
LCMV.  
Throughout the time course of persistence examined in this study, NP mRNA/S 
antigenome is generally expressed at higher levels than GPC mRNA/S genome (up to 5-
fold higher levels) (Figure 2.9B and Table 2.1). The ratio between levels of NP mRNA/S 
antigenome and L mRNA/L antigenome over this time period is much more variable. At 
time points such as 13 and 20 dpi when most cells in the culture are positively expressing 
all viral RNA species, NP mRNA/S antigenome greatly outnumbers L mRNA/L 
antigenome (~25-fold higher levels) (Figure 2.9E and Table 2.1). However, at other times 
such as 8, 16, 27, and 34 dpi when substantial proportions of cells have lost expression of 
one or more viral RNAs, the ratio between NP mRNA/S antigenome and L mRNA/L 
antigenome in the double-positive cells is greatly reduced (~2-fold higher levels of NP than 
L mRNA) (Figure 2.9E and Table 2.1). Notably, the magnitude of viral RNA expression 
during persistence never returned the high levels observed at the peak of acute infection 
(Figure 2.9). 
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2.5. Discussion 
In the current study, we developed a high throughput smFISH assay that allowed 
us to visualize, single copies of LCMV RNAs in individual cells. Taking advantage of the 
sensitivity and quantitative aspect of this assay, we tracked the dynamics of viral 
replication and transcription spanning the moments following initial virus entry to late 
times during persistent infection. We observed that transcription of the negative-sense 
encoded NP and L mRNAs precede that of the pseudo positive-sense encoded GPC mRNA, 
confirming the temporal separation of gene expression predicted by the ambisense coding 
strategy of the arenaviruses and suggesting that antigenomic RNA in virions is not 
transcriptionally active following release into a newly infected cell. Our studies 
demonstrated a hierarchal pattern of expression among viral RNAs and indicate that many 
infecting virus particles may lack L genomic RNA. Finally, over the course of persistent 
infection, we observed repeated cycles whereby cells transition from supporting active 
viral replication and transcription to clearing all viral RNAs. Collectively, these studies 
advance our understanding of the natural history of arenavirus replication and transcription 
and suggest a modified model for how arenaviruses may regulate these processes to limit 
their impact on the fitness of their rodent reservoirs.  
The smFISH assay developed here provided us with an opportunity to build upon 
prior studies and examine arenavirus genome replication and transcription with greater 
sensitivity and detail. Previous studies aimed at elucidating the early events of arenavirus 
transcription and genome replication used Northern blot to visualize individual viral RNA 
species (Franze-Fernandez et al., 1987; Fuller-Pace and Southern, 1988; Shivaprakash et 
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al., 1988). Analysis of RNA from cells infected with LCMV or the New World arenavirus 
Pichinde failed to detect viral RNA from infected cells prior to 9 hpi (Fuller-Pace and 
Southern, 1988) or 12 hpi (Shivaprakash et al., 1988), respectively. In the setting of 
infection with the New World arenavirus Tacaribe, Franze-Fernandez et al. detected S 
genomic RNA and NP mRNA at 2 hpi and S antigenomic RNA at 4 hpi, while GPC mRNA 
appeared several hours following the synthesis of S antigenomic RNA (Franze-Fernandez 
et al., 1987). The earliest the viral L segment has been observed was at 12 hpi (Fuller-Pace 
and Southern, 1988). In the current study, we are able to detect viral NP and L mRNAs at 
1 hpi. Our data supports previous observations that viral NP mRNA expression occurs 
immediately following infection, and that GPC mRNA expression occurs following a lag 
of several hours (Franze-Fernandez et al., 1987; Meyer et al., 2002). By probing single 
cells, we build upon this prior work by demonstrating that GPC mRNA expression is not 
detected, even at low levels, in the first hours following infection. In light of previous 
observations that antigenomic L and S segment RNAs are packaged in viral particles 
(Franze-Fernandez et al., 1987; Haist et al., 2015), our inability to observe GPC mRNA in 
cells immediately following viral entry suggests that S antigenomic RNA packaged in 
virions is unable to be transcribed. Further, it suggests that GPC mRNAs are not packaged 
into viral particles, as has been suggested for Z mRNA (Salvato and Shimomaye, 1989). 
An interesting observation from our study was that, despite infecting cells at an 
MOI of 0.1, ~65-90% of cells expressed one or more genes encoded on the S genomic 
RNA segment at 6 hpi. Because it takes ~ 8 h for an infected cell to make new infectious 
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progeny (Buchmeier et al., 1978; Dutko and Pfau, 1978; Lehmann-Grube, 1971; Lehmann-
Grube et al., 1975), we were surprised to see such a high frequency of cells expressing 
these viral mRNAs at a time when the originally-infected cells could not yet have spread 
virus to additional uninfected cells in the monolayer. Notably, at this same 6 hpi time point, 
approximately 8% of cells expressed viral L mRNAs, which is consistent with the utilized 
MOI. This suggests that, within the viral stock, there may be a significant population of 
incomplete viral particles that possess the S segment but lack the L segment genomic RNA 
or a functional copy of this RNA. Considering that the genetic basis for how arenavirus DI 
particles block the propagation of infectious virus particles is unknown, these results may 
provide clues for future studies to define the mechanism at work.  
A hallmark characteristic of LCMV infection is the ability to establish an 
asymptomtatic, persistent infection in reservoir rodents (Francis et al., 1987). Further, it is 
possible to recapitulate key aspects of this persistent infection in cell culture models of 
infection (Lehmann-Grube, 1967; Lehmann-Grube et al., 1969; Meyer et al., 2002; 
Oldstone and Buchmeier, 1982). One notable characteristic of cell culture models of 
LCMV infection is the cyclical rise and fall of release of infectious virus seen during 
persistence (Hotchin, 1974a; Hotchin et al., 1975; Lehmann-Grube, 1967; Lehmann-Grube 
et al., 1969; Staneck et al., 1972). Several models have been proposed to explain how 
LCMV restricts its spread to establish and maintain a noncytopathic persistent infection, 
both in vitro and in vivo. The first suggests that DI particles, which are produced in 
abundance by LCMV, can enter permissive host cells and interfere with the ability of 
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standard infectious virus particles to successfully infect and complete the viral life cycle 
(Burns and Buchmeier, 1993; Huang, 1973; Huang and Baltimore, 1970; Oldstone, 1998; 
Welsh et al., 1972). Hotchin proposed a second model that he termed cyclical, transient 
infection. In this model, cells infected with LCMV are initially productive in making 
infectious virus particles, but later become refractory to superinfection and ultimately clear 
virus, only to once again become susceptible to reinfection by the small number of cells 
that remain productively infected (Hotchin, 1973, 1974a, b; Hotchin et al., 1975). Southern 
and colleagues proposed a third model that was based upon the dynamics and genetic 
identity of viral RNA species profiled during acute and persistent infection. In particular, 
they demonstrated by Northern blot that LCMV RNAs (genome, antigenome, and mRNAs) 
accumulate to high levels during persistence, both in vitro and in vivo (Francis and 
Southern, 1988b; Meyer et al., 2002; Meyer and Southern, 1994, 1997). Further, they 
showed that a proportion of these genomic and antigenomic RNAs, but not mRNAs, 
contained short deletions in the untranslated regions at their termini (Meyer et al., 2002; 
Meyer and Southern, 1993, 1994, 1997). They proposed that these deleted RNAs were 
replication competent, but transcriptionally incompetent. These data suggest a model 
where, during persistence, viral protein expression and infectious virus production are 
inhibited due to the accumulation of high levels of transcriptionally defective genomic and 
antigenomic RNAs. Further, because these deleted RNAs were found in virions, it was 
proposed that they serve as the molecular basis for DI particle interference. Finally, it was 
proposed that these deleted RNAs can be repaired by the viral polymerase to initiate bursts 
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of productive replication/infectious virus production during persistence. This would 
support the cyclical aspect of Hotchin’s model, but not the transience of infection as viral 
genetic material would not be cleared from infected cells. Each of these models, whether 
acting independently or in combination, would presumably restrict virus spread, allowing 
the virus to minimize its impact on host fitness while retaining its ability to propagate and 
ultimately maintain itself in nature. 
In reality, it seems likely that a holistic model describing the establishment and 
maintenance of arenavirus persistence will incorporate elements of each model. The data 
in the current study, indeed, suggest elements of each could be important. Our observation 
that many cells lose then regain expression of viral RNAs at multiple time points during 
persistence strongly supports the hypothesis of coordinated cycles of viral clearance 
followed by reinfection. Hotchins et al. demonstrated a similar pattern using the expression 
of viral antigen and production of infectious virus as readouts (Hotchin, 1973, 1974a, b; 
Hotchin et al., 1975). One interpretation of our data is that the loss of antigen expression 
(and infectious virus production) seen in those studies was the result of cells completely 
clearing virus, including viral genetic material. Alternatively, it is possible that loss of viral 
antigen expression could have been due to the accumulation of transcriptionally-defective 
genomes in infected cells. Because our smFISH probe sets for encapsidated genomic and 
antigenomic RNAs lack the sensitivity seen by those that are specific for unencapsidated 
viral mRNAs, it is possible that some of the cells examined do in fact contain very low 
levels of terminally-deleted genomic or antigenomic RNAs. However, in this scenario, we 
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feel the subsequent cycles of viral RNA rescue in most cells would be unlikely if 
completely dependent on the repair of terminally truncated genomes through the addition 
of random non-templated bases to regenerate functional terminal untranslated regions. We 
think it more likely that the accumulation of transcriptionally non-functional genomes 
along with the polymerase inhibitory activity of the viral Z protein (Cornu and de la Torre, 
2001, 2002; Kranzusch and Whelan, 2011; Lopez et al., 2001) both play a key role in 
negatively regulating viral transcription and replication following the peak of acute 
infection, providing an environment that permits cells to eliminate infection. The 
accumulation of terminally-deleted viral RNAs, if they are indeed the basis for DI particle 
interference with standard virus, could further work to preserve host fitness by driving the 
formation of DI particles to preserve nearby uninfected cells from infection. Reinfection 
of susceptible cells with virus from productively-infected reservoir cells within the 
population that express full length functional genome could restart the infection cycle as 
evidenced by the near 100% of cells expressing viral RNAs at multiple subsequent 
persistent time points. Being able to specifically visualize genomic and antigenomic RNAs 
with improved sensitivity by smFISH will be important to further define the exact 
mechanism employed by arenaviruses to restrict their spread and impact on host cells 
during persistent infection.  
In summary, we have used fluorescence microscopy to visualize fluorescently-
labeled arenavirus RNA molecules in infected cells. Further, we have described a flexible 
labeling, imaging, and image analysis pipeline that could be easily adapted to interrogate 
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the events of transcription or genomic replication of any RNA virus, particularly where it 
is critical to image and quantify RNA levels in hundreds to thousands of cells per 
experimental condition. We have taken advantage of this pipeline to gain new insights into 
the transcription and replication kinetics of LCMV RNAs over the course of infection that 
build upon previous studies. In particular, our data strongly support the transient, cyclical 
infection model originally proposed by Hotchin (Hotchin, 1973, 1974a, b; Hotchin et al., 
1975) and suggest that, following a period of productive infection, cells can clear infection, 
including viral genetic material, before becoming susceptible to reinfection. Further, our 
data suggest that viral antigenomic RNA in virions may not be transcriptionally functional 
upon virus entry and that a significant fraction of virus particles may lack functional L 
genomic RNA. Our findings give new insights into longstanding questions about how viral 
RNA transcription and replication are regulated during infection and how viruses may 
establish a long-lived, persistent infection. Developing the ability to label genomic and 
antigenomic RNAs with greater sensitivity will be an important next step toward the 
construction of a quantitative model of the regulation of viral RNA replication and 
transcription over time with the goal of explaining the oscillatory behavior of viral RNA 
synthesis during persistence.  
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2.6. Materials and Methods 
2.6.1.  Cells and Viruses.  
A549 (CCL-185) were obtained from American Type Culture Collection (ATCC, 
Manassas, VA). A549 cells were cultured in DMEM-F12 (11320-033, Thermo Fisher), 
containing 10% fetal bovine serum and 1% Penicillin-Streptomycin (15140-163, Thermo 
Fisher). LCMV Armstrong 53b was provided by J. L. Whitton (The Scripps Research 
institute, La Jolla, CA). A549 cells were infected with LCMV Arm53b at an MOI of 0.1 
(Figure 2.5 to 2.6) or an MOI of 0.01 (Figure 2.1, 2.2, 2.4, 2.7, 2.8, and 2.9). For 
experiments examining late, persistent time points following infections, a T25 tissue 
culture flask of A549 cells was infected. The flask of infected cells was trypsinized and 
cells were plated on glass coverslips 24 hours prior to the reported time points where cover 
slips were fixed, stained, and imaged as described below (Figure 2.9). Remaining cells 
were diluted and re-plated in a T25 flask until 24 hours before the next examined time point 
where this process was repeated. 
2.6.2.  Single molecule RNA-FISH.  
Cells were plated on 14 mm round #1 glass coverslips. Following infection, cells 
were briefly washed in room temperature DPBS (with Calcium and Magnesium) 
(14040133, Thermo Fisher) and fixed in 4% PFA in 1x PBS for 10 minutes at room 
temperature. Coverslips were washed twice in room temperature PBS and fixed again at -
20○ C with 70% ethanol for at least two hours. Coverslips were washed twice with 2x SSC 
(AM9770, Thermo Fisher) and washed once with 2x SSC and 10% Formamide (BP227, 
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Fisher Scientific). smFISH probes to different viral RNA species (Figure 2.1A) were 
designed using the Stellaris Probe Designer at https://www.biosearchtech.com/ (Table 
S2.2). Unlabeled smFISH probes had a 3’ modified base with an amine functional group. 
Pools of 48 individual smFISH probes to a particular target RNA were combined at 
equimolar ratios and were covalently labeled with Cy3 (PA23001, GE Healthcare), 
AlexaFluor 568 (A20003, Thermo Fisher), or Cy5 (PA25001, GE Healthcare) as 
previously described (Zenklusen and Singer, 2010). Coverslips were placed face down on 
a 100 ul drop of hybridization mix containing 75 ng of smFISH probe dissolved in 
hybridization buffer composed of 10% dextran sulfate (D8906, Sigma-Aldrich), 2x SSC, 
and 10% Formamide. Hybridization occurred in a humidified chamber at 37○ C overnight. 
Coverslips were washed twice in 2x SSC, 10% formamide at 37○ C for 30 minutes. 
Coverslips were then washed once in 1x PBS. For cellular segmentation, cells were stained 
with HCS CellMask™ Green stain (H32714, Thermo Fisher) diluted at 50 ng/ml in PBS 
for 5 minutes at room temperature (note: this is significantly more dilute than 
recommended in the product information, but we found it necessary to prevent overstaining 
cells and thus to prevent spectral bleed through into the AlexaFluor 568 fluorescence 
channel). Nuclei were stained with 4’, 6-diamidino-2-phenylindole hydrochloride 30 
(DAPI) (D9542, Sigma-Aldrich) at 1 µg/ml in PBS for 5 minutes at room temperature. 
Cells were washed a final time in PBS, briefly washed in water, dried and mounted with 
ProLong Gold Antifade Reagent (P36934, Thermo Fisher). 
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2.6.3.  Image Acquisition.  
Wide-field fluorescent Z-stacks were acquired using a Nikon Ti Eclipse microscope 
with a 60 × 1.4 NA objective. Samples were illuminated with an LED light-source 
(Lumencor Spectra X light engine) with appropriate filter sets and images were captured 
with a Hamamatsu Orca flash 4.0 LT sCMOS camera. Z-stacks were captured at 300 nm 
increments, and the microscope was controlled by Nikon NIS Elements software. Captured 
ND2 images were converted to Tiffs using the open source Bio-formats tool kit 
(http://www.openmicroscopy.org/) (Goldberg et al., 2005). 
2.6.4.  Image Segmentation and Analysis.  
DAPI and CellMask Green Z-stacks were projected using a focus-based projection 
method as previously described (Tsanov et al., 2016). Projected DAPI images were used 
for automatic nuclear segmentation in CellProfiler (Broad Institute) (Kamentsky et al., 
2011) and served as the seed for automatic secondary cellular segmentation using the 
projected CellMask Green images (Figure 2.4A). Statistics including average pixel 
intensity within the regions defined by primary and secondary segmentation were extracted 
from maximum intensity projections of smFISH Z-stacks using CellProfiler (Figure 2.4B 
to D). 
Single smFISH labeled RNAs were detected and localized in 3D using FISH-quant 
(Mueller et al., 2013). Briefly, smFISH Z-stacks were filtered using the “Dual Gaussian 
Filter” and spots were detected using the “Local Maximum” method. As a large number of 
acquired images required analysis, images were analyzed in “Batch Mode” with settings 
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determined to give low rates of false positive detections. The signal-to-noise ratio of 
different smFISH probe sets was determined as the average signal amplitude of identified 
smFISH spots in an individual cell divided by the standard deviation of the fluorescent 
signal in a region of the same cell where smFISH spots were absent (Figure 2.3). 
Box and whisker plots were created using the ggplot2 package in R. The box 
represents the interquartile range of the data with the center line representing the median. 
Individual dots represent cells that are more than 1.5 times the interquartile range away 
from the median of the data. 
  
 85 
 
2.7. Funding Information 
We also gratefully acknowledge funding support from NIH grants T32 
HL076122-10 (BRK), T32 AI055402 (CMZ), R21 AI088059 (JB), and P20RR021905 & 
P30GM118228 (Immunobiology and Infectious Disease COBRE awards) (JB). DZ is 
supported by the Canadian Institute for Health Research (Project Grant-366682), Fond de 
recherche du Quebec (Chercheur-boursier Junior 2), and the Canadian Foundation for 
Innovation. CZ, FM, and AS were supported by Institut Pasteur and the Fondation pour la 
Recherche Médicale (FRM). BRK was supported by a Chateaubriand fellowship from the 
Office for Science & Technology at the Embassy of France in the United States. The 
funders had no role in study design, data collection and analysis, decision to publish, or 
preparation of the manuscript. 
 
 
 
 
 86 
 
2.8. Acknowledgments 
We gratefully acknowledge J. Lindsay Whitton for providing us with LCMV 
strain Arm53b and Samir Rahman, Philippe Clerc, Christian Weber, and Sophie Abélanet 
for technical assistance. We thank Pablo Navarro and Jason Stumpff for graciously offering 
the use of their microscopy equipment and for providing their expertise and Jean-Michel 
Arbona and Wei Ouyang for helpful discussions. 
 
 87 
 
2.9. Tables 
Table 2.1.  Ratio in the expression levels of viral mRNAs in individual infected cells. 
  
Time 
points 
Ratio NP mRNA and S 
antigenome /GPC mRNA and S 
genome (± SD) 
Ratio NP mRNA and S 
antigenome /L mRNA and 
L antigenome (± SD) 
Early time 
points (hpi) 
MOI = 0.1 
0.5 
 
ND 
  
ND 
 
1 
 
ND 
  
ND 
 
2 
 
ND 
  
ND 
 
3 
 
ND 
  
ND 
 
4a 4.3 ± 3.4 
 
ND 
 
6a 6.0 ± 4.0 14.7 ± 9.5 
8 4.9 ± 4.1 14.8 ± 12.1 
10 5.6 ± 5.4 12.5 ± 9.7 
12 5.0 ± 4.9 10.8 ± 9.5 
Peak time 
points (hpi) 
MOI = 0.01 
12 4.6 ± 4.1 8.8 ± 6.7 
24 3.5 ± 3.4 14.8 ± 7.2 
36 2.3 ± 1.9 18.0 ± 12.8 
48 2.2 ± 1.2 28.7 ± 14.8 
60 2.9 ± 1.2 34.1 ± 13.3 
72 2.9 ± 1.1 30.1 ± 16.2 
96 4.0 ± 1.9 24.5 ± 13.4 
Persistent 
time (dpi) 
MOI = 0.01 
1.5 2.3 ± 1.6 10.2 ± 12.3 
4 4.3 ± 2.0 10.5 ± 10.4 
6 3.9 ± 2.4 4.9 ± 6.8 
8 1.0 ± 0.7 2.0 ± 3.0 
13 4.4 ± 2.8 24.1 ± 23.9 
16 1.8 ± 1.7 2.4 ± 3.5 
20 6.2 ± 3.7 28.1 ± 23.5 
23 3.2 ± 2.0 5.8 ± 7.3 
27 4.9 ± 4.2 2.7 ± 4.5 
30 4.0 ± 2.3 9.1 ± 8.9 
34 0.7 ± 1.2 2.2 ± 3.4 
37 4.5 ± 3.8 6.1 ± 9.1 
41 1.0 ± 1.3 7.3 ± 9.0 
aNote that for time points prior to 8 hpi, genomic and antigenomic RNAs are not detectable by FISH probe 
sets with exclusive specificity for these RNAs (data not shown). Therefore, spots detected before 8 hpi are 
presumed to represent only the mRNAs, but not the genome or antigenome, recognized by each respective 
probe set. Spots detect at 8 hpi or later are presumed to be a mixture of all RNAs recognized by a particular 
probe set (e.g. mRNA and genome or antigenome). 
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2.10. Figures 
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Figure 2.1.  LCMV RNA species can be specifically visualized using multiple, singly-labeled 
oligonucleotide smFISH probes. 
(A) Overview of the scheme used by arenaviruses to transcribe and replicate their single-stranded, ambisense, 
bisegmented genome. smFISH probes that recognize the S segment genomic RNA are shown in gray, probes 
that recognize the S segment genome and GPC mRNA are shown in red, probes that recognize the S segment 
antigenome and NP mRNA are shown in green, and probes that recognize the L segment antigenome and L 
mRNA are shown in pink. smFISH probe sets consist of pools of 48 individual 20mer oligonucleotides each 
labeled with a single fluorophore at their 3’ terminus. (B) Uninfected cells were stained with a control 
smFISH probe set specific to the cellular mRNA MDN1 labeled with Cy3. (C) Cells were either infected 
with LCMV at an MOI of 0.01 or, as a control, remained uninfected (mock). Cells were fixed at 24 hpi and 
stained with a Cy5-labeled smFISH probe set specific for S segment genomic RNA and GPC mRNA. Boxed 
regions of the cell are magnified and shown in columns labeled “Zoom”. Green arrows indicate example 
smFISH stained spots most likely representing single labeled RNAs. Nuclear (hatched line) and cytoplasmic 
(solid line) boundaries are shown in blue. The same intensity levels for a particular probe set were applied to 
all images of mock- and LCMV-infected cells to permit comparisons. Scale bars are 10 µm. 
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Figure 2.2.  smFISH probe sets recognizing viral mRNA species exhibit high signal-to-noise staining. 
Mock- or LCMV-infected cells (24 hr pi) were simultaneously stained with smFISH probe sets specific for 
either GPC mRNA and S genome (Cy5; green) or S genome only (AlexaFluor 568; red). Representative 
LCMV infected cells with moderate (A) or high (B) levels of viral RNA as well as a representative mock-
infected cell (C) are displayed. Multiple Z stacks were acquired spanning the thickness of the cell and max 
intensity projections are displayed. Boxed regions of the cell are magnified and shown in rows labeled 
“Zoom”. Nuclear (hatched line) and cytoplasmic (solid line) boundaries are shown in blue. (A to C) The 
same intensity levels for a particular probe set were applied to all images of mock- and LCMV-infected cells 
to permit comparisons. Scale bars are 10 µm.  
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Figure 2.3.  smFISH probe sets recognizing viral mRNA species exhibit high signal-to-noise staining 
Signal-to-noise ratio of different smFISH probe sets labeled with the indicated fluorophores. Signal-to-noise 
ratio was calculated as average amplitude of detected smFISH spots divided by the standard deviation of 
signal in a region of the cell with no detected spots. The signal-to-noise ratio of 20 cells per smFISH probe 
set labeled with the indicated fluorophore was calculated, and the mean and standard deviation are graphed. 
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Figure 2.4.  Automated detection and quantitation of LCMV RNAs labeled with spectrally distinct 
fluorophores. 
(A) Cell nuclei and cytoplasms were automatically segmented using focus-based projections of DAPI 
(nuclei) or CellMask Green (cytoplasm) Z stacks acquired through the thickness of the cell. Note that pixel 
intensities of the CellMask Green projection displayed here have been log transformed to aid visualization. 
Nuclear (hatched line) and cytoplasmic (solid line) boundaries are shown in white. The scale bar is 10 µm. 
(B and C) Maximum intensity projections of LCMV-infected cells were fixed 24 hpi and stained with 
smFISH probe sets to the NP mRNA/S antigenome (Cy5; green) and GPC mRNA/S genome (A568; red). 
The boxed region of each cell is magnified and shown in the row labeled “Zoom”. Cells were segmented 
based on DAPI and CellMask Green staining (see panel A) and spots were detected and localized in 3D using 
FISH-quant. Individually detected RNAs are circled in green (NP mRNA/S antigenome) or red (GPC 
mRNA/S genome). The “Spots only” column shows only the position of detected spots in relation to the cell 
boundaries defined by segmentation. Nuclear (hatched line) and cytoplasmic (solid line) boundaries are 
shown in blue. The same intensity levels for a particular probe set were applied to both images of LCMV-
infected cells to permit comparisons. The scale bar is 10 µm.  
(D) Scatter plot shows the relationship between the fluorescence intensity in the smFISH channel in the 
maximum intensity projection of smFISH images and the number of smFISH spots detected by FISH-quant 
for LCMV-infected cells fixed 24 hpi and stained with the Cy5-labeled smFISH probes specific for NP 
mRNA/S antigenome.  
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Figure 2.5.  Transcription of NP and L genes is detectable soon following infection while GPC 
transcription exclusively occurs after a several hour lag. 
Cells were infected with LCMV at an MOI of 0.1, fixed at various times following infection, and stained for 
NP mRNA (green) using a Cy5-labeled NP mRNA/S antigenome probe set, GPC mRNA (red) using an 
A568-labled GPC mRNA/S genome probe set (A) or NP mRNA (green) using an A568-labeled NP mRNA/S 
antigenome probe set and L mRNA (magenta) using a Quasar 670-labeled L mRNA/L antigenome probe set 
(B). Note that for the time points shown (less than 8 hpi), genomic and antigenomic RNAs are not detectable 
by smFISH probe sets with exclusive specificity for these RNAs (data not shown). Therefore, spots detected 
in this figure are presumed to represent only the mRNAs, but not the genome or antigenome, targeted by 
each respective probe set. Nuclear (hatched line) and cytoplasmic (solid line) boundaries as determined by 
Cell Profiler are shown in blue. Identified spots are outline by circles that are green for NP mRNA, red for 
GPC mRNA, and magenta for L mRNA. (A and B) The same intensity levels for a particular probe set were 
applied to all images of mock- and LCMV-infected cells across the time course to permit comparisons. 
Representative maximum intensity projections from 1 of 2 independent experiments are shown. Scale bar is 
10 µm. 
 
 
 
  
 96 
 
 
 
Figure 2.6.  Transcription of NP and L genes is detectable immediately upon infection while GPC 
transcription exclusively occurs after a several hour lag. 
Related to  Figure 2.5. (A and B) Boxplots represent the number of viral RNAs detected in cells at early time 
points following infection with LCMV (see Figure 2.5). (C and D) Stacked bar graphs show the proportion 
of cells expressing RNAs detected by one, both, or neither viral RNA smFISH probe set. Between 620 and 
1316 cells were examined at each time point (see Table S2.1 for exact numbers). In each case RNAs identified 
by specific probe sets are designated by color (green for NP mRNA/S antigenome probes, red for GPC 
mRNA/S genome probes, and magenta for L mRNA/L antigenome probes). Note that for time points prior 
to 8 hpi, genomic and antigenomic RNAs are not detectable by smFISH probe sets with exclusive specificity 
for these RNAs (data not shown). Therefore, spots detected before 8 hpi are presumed to represent only the 
mRNAs, but not the genome or antigenome, recognized by each respective probe set. Spots detected at 8 hpi 
or later are presumed to be a mixture of all RNAs recognized by a particular probe set (e.g. mRNA and 
genome or antigenome). 
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Figure 2.7.  Peak viral RNA replication and transcription occurs 36 hpi and is slowly lost from infected 
cells over the following days. 
Cells were infected with LCMV at an MOI of 0.01, fixed at various times following infection, and stained 
using smFISH probe sets specific for NP mRNA/S antigenome (Cy5; green) and GPC mRNA/S genome 
(A568; red) (A) or NP mRNA/S antigenome (A568; green) and L mRNA/L antigenome (Quasar 670; 
magenta) (B). (A and B) Representative maximum intensity projections of fields of infected cells at various 
time points from 1 of 2 independent experiments are shown. Each probe set is shown in its own row to 
highlight the difference in levels to which these RNAs accumulate. The same intensity levels for a particular 
probe set were applied to all images of mock- and LCMV-infected cells across the time course to permit 
comparisons. Scale bars = 10 µm. 
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Figure 2.8.  Peak viral RNA replication and transcription occurs 36 hpi and is slowly lost from infected 
cells over the following days. 
Related to  Figure 2.7. (A and B) Boxplots represent the number of mRNAs detected in cells at time points 
during the peak period of LCMV infection. (C and D) Stacked bar graph shows the proportion of cells 
expressing RNAs detected by one, both, or neither viral smFISH probe set. Between 480 and 1659 cells were 
examined at each time point (see Table S2.1 for exact numbers). RNAs identified by specific probe sets are 
designated by color (green for NP mRNA/S antigenome probes, red for GPC mRNA/S genome probes, and 
magenta for L mRNA/L antigenome probes).  
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Figure 2.9.  Cyclic periods of viral RNA production and viral RNA loss occur during persistence. 
Cells were infected with LCMV at an MOI of 0.01, fixed at the indicated time points following infection, 
and stained using smFISH probe sets specific for NP mRNA/S antigenome (Cy5; green) and GPC mRNA/S 
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genome (A568; red) (A) or NP mRNA/S antigenome (A568; green) and L mRNA/L antigenome (Quasar 
670; magenta) (D). (A and D) Representative maximum intensity projections of fields of infected cells at 
various time points from 1 of 2 independent experiments are shown. Each probe set is shown in its own row 
to highlight the difference in levels to which these RNAs accumulate. The same intensity levels for a 
particular probe set were applied to all images of mock- and LCMV-infected cells across the time course to 
permit comparisons. Scale bar is 10 µm. (B and E) Line graphs show the average number of the indicated 
viral RNAs detected in cells at time points during the persistent phase of LCMV infection. (C and F) Stacked 
bar graph shows the proportion of cells expressing RNAs detected by one, both, or neither viral smFISH 
probe set. Between 316 and 1218 cells were examined at each time point (see Table S2.1 for exact numbers). 
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2.12. Supplemental Tables 
Table S2.1.  Number of cells analyzed at each time point in selected Figures 
  
Number of cells analyzed per FISH probe set per time point in Figures 5 & 6 
Hours post infection 
NP mRNA/ S antigenome GPC 
mRNA/ S genome 
L mRNA/L antigenome NP 
mRNA/ S antigenome 
0 752 634 
1 759 659 
2 1228 699 
3 1316 748 
4 1173 691 
6 758 620 
8 1037 645 
10 940 629 
12 1195 740    
 
Number of cells analyzed per FISH probe set per time point in  Figures 7 & 8 
Hours post infection 
NP mRNA/ S antigenome GPC 
mRNA/ S genome 
L mRNA/L antigenome NP 
mRNA/ S antigenome 
0 1119 760 
12 733 494 
24 757 480 
36 731 565 
48 789 585 
60 719 494 
72 886 713 
96 1659 1064    
 Number of cells analyzed per FISH probe set per time point in  Figure 9 
Days post infection 
NP mRNA/ S antigenome GPC 
mRNA/ S genome 
L mRNA/L antigenome NP 
mRNA/ S antigenome 
0 813 787 
1.5 541 440 
4 659 602 
6 1130 649 
8 955 787 
13 649 316 
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16 1006 920 
20 1181 902 
23 997 903 
27 1143 956 
30 1046 874 
34 1183 824 
37 970 802 
41 1218 926 
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Table S2.2.  Full list and sequence of the FISH probes used in the current study 
 
Target Probe Sequence Probe Name Fluorophore 
LCMV S Genome tttagaggcccaaatgttgt LCMV_S_Genome_1 AlexaFluor 568 
LCMV S Genome gctcccagatctgaaaactg LCMV_S_Genome_2 AlexaFluor 568 
LCMV S Genome cactcatggactgcatcatt LCMV_S_Genome_3 AlexaFluor 568 
LCMV S Genome tcgatgttgaaatgaccagg LCMV_S_Genome_4 AlexaFluor 568 
LCMV S Genome ggactcacagaataggaagg LCMV_S_Genome_5 AlexaFluor 568 
LCMV S Genome ccgatgacatcagaaagctt LCMV_S_Genome_6 AlexaFluor 568 
LCMV S Genome atggttctaagctgtcaagg LCMV_S_Genome_7 AlexaFluor 568 
LCMV S Genome tcgtcagttataggtgctct LCMV_S_Genome_8 AlexaFluor 568 
LCMV S Genome gatcttgccgacctcttcaa LCMV_S_Genome_9 AlexaFluor 568 
LCMV S Genome gattccaagtactcacacgg LCMV_S_Genome_10 AlexaFluor 568 
LCMV S Genome ggaacccgttgatcaaaaac LCMV_S_Genome_11 AlexaFluor 568 
LCMV S Genome cgggcagttcatacactttt LCMV_S_Genome_12 AlexaFluor 568 
LCMV S Genome tgatccagtggaaatagcaa LCMV_S_Genome_13 AlexaFluor 568 
LCMV S Genome caacgctcctacatggattg LCMV_S_Genome_14 AlexaFluor 568 
LCMV S Genome tacagccagacaatgctttt LCMV_S_Genome_15 AlexaFluor 568 
LCMV S Genome agaaacctgcagtcaattca LCMV_S_Genome_16 AlexaFluor 568 
LCMV S Genome gcatgggaaaacacaacaat LCMV_S_Genome_17 AlexaFluor 568 
LCMV S Genome gatggccatacatagcttgt LCMV_S_Genome_18 AlexaFluor 568 
LCMV S Genome aaagtttgcctttcaggtga LCMV_S_Genome_19 AlexaFluor 568 
LCMV S Genome caggaacccttatgaaaaca LCMV_S_Genome_20 AlexaFluor 568 
LCMV S Genome ttgtttcagaccaagttggg LCMV_S_Genome_21 AlexaFluor 568 
LCMV S Genome ggccaagagaaaactcaaca LCMV_S_Genome_22 AlexaFluor 568 
LCMV S Genome gacctcttgaaggcagttct LCMV_S_Genome_23 AlexaFluor 568 
LCMV S Genome ttttgatcaagccaagcaac LCMV_S_Genome_24 AlexaFluor 568 
LCMV S Genome aactttagtcttggtgctgc LCMV_S_Genome_25 AlexaFluor 568 
LCMV S Genome gtcatcactgaacagcagtc LCMV_S_Genome_26 AlexaFluor 568 
LCMV S Genome tcttgaaaggctgaaagaca LCMV_S_Genome_27 AlexaFluor 568 
LCMV S Genome ggcttgctttacacagtcaa LCMV_S_Genome_28 AlexaFluor 568 
LCMV S Genome tcaatgacgttgtacaagcg LCMV_S_Genome_29 AlexaFluor 568 
LCMV S Genome ctatggcttgtatggccaaa LCMV_S_Genome_30 AlexaFluor 568 
LCMV S Genome aatcaatttggcacaatgcc LCMV_S_Genome_31 AlexaFluor 568 
LCMV S Genome gggatgtgaaagactcatca LCMV_S_Genome_32 AlexaFluor 568 
LCMV S Genome ttgggatgagaaagcctcag LCMV_S_Genome_33 AlexaFluor 568 
LCMV S Genome gaccaaagatctcagatcct LCMV_S_Genome_34 AlexaFluor 568 
LCMV S Genome gggaacttaacaacacagca LCMV_S_Genome_35 AlexaFluor 568 
LCMV S Genome ccaggcttcaggggtatata LCMV_S_Genome_36 AlexaFluor 568 
LCMV S Genome ccaagatcatgaggtctgaa LCMV_S_Genome_37 AlexaFluor 568 
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LCMV S Genome gctgaccttgagaagctgaa LCMV_S_Genome_38 AlexaFluor 568 
LCMV S Genome cagtgcagaagaactgatgt LCMV_S_Genome_39 AlexaFluor 568 
LCMV S Genome actgtacattctcttgtgga LCMV_S_Genome_40 AlexaFluor 568 
LCMV S Genome gagactcagaagtctcaacc LCMV_S_Genome_41 AlexaFluor 568 
LCMV S Genome aagagagatgacaaagacct LCMV_S_Genome_42 AlexaFluor 568 
LCMV S Genome cttctctgaggtcagcaatg LCMV_S_Genome_43 AlexaFluor 568 
LCMV S Genome ccaaccttctgaatgggttg LCMV_S_Genome_44 AlexaFluor 568 
LCMV S Genome ggctgctgtcattaaggatg LCMV_S_Genome_45 AlexaFluor 568 
LCMV S Genome gcagagcttcacatcagatg LCMV_S_Genome_46 AlexaFluor 568 
LCMV S Genome cgcaagcattgagaagagaa LCMV_S_Genome_47 AlexaFluor 568 
LCMV S Genome aggaagttaagagcttccaa LCMV_S_Genome_48 AlexaFluor 568 
LCMV NP mRNA/ S antigenome ttggaagctcttaacttcct LCMV_NP_mRNA_1 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome ttctcttctcaatgcttgcg LCMV_NP_mRNA_2 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome catctgatgtgaagctctgc LCMV_NP_mRNA_3 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome catccttaatgacagcagcc LCMV_NP_mRNA_4 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome caacccattcagaaggttgg LCMV_NP_mRNA_5 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome cattgctgacctcagagaag LCMV_NP_mRNA_6 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome gttcttctgcactgagcctc LCMV_NP_mRNA_7 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome aggtcagccgcaagagacat LCMV_NP_mRNA_8 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome ctgaagcctggggcctttca LCMV_NP_mRNA_9 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome tgtgttgttaagttccccat LCMV_NP_mRNA_10 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome ctgagatctttggtctagtt LCMV_NP_mRNA_11 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome tcatcccaactatctgtagg LCMV_NP_mRNA_12 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome cttgcaccctgctgaggctt LCMV_NP_mRNA_13 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome gatgagtctttcacatccca LCMV_NP_mRNA_14 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome tgtgccaaattgattgttca LCMV_NP_mRNA_15 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome aagccatagttagacttggc LCMV_NP_mRNA_16 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome gtctgtgactgtttggccat LCMV_NP_mRNA_17 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome ttgtacaacgtcattgagcg LCMV_NP_mRNA_18 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome ttgactgtgtaaagcaagcc LCMV_NP_mRNA_19 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome tgtctttcagcctttcaaga LCMV_NP_mRNA_20 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome gcagcaccaagactaaagtt LCMV_NP_mRNA_21 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome gttgcttggcttgatcaaaa LCMV_NP_mRNA_22 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome gagaactgccttcaagaggt LCMV_NP_mRNA_23 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome tgttgagttttctcttggcc LCMV_NP_mRNA_24 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome cccaacttggtctgaaacaa LCMV_NP_mRNA_25 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome tgttttcataagggttcctg LCMV_NP_mRNA_26 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome tcacctgaaaggcaaacttt LCMV_NP_mRNA_27 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome acaagctatgtatggccatc LCMV_NP_mRNA_28 AlexaFluor 568 or Cy5 
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LCMV NP mRNA/ S antigenome attgttgtgttttcccatgc LCMV_NP_mRNA_29 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome gagttgactgcaggtttctc LCMV_NP_mRNA_30 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome aggtggacctgctgctccag LCMV_NP_mRNA_31 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome cattgtctggctgtagctta LCMV_NP_mRNA_32 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome ctcccatgaggtcttttaaa LCMV_NP_mRNA_33 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome caatccatgtaggagcgttg LCMV_NP_mRNA_34 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome ttgctatttccactggatca LCMV_NP_mRNA_35 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome aaaagtgtatgaactgcccg LCMV_NP_mRNA_36 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome gtttttgatcaacgggttcc LCMV_NP_mRNA_37 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome tgagtacttggaatcttgct LCMV_NP_mRNA_38 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome agaggtcggcaagatccatg LCMV_NP_mRNA_39 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome gtcaacccgggttgcgcatt LCMV_NP_mRNA_40 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome cggaagagcacctataactg LCMV_NP_mRNA_41 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome ttgacagcttagaaccatcc LCMV_NP_mRNA_42 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome gctttctgatgtcatcggag LCMV_NP_mRNA_43 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome ttcctattctgtgagtccag LCMV_NP_mRNA_44 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome aacatcgataagcttaatgt LCMV_NP_mRNA_45 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome tcgaagcttccctggtcatt LCMV_NP_mRNA_46 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome tttcagatctgggagccttg LCMV_NP_mRNA_47 AlexaFluor 568 or Cy5 
LCMV NP mRNA/ S antigenome cacaacatttgggcctctaa LCMV_NP_mRNA_48 AlexaFluor 568 or Cy5 
LCMV GPC mRNA/ S genome agagcctcaaacattgtcac LCMV_GPC_mRNA_1 AlexaFluor 568 
LCMV GPC mRNA/ S genome cacctcatcgatgatgtgag LCMV_GPC_mRNA_2 AlexaFluor 568 
LCMV GPC mRNA/ S genome cgtgatcacgataagcacaa LCMV_GPC_mRNA_3 AlexaFluor 568 
LCMV GPC mRNA/ S genome gcaaaattgtagacagcctt LCMV_GPC_mRNA_4 AlexaFluor 568 
LCMV GPC mRNA/ S genome caatgcgaatatcccacagg LCMV_GPC_mRNA_5 AlexaFluor 568 
LCMV GPC mRNA/ S genome cagccagaagtaggaaactg LCMV_GPC_mRNA_6 AlexaFluor 568 
LCMV GPC mRNA/ S genome cttaagaccgtacatgccac LCMV_GPC_mRNA_7 AlexaFluor 568 
LCMV GPC mRNA/ S genome ctcctttgtaaatgtcgggt LCMV_GPC_mRNA_8 AlexaFluor 568 
LCMV GPC mRNA/ S genome actccactgacttaaattgg LCMV_GPC_mRNA_9 AlexaFluor 568 
LCMV GPC mRNA/ S genome catggtcaggttcagatgtg LCMV_GPC_mRNA_10 AlexaFluor 568 
LCMV GPC mRNA/ S genome gagttgttggctgaacatgc LCMV_GPC_mRNA_11 AlexaFluor 568 
LCMV GPC mRNA/ S genome agaagtccccatactgatgt LCMV_GPC_mRNA_12 AlexaFluor 568 
LCMV GPC mRNA/ S genome cattggtgaaggtcaattct LCMV_GPC_mRNA_13 AlexaFluor 568 
LCMV GPC mRNA/ S genome cagattgcaaaagttgtgac LCMV_GPC_mRNA_14 AlexaFluor 568 
LCMV GPC mRNA/ S genome ggctcgaaactatactcatg LCMV_GPC_mRNA_15 AlexaFluor 568 
LCMV GPC mRNA/ S genome ttccctctgatactgaggtg LCMV_GPC_mRNA_16 AlexaFluor 568 
LCMV GPC mRNA/ S genome ggatactgccttatagttgg LCMV_GPC_mRNA_17 AlexaFluor 568 
LCMV GPC mRNA/ S genome ttatgccattgttgaagtcg LCMV_GPC_mRNA_18 AlexaFluor 568 
LCMV GPC mRNA/ S genome gttctacactggctctgagc LCMV_GPC_mRNA_19 AlexaFluor 568 
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LCMV GPC mRNA/ S genome atctaggactctacctctga LCMV_GPC_mRNA_20 AlexaFluor 568 
LCMV GPC mRNA/ S genome ccccgaaggcagttctaaac LCMV_GPC_mRNA_21 AlexaFluor 568 
LCMV GPC mRNA/ S genome aggtggtcttgccatctgag LCMV_GPC_mRNA_22 AlexaFluor 568 
LCMV GPC mRNA/ S genome gtattggtaactcgtctggc LCMV_GPC_mRNA_23 AlexaFluor 568 
LCMV GPC mRNA/ S genome ccaaaaggacctgcatatgt LCMV_GPC_mRNA_24 AlexaFluor 568 
LCMV GPC mRNA/ S genome ggaaaggagaatcctggaca LCMV_GPC_mRNA_25 AlexaFluor 568 
LCMV GPC mRNA/ S genome agtgaagaacttagtcttct LCMV_GPC_mRNA_26 AlexaFluor 568 
LCMV GPC mRNA/ S genome tgaatgtgcccgctagtctc LCMV_GPC_mRNA_27 AlexaFluor 568 
LCMV GPC mRNA/ S genome ccctgaagagtctgacaaag LCMV_GPC_mRNA_28 AlexaFluor 568 
LCMV GPC mRNA/ S genome gcaataaccacctggattct LCMV_GPC_mRNA_29 AlexaFluor 568 
LCMV GPC mRNA/ S genome tgcagcaagaatcatccatt LCMV_GPC_mRNA_30 AlexaFluor 568 
LCMV GPC mRNA/ S genome tgttcccgaaacacttaagc LCMV_GPC_mRNA_31 AlexaFluor 568 
LCMV GPC mRNA/ S genome tacattgcatttcgcaactg LCMV_GPC_mRNA_32 AlexaFluor 568 
LCMV GPC mRNA/ S genome tcaattagtcgcagcatgtc LCMV_GPC_mRNA_33 AlexaFluor 568 
LCMV GPC mRNA/ S genome ttactcaaagcagccttgtt LCMV_GPC_mRNA_34 AlexaFluor 568 
LCMV GPC mRNA/ S genome aagtgcaaggcagattctac LCMV_GPC_mRNA_35 AlexaFluor 568 
LCMV GPC mRNA/ S genome tcaaagaattcactgttgtt LCMV_GPC_mRNA_36 AlexaFluor 568 
LCMV GPC mRNA/ S genome agtggttcctcatcagtagt LCMV_GPC_mRNA_37 AlexaFluor 568 
LCMV GPC mRNA/ S genome gtaattgcaatatggcaccc LCMV_GPC_mRNA_38 AlexaFluor 568 
LCMV GPC mRNA/ S genome tgttctaggtaccaaaactt LCMV_GPC_mRNA_39 AlexaFluor 568 
LCMV GPC mRNA/ S genome actagtttcgccggtctttg LCMV_GPC_mRNA_40 AlexaFluor 568 
LCMV GPC mRNA/ S genome agtaagaaccattggtgaca LCMV_GPC_mRNA_41 AlexaFluor 568 
LCMV GPC mRNA/ S genome tcactgaagtgggtctcatt LCMV_GPC_mRNA_42 AlexaFluor 568 
LCMV GPC mRNA/ S genome atcggcttcctgttcgattt LCMV_GPC_mRNA_43 AlexaFluor 568 
LCMV GPC mRNA/ S genome gcaggaagatgctgactaga LCMV_GPC_mRNA_44 AlexaFluor 568 
LCMV GPC mRNA/ S genome cttttatgtgcctgtgtgtt LCMV_GPC_mRNA_45 AlexaFluor 568 
LCMV GPC mRNA/ S genome tcctttgttggttaatcggt LCMV_GPC_mRNA_46 AlexaFluor 568 
LCMV GPC mRNA/ S genome caccaggcaccttaaatgca LCMV_GPC_mRNA_47 AlexaFluor 568 
LCMV GPC mRNA/ S genome cgtcttttccagacggtttt LCMV_GPC_mRNA_48 AlexaFluor 568 
LCMV L mRNA/L antigenome ctctcatcctgttctatata LCMV_L_mRNA_1 Quasar 670 
LCMV L mRNA/L antigenome tcccagaaagttgagtttct LCMV_L_mRNA_2 Quasar 670 
LCMV L mRNA/L antigenome caatcagaaccattctgggt LCMV_L_mRNA_3 Quasar 670 
LCMV L mRNA/L antigenome cagcgtgacagcaacttgag LCMV_L_mRNA_4 Quasar 670 
LCMV L mRNA/L antigenome ttgtctgcactgtctatttc LCMV_L_mRNA_5 Quasar 670 
LCMV L mRNA/L antigenome tgtttccacagacttatcgt LCMV_L_mRNA_6 Quasar 670 
LCMV L mRNA/L antigenome tgtctatcagcttgtaacca LCMV_L_mRNA_7 Quasar 670 
LCMV L mRNA/L antigenome caaaactggctggagtgctc LCMV_L_mRNA_8 Quasar 670 
LCMV L mRNA/L antigenome ctgatgcatgccaatttgtt LCMV_L_mRNA_9 Quasar 670 
LCMV L mRNA/L antigenome tggaactaatgtgacacccg LCMV_L_mRNA_10 Quasar 670 
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LCMV L mRNA/L antigenome gatagtagtcttcagggact LCMV_L_mRNA_11 Quasar 670 
LCMV L mRNA/L antigenome ttttcatagagtccataccg LCMV_L_mRNA_12 Quasar 670 
LCMV L mRNA/L antigenome attatgagttgacctcgcat LCMV_L_mRNA_13 Quasar 670 
LCMV L mRNA/L antigenome ggcacatcctcataatttca LCMV_L_mRNA_14 Quasar 670 
LCMV L mRNA/L antigenome atctcttctaaacctgctga LCMV_L_mRNA_15 Quasar 670 
LCMV L mRNA/L antigenome gtttctctttaatttcccac LCMV_L_mRNA_16 Quasar 670 
LCMV L mRNA/L antigenome cttcagggtttactttctga LCMV_L_mRNA_17 Quasar 670 
LCMV L mRNA/L antigenome gagctcagagaattccttga LCMV_L_mRNA_18 Quasar 670 
LCMV L mRNA/L antigenome tcatcactatcagcaaggtt LCMV_L_mRNA_19 Quasar 670 
LCMV L mRNA/L antigenome ctccctgcttaatgttaaga LCMV_L_mRNA_20 Quasar 670 
LCMV L mRNA/L antigenome taacatagagaggagcctct LCMV_L_mRNA_21 Quasar 670 
LCMV L mRNA/L antigenome caactgtctccttctagtat LCMV_L_mRNA_22 Quasar 670 
LCMV L mRNA/L antigenome tactatagcaacaacccacc LCMV_L_mRNA_23 Quasar 670 
LCMV L mRNA/L antigenome aaagcttaccagcctatcat LCMV_L_mRNA_24 Quasar 670 
LCMV L mRNA/L antigenome atgaactcctctttagtgct LCMV_L_mRNA_25 Quasar 670 
LCMV L mRNA/L antigenome cacctttctaaacacctttg LCMV_L_mRNA_26 Quasar 670 
LCMV L mRNA/L antigenome agtccgtaatgctcgaaact LCMV_L_mRNA_27 Quasar 670 
LCMV L mRNA/L antigenome tcagtgaatggtatgtggca LCMV_L_mRNA_28 Quasar 670 
LCMV L mRNA/L antigenome atacattatcgggtgagctc LCMV_L_mRNA_29 Quasar 670 
LCMV L mRNA/L antigenome gtgctgggttggaaattgta LCMV_L_mRNA_30 Quasar 670 
LCMV L mRNA/L antigenome cttagtctagcaactgagct LCMV_L_mRNA_31 Quasar 670 
LCMV L mRNA/L antigenome ctcacagaccctatttgatt LCMV_L_mRNA_32 Quasar 670 
LCMV L mRNA/L antigenome attcttcagagtccagtttt LCMV_L_mRNA_33 Quasar 670 
LCMV L mRNA/L antigenome ctccagtcttctggtataat LCMV_L_mRNA_34 Quasar 670 
LCMV L mRNA/L antigenome atggagtagcaccttgaaga LCMV_L_mRNA_35 Quasar 670 
LCMV L mRNA/L antigenome aattaaatgaccatccgggc LCMV_L_mRNA_36 Quasar 670 
LCMV L mRNA/L antigenome ccttttaggatctgcataga LCMV_L_mRNA_37 Quasar 670 
LCMV L mRNA/L antigenome tcggtgagacagtctttcaa LCMV_L_mRNA_38 Quasar 670 
LCMV L mRNA/L antigenome gcattagcaacaatagggtc LCMV_L_mRNA_39 Quasar 670 
LCMV L mRNA/L antigenome atttctctttgttgggttgg LCMV_L_mRNA_40 Quasar 670 
LCMV L mRNA/L antigenome tatctgacactctgtacctg LCMV_L_mRNA_41 Quasar 670 
LCMV L mRNA/L antigenome tccctcaacttatccattaa LCMV_L_mRNA_42 Quasar 670 
LCMV L mRNA/L antigenome cttatacaccaccttctcag LCMV_L_mRNA_43 Quasar 670 
LCMV L mRNA/L antigenome ggtctcctttgtgatcaaat LCMV_L_mRNA_44 Quasar 670 
LCMV L mRNA/L antigenome caggagtgattgcttccttg LCMV_L_mRNA_45 Quasar 670 
LCMV L mRNA/L antigenome gtgaatctcttcatttgctc LCMV_L_mRNA_46 Quasar 670 
LCMV L mRNA/L antigenome tgctgacagtcaatttcttt LCMV_L_mRNA_47 Quasar 670 
LCMV L mRNA/L antigenome ccagattaacacctggagtt LCMV_L_mRNA_48 Quasar 670 
MDN1 exon tcgttcttggctgcgattaa hsMDN1_exon_1 Cy3 
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MDN1 exon taaggtactcaggacacact hsMDN1_exon_2 Cy3 
MDN1 exon cacagtacagtccttatcca hsMDN1_exon_3 Cy3 
MDN1 exon agcaaatccaaaaggagagg hsMDN1_exon_4 Cy3 
MDN1 exon ttgaaagactggggatgtgt hsMDN1_exon_5 Cy3 
MDN1 exon gcatctgaactctctaggaa hsMDN1_exon_6 Cy3 
MDN1 exon gtgctcttcattcatacagg hsMDN1_exon_7 Cy3 
MDN1 exon cctcaacctgaaatggatca hsMDN1_exon_8 Cy3 
MDN1 exon aaaaccaaggccttctccaa hsMDN1_exon_9 Cy3 
MDN1 exon aaagggagacttctggattg hsMDN1_exon_10 Cy3 
MDN1 exon tcagacgaaacaagatgtcc hsMDN1_exon_11 Cy3 
MDN1 exon accagcacataagacctaag hsMDN1_exon_12 Cy3 
MDN1 exon gaagacttttgcagacagac hsMDN1_exon_13 Cy3 
MDN1 exon acagcattctgagaagcaac hsMDN1_exon_14 Cy3 
MDN1 exon tcctattggtccttccaaca hsMDN1_exon_15 Cy3 
MDN1 exon cctgtcactgcagctaaata hsMDN1_exon_16 Cy3 
MDN1 exon aagctggactttgagaagct hsMDN1_exon_17 Cy3 
MDN1 exon acatctgtgcagcgatacat hsMDN1_exon_18 Cy3 
MDN1 exon atatcctccagaaggatcca hsMDN1_exon_19 Cy3 
MDN1 exon aagagctctccattctccaa hsMDN1_exon_20 Cy3 
MDN1 exon aaatccaggtgccactttca hsMDN1_exon_21 Cy3 
MDN1 exon caatttcctccacagctcaa hsMDN1_exon_22 Cy3 
MDN1 exon atgactgtttagcggtcgat hsMDN1_exon_23 Cy3 
MDN1 exon ccaggtgaattttggtccaa hsMDN1_exon_24 Cy3 
MDN1 exon cagttctctcttatccaggt hsMDN1_exon_25 Cy3 
MDN1 exon gtttctctccagtaagttgg hsMDN1_exon_26 Cy3 
MDN1 exon gaactatcactccaagagtg hsMDN1_exon_27 Cy3 
MDN1 exon aacttcttcaggtgcctgtt hsMDN1_exon_28 Cy3 
MDN1 exon ctcaagggttggtcttttgt hsMDN1_exon_29 Cy3 
MDN1 exon gggcaatcctattacaccaa hsMDN1_exon_30 Cy3 
MDN1 exon ctcagaaagcattgctgtga hsMDN1_exon_31 Cy3 
MDN1 exon gcttccaataacttctgcca hsMDN1_exon_32 Cy3 
MDN1 exon tttgctgacacacactgcaa hsMDN1_exon_33 Cy3 
MDN1 exon atggtagaggttttgccagt hsMDN1_exon_34 Cy3 
MDN1 exon cctgtaatgtgagccaagta hsMDN1_exon_35 Cy3 
MDN1 exon attgacaaccctcaaacggt hsMDN1_exon_36 Cy3 
MDN1 exon gcaagtctgcagtatcactt hsMDN1_exon_37 Cy3 
MDN1 exon atggtccaccggtttataac hsMDN1_exon_38 Cy3 
MDN1 exon gtaagggtagccaaataagc hsMDN1_exon_39 Cy3 
MDN1 exon aagagttcctcaaatgcctc hsMDN1_exon_40 Cy3 
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MDN1 exon gccccaagaacgtaaagttt hsMDN1_exon_41 Cy3 
MDN1 exon ctgtctgtaacaggtctgaa hsMDN1_exon_42 Cy3 
MDN1 exon ttagtctcaggagatcatgc hsMDN1_exon_43 Cy3 
MDN1 exon agcagacttgtgtacatgct hsMDN1_exon_44 Cy3 
MDN1 exon cactgtcttttccatccttg hsMDN1_exon_45 Cy3 
MDN1 exon ccaaatgcttcccatttctc hsMDN1_exon_46 Cy3 
MDN1 exon ttgggcatggttgagtctaa hsMDN1_exon_47 Cy3 
MDN1 exon ctttacagcctgagctaatg hsMDN1_exon_48 Cy3 
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3.1. Abstract 
We report a fluorescence in situ hybridization (FISH) assay that allows the 
visualization of lymphocytic choriomeningitis mammarenavirus (LCMV) genomic RNAs 
in individual cells. We show that viral S segment genomic and antigenomic RNA, along 
with viral nucleoprotein, colocalize in subcellular structures we presume to be viral 
replication factories. These viral RNA structures are highly dynamic during acute infection, 
with the many small foci seen early coalescing into larger perinuclear foci later in infection. 
These late-forming perinuclear viral RNA aggregates are located near the cellular 
microtubule organizing center and colocalize with the early endosomal marker Rab5c and 
the viral glycoprotein in a proportion of infected cells. We propose that the virus is using 
the surface of a cellular membrane bound organelle as a site for the pre-assembly of viral 
components including genomic RNA and viral glycoprotein prior to their transport to the 
plasma membrane where new particles will bud.  
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3.2. Main Text 
The major events of transcription and replication of the arenavirus genomic RNA 
are well understood at a population level (Figure 3.1A) (Fuller-Pace and Southern, 1988; 
Haist et al., 2015). However, technical limitations of Northern blot and quantitative RT-
PCR have hindered our ability to examine these processes in individual cells and to 
visualize these events with subcellular resolution. Recent improvements in fluorescence in 
situ hybridization (FISH) technologies now permit the fluorescent labeling and 
microscopic visualization of RNA species at the single-cell and single-molecule level (Raj 
et al., 2008). This labeling strategy, relying on pools of fluorescently labeled 20mer 
oligonucleotide probes, allows visualization of target RNAs with a high signal-to-noise 
ratio and exquisite specificity (Raj et al., 2008). The replication dynamics of influenza A 
and Rift Valley Fever viruses (an orthomyxovirus and bunyavirus, respectively) have been 
examined using this RNA FISH labeling strategy, and have revealed subcellular sites of 
genomic RNA replication, assembly, and/or selectivity of genome recruitment into 
assembling particles (Chou et al., 2013; Lakdawala et al., 2014; Wichgers Schreur and 
Kortekaas, 2016).  
Arenaviruses, like orthomyxoviruses and bunyaviruses, have a single-stranded, 
segmented, negative-sense RNA genome (Buchmeier et al., 2013). Previous work has 
suggested that the genomic RNA of Tacaribe virus (a New World arenavirus) associates 
with intracellular membranes (Baird et al., 2012). However, fluorescence microscopy 
visualizing the subcellular distribution of viral RNAs (nonspecifically-labeled with a 
chemically modified nucleotide) with various protein markers failed to identify the 
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subcellular compartment targeted by the virus (Baird et al., 2012). In the present study, we 
used pools of singly labeled FISH probes to specifically visualize the genomic RNA of 
lymphocytic choriomeningitis virus (LCMV), the prototypic mammarenavirus, with the 
goal to (i) define the dynamics of genomic RNA replication during the course of acute 
infection, (ii) characterize the subcellular localization of the genomic and antigenomic 
RNA, (iii) identify the membrane-bound compartment targeted by arenavirus genomic 
RNA, and (iv) describe how the virus may be taking advantage of this virus-targeted, 
intracellular compartment. 
The arenaviruses have a bisegmented genome with each genomic segment 
encoding two genes in ambisense polarity (Buchmeier et al., 2013). The S genomic 
segment contains the negative-sense nucleoprotein (NP) gene and the pseudo-positive-
sense glycoprotein precursor (GPC) gene (Figure 3.1A) (Buchmeier et al., 2013). The 
Stellaris Probe Designer tool (Biosearch Technologies, Inc.) was used to design custom 
pools of 3' amine oligo FISH probes that would specifically hybridize to the S genomic or 
S antigenomic RNAs (Figure 3.1A, Table S3.1). Probes were labeled post synthesis with 
Cy3 or Cy5 dyes and purified as described previously (Zenklusen and Singer, 2010). To 
follow the replication dynamics of the S genomic and S antigenomic RNAs, we infected 
A549 cells with LCMV at a MOI of 0.01, fixed infected cells as previously described (Raj 
et al., 2008) at the indicated times post-infection, and performed FISH hybridization with 
S genome and S antigenome probes as previously described (Castelnuovo et al., 2013). 3D 
datasets spanning the entire volume of the cells were acquired using a DeltaVision 
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restoration microscopy system (GE Healthcare), and images were deconvolved using 
softWoRx software. Bright signal was observed in cells infected with LCMV, but very 
little signal was detected in uninfected cells, confirming that FISH probes specifically 
recognize S genome and S antigenome (Figure 3.1B to C). As expected, RNA signal was 
mainly observed in the cytoplasm, where S genome and S antigenome concentrated in 
cytoplasmic foci of varying size, brightness, and subcellular localization (Figure 3.1B to 
C). It is known that genomic and antigenomic RNA is encapsidated by the viral NP 
(Buchmeier et al., 2013). Thus, we stained for both the viral NP and the S genome to 
confirm their colocalization. For joint protein and RNA staining, we combined the 
immunofluorescence and FISH staining protocols as previously described (Song et al., 
2015). NP and S genome strongly colocalized in LCMV-infected cells (Figure 3.1D). The 
line scan of the two fluorescent signals (shown in the inset in Figure 3.1D) further confirms 
the colocalization between NP and S genome (Figure 3.1E). 
Baird et al. (Baird et al., 2012) referred to foci of Tacaribe virus RNA colocalizing 
with viral NP as “replication-transcription complexes.” With the ability to label bona fide 
arenavirus genomic and antigenomic RNA, we next wanted to profile the composition and 
dynamics of these viral replication complexes. We first asked whether S genome and S 
antigenome traffic to distinct subcellular locations or whether they remain associated in the 
same subcellular compartments. We therefore stained for both viral RNAs within the same 
cells and found that S genome and S antigenome exhibit strong colocalization, supporting 
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the idea that the genomic and antigenomic RNAs remain in close spatial proximity at the 
peak of acute infection (Figure 3.1F to G). 
To explore the temporal evolution of viral replication complexes, we next infected 
A549 cells with LCMV, fixed cells at different time points post-infection, and stained for 
S genome and S antigenome (Figure 3.2). At 8 hours post-infection (h p.i.), S genome and 
S antigenome first become visible as small spots that are distributed throughout the 
cytoplasm, likely representing single viral genomes (Figure 3.2). Interestingly, few of these 
individual genome and anti-genome signal co-localize, suggesting that clustering of viral 
RNAs occur at a later stage during infection. At 12 and 24 h p.i., many cytoplasmic S 
genome/S antigenome foci are visible, and their size and intensity progressively increases, 
as well as the frequency of co-localization of genome and anti-genome signal (Figure 3.2). 
At 48 h p.i., in many cells, the multiple bright cytoplasmic foci coalesce into one or a few 
large aggregates located adjacent to the nucleus (Figure 3.2).  
We were intrigued by the perinuclear localization of genomic RNA at the peak of 
acute infection and hypothesized that the arenavirus S genome RNA foci seen earlier in 
infection might be utilizing minus end-directed transport along microtubules to coalesce in 
larger structures near the cell’s microtubule organizing center (MTOC). To test this, we 
stained cells for both gamma-tubulin (a marker of the MTOC) and S genome. Indeed, in 
most cases we found the perinuclear S genome aggregate was located immediately adjacent 
to the MTOC (Figure 3.3A). Previous observations that arenavirus ribonucleoprotein 
complexes copurified with cellular membranes (Baird et al., 2012), together with our 
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observation that perinuclear S genome aggregates concentrate near the MTOC, led us to 
postulate that the S genome could be localizing to endosomal membranes and taking 
advantage of this organelle’s directed transport along microtubules (Nielsen et al., 1999). 
It was previously demonstrated that Rab5c, an early endosomal marker (Bucci et al., 1995), 
was required for the propagation of LCMV (Panda et al., 2011). Rab5c is a Rab GTPase, a 
family of proteins that play critical roles in establishment of vesicular identity, trafficking, 
and effector protein recruitment (Stenmark, 2009). Thus, we hypothesized that S genomic 
RNA may be localizing to Rab5c positive membranes to promote some aspect of the 
LCMV life cycle. To test this, we stained cells infected with LCMV for either 24 or 48 
hours with an antibody specifically recognizing Rab5c and with FISH probes specific for 
S genome. Notably, at 48 h p.i., in a subset of cells, we observed increased levels of Rab5c 
and a perinuclear redistribution of this protein that resulted in strong colocalization with 
viral genome (Figure 3.3B to D). However, the colocalization of S genome appeared highly 
time-dependent as no colocalization was observed at 24 h p.i. (Figure 3B to D). These data 
suggest that Rab5c may play an important role late in the LCMV life cycle, complementing 
previous work showing the importance of Rab5 for arenavirus entry (Martinez et al., 2009; 
Rojek et al., 2008). Furthermore, our observation of Rab5c’s involvement in the replication 
of arenaviral RNA is intriguing in light of other studies showing Rab5c as a cellular 
dependency factor for the replication of Zika virus, a flavivirus (Savidis et al., 2016).  
Our finding that Rab5c colocalizes with LCMV RNA was somewhat surprising 
given that previous work by Baird et al. did not observe any colocalization of Tacaribe 
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virus replication-transcription complexes with endosomal markers, including Rab5a, 
which is closely related to Rab5c (Baird et al., 2012; Bucci et al., 1995). The previous 
studies of Tacaribe virus examined a single time point after infection. Given the temporal 
specificity of the Rab5c-LCMV RNA association observed in the current study, it is 
possible that New World arenaviruses like Tacaribe do associate with endosomal markers, 
but that a kinetic study would be required to uncover such a result. Alternatively, it is 
possible that individual arenaviruses utilize different host machinery for genome 
replication and virus assembly. Indeed, related studies in our laboratory have demonstrated 
that replication of LCMV, but not the New World arenavirus Junín Candid #1, is impaired 
following siRNA silencing of Rab5c (C. M. Ziegler, P. Eisenhauer, J. A. Kelly, L. N. Dang, 
V. Beganovic, E. A. Bruce, B. R. King, D. J. Shirley, M. E. Weir, B. A. Ballif, and J. 
Botten, unpublished results). This result, which confirms the previously demonstrated 
importance of Rab5c for LCMV propagation (Panda et al., 2011), suggests that Old World 
arenaviruses such as LCMV, but not those of the New World lineage, are uniquely 
dependent upon Rab5c for successful completion of the life cycle. Further studies will be 
required to determine the extent to which Rab5c and other proteins in the Rab GTPase 
family are utilized by genetically diverse arenaviruses. 
It is known that arenaviruses bud from the plasma membrane of infected cells 
(Buchmeier et al., 2007). Why, then, would LCMV S genome concentrate on the surface 
of Rab5c positive vesicular structures in infected cells? One possibility is that these 
structures represent sites where different viral components pre-assemble before being 
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trafficked together to the plasma membrane for budding. Indeed, it has been suggested that 
influenza A virus uses Rab11-positive membranes for trafficking of viral 
ribonucleoproteins to the plasma membrane (Amorim et al., 2011; Eisfeld et al., 2011; 
Momose et al., 2011). To test this possibility in the current system, we stained for another 
LCMV structural protein, its glycoprotein (GPC) (monoclonal antibody 33.6 (Weber and 
Buchmeier, 1988)), and S genome at 12, 24, and 48 h p.i.. We found that at 48 h p.i., in 
most cells, there was a high degree of colocalization between GPC and S genome (Figure 
3.3E to G). As with Rab5c, the colocalization between these two viral components was 
variable at different stages of infection, and little colocalization was observed at earlier 
time points (Figure 3.3E to G). As no direct NP-GPC interaction has been reported in the 
literature, GPC recruitment to encapsidated S genomic RNA would likely be dependent on 
the presence of the viral matrix protein, Z, which has been shown to interact with both NP 
and GPC (Capul et al., 2007; Eichler et al., 2004). 
In summary, we describe the use of single-molecule resolution RNA FISH to 
specifically visualize LCMV S genome and S antigenome during the course of acute 
infection. For the first time, we reveal that the S genome and antigenome largely 
colocalize in the same subcellular structures during acute infection. Viral genomic RNA 
is highly dynamic during the course of acute infection with many dim genomic RNA 
foci, likely representing individual viral genomes, progressively increasing in intensity 
and eventually coalescing into larger perinuclear structures, which, in many cells, appear 
to colocalize with the early endosomal marker Rab5c –shown by us and others to have a 
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critical role in supporting the LCMV life cycle (Panda et al., 2011) (C. M. Ziegler, P. 
Eisenhauer, J. A. Kelly, L. N. Dang, V. Beganovic, E. A. Bruce, B. R. King, D. J. Shirley, 
M. E. Weir, B. A. Ballif, and J. Botten, unpublished results). We propose LCMV is using 
this intracellular membrane as a scaffold for genome replication and possibly pre-
assembly of viral components prior to being trafficked to the plasma membrane where 
they will bud as infectious virions. 
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3.5. Figures 
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Figure 3.1. Visualization of S genome and antigenomic RNAs by multiple, singly-labeled FISH probes.  
(A) Diagram showing the transcription and replication scheme of the LCMV S genomic RNA. Briefly, S 
genome serves as the template for the viral polymerase to generate full-length, antigenome replicative 
intermediates. S genome and S antigenome serve as templates for transcription of the NP and GPC mRNAs, 
respectively. FISH probe sets (each containing 48 individual 20mer probes bearing a single fluorophore at 
their 3’ terminus) were used to specifically visualize either the S genomic or S antigenomic RNA.  
(B) Maximum intensity projection of either mock- or LCMV-infected cells (48 h p.i.) stained with S genome 
FISH probes labeled with Cy3.  
(C) Maximum intensity projection of either mock- or LCMV-infected cells (48 h p.i.) stained with S 
antigenome FISH probes labeled with Cy3.  
(D) Single Z stack of either mock- or LCMV-infected cells (48 h p.i.) stained for S genome (Cy5) and LCMV 
nucleoprotein (1-1.3 (from M. Buchmeier, University of California Irvine) [primary antibody] as previously 
described (King et al., 2017); goat, anti-mouse AlexaFluor 488) [secondary antibody]).  
(E) Fluorescence line scan of S genome and NP signals along the line indicated in the inset of the merged 
image in (d).  
(F) Single Z stack of either mock- or LCMV-infected cells (48 h p.i.) stained with S genome (Cy5) and S 
antigenome (Cy3) FISH probes.  
(G) Fluorescence line scan of S genome and S antigenome signals along the line indicated in the inset of the 
merged image in (f). Scale bar = 10 µm. 
  
 129 
 
 
 
Figure 3.2. Dynamics of S genome and S antigenome during acute LCMV infection. 
Cells were infected with LCMV at an MOI of 0.01 or not (mock) and fixed at multiple time points following 
infection. Maximum intensity projections of cells stained with S genome (Cy5) and S antigenome (Cy3) 
FISH probes are presented. Scale bar = 10 µm. 
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Figure 3.3. LCMV S segment genome selectively colocalizes with Rab5c and viral glycoprotein later 
during acute infection.  
(A) At 48 h p.i., perinuclear S genome aggregates localize near the microtubule organizing center (MTOC) 
as visualized by gamma-tubulin (GTU-88, Sigma-Aldrich [primary]; goat, anti-mouse AlexaFluor 488) 
[secondary]) and S genome (Cy5-labeled FISH probes). A maximum intensity projection of a representative 
cell is shown.  
(B) Single Z stack of either mock- or LCMV-infected cells at the indicated time points after infection were 
stained for S genome (Cy5-labeled FISH probes) and Rab5c (sc-365667, Santa Cruz Biotechnology 
[primary]; goat, anti-rabbit AlexaFluor 488) [secondary]).  
(C) Fluorescence line scan of S genome and Rab5c along the line indicated in the inset of the merged image 
at 48 h p.i. (b) is shown.  
(D) The Pearson’s correlation coefficient between S genome and Rab5c fluorescence signal in individual 
infected cells at either 24 or 48 h p.i. was calculated in softWoRx software and the scores of individual cells 
were graphed.  
(E) Single Z stacks of either mock- or LCMV-infected cells that were stained for S genome (Cy5-labeled 
FISH probes) and viral glyocoprotein (GPC) (mouse anti-GPC, 33.6 (from M. Buchmeier, University of 
California Irvine) [primary] at 1:500; goat, anti-mouse AlexaFluor 488) [secondary]) are shown.  
(F) Fluorescence line scan of S genome and GPC along the line indicated in the inset of the merged image at 
48 h p.i. (e) is shown.  
(g) The Pearson’s correlation coefficient between S genome and GPC fluorescence signal in individual 
infected cells at either 12, 24, or 48 h p.i. was calculated in softWoRx software and the scores of individual 
cells were graphed. 
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3.7. Supplemental Table 
Table S3.1.  Full list and sequence of the FISH probes used in the current study. 
 
Target Probe Name Probe Sequence (5' to 3') 
LCMV S Genome Genome 1 tttagaggcccaaatgttgt 
LCMV S Genome Genome 2 gctcccagatctgaaaactg 
LCMV S Genome Genome 3 cactcatggactgcatcatt 
LCMV S Genome Genome 4 tcgatgttgaaatgaccagg 
LCMV S Genome Genome 5 ggactcacagaataggaagg 
LCMV S Genome Genome 6 ccgatgacatcagaaagctt 
LCMV S Genome Genome 7 atggttctaagctgtcaagg 
LCMV S Genome Genome 8 tcgtcagttataggtgctct 
LCMV S Genome Genome 9 gatcttgccgacctcttcaa 
LCMV S Genome Genome 10 gattccaagtactcacacgg 
LCMV S Genome Genome 11 ggaacccgttgatcaaaaac 
LCMV S Genome Genome 12 cgggcagttcatacactttt 
LCMV S Genome Genome 13 tgatccagtggaaatagcaa 
LCMV S Genome Genome 14 caacgctcctacatggattg 
LCMV S Genome Genome 15 tacagccagacaatgctttt 
LCMV S Genome Genome 16 agaaacctgcagtcaattca 
LCMV S Genome Genome 17 gcatgggaaaacacaacaat 
LCMV S Genome Genome 18 gatggccatacatagcttgt 
LCMV S Genome Genome 19 aaagtttgcctttcaggtga 
LCMV S Genome Genome 20 caggaacccttatgaaaaca 
LCMV S Genome Genome 21 ttgtttcagaccaagttggg 
LCMV S Genome Genome 22 ggccaagagaaaactcaaca 
LCMV S Genome Genome 23 gacctcttgaaggcagttct 
LCMV S Genome Genome 24 ttttgatcaagccaagcaac 
LCMV S Genome Genome 25 aactttagtcttggtgctgc 
LCMV S Genome Genome 26 gtcatcactgaacagcagtc 
LCMV S Genome Genome 27 tcttgaaaggctgaaagaca 
LCMV S Genome Genome 28 ggcttgctttacacagtcaa 
LCMV S Genome Genome 29 tcaatgacgttgtacaagcg 
LCMV S Genome Genome 30 ctatggcttgtatggccaaa 
LCMV S Genome Genome 31 aatcaatttggcacaatgcc 
LCMV S Genome Genome 32 gggatgtgaaagactcatca 
LCMV S Genome Genome 33 ttgggatgagaaagcctcag 
LCMV S Genome Genome 34 gaccaaagatctcagatcct 
LCMV S Genome Genome 35 gggaacttaacaacacagca 
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LCMV S Genome Genome 36 ccaggcttcaggggtatata 
LCMV S Genome Genome 37 ccaagatcatgaggtctgaa 
LCMV S Genome Genome 38 gctgaccttgagaagctgaa 
LCMV S Genome Genome 39 cagtgcagaagaactgatgt 
LCMV S Genome Genome 40 actgtacattctcttgtgga 
LCMV S Genome Genome 41 gagactcagaagtctcaacc 
LCMV S Genome Genome 42 aagagagatgacaaagacct 
LCMV S Genome Genome 43 cttctctgaggtcagcaatg 
LCMV S Genome Genome 44 ccaaccttctgaatgggttg 
LCMV S Genome Genome 45 ggctgctgtcattaaggatg 
LCMV S Genome Genome 46 gcagagcttcacatcagatg 
LCMV S Genome Genome 47 cgcaagcattgagaagagaa 
LCMV S Genome Genome 48 aggaagttaagagcttccaa 
LCMV S Antigenome Antigenome 1 ggtgtaaaaaccgtctggaa 
LCMV S Antigenome Antigenome 2 accgattaaccaacaaagga 
LCMV S Antigenome Antigenome 3 ataaaaggtggctcatgtcc 
LCMV S Antigenome Antigenome 4 ctagtcagcatcttcctgca 
LCMV S Antigenome Antigenome 5 gatgttttccacatctgcat 
LCMV S Antigenome Antigenome 6 ccctagcattgatggacctt 
LCMV S Antigenome Antigenome 7 aacaggaagccgataacatg 
LCMV S Antigenome Antigenome 8 aaatgagacccacttcagtg 
LCMV S Antigenome Antigenome 9 gcttgtcaccaatggttctt 
LCMV S Antigenome Antigenome 10 gaaactagtgtccccaagtg 
LCMV S Antigenome Antigenome 11 acctagaacatgcaaagacc 
LCMV S Antigenome Antigenome 12 gggtgccatattgcaattac 
LCMV S Antigenome Antigenome 13 actactgatgaggaaccact 
LCMV S Antigenome Antigenome 14 gtagaatctgccttgcactt 
LCMV S Antigenome Antigenome 15 aggctgctttgagtaagttc 
LCMV S Antigenome Antigenome 16 gctgcgactaattgactaca 
LCMV S Antigenome Antigenome 17 tcatgatgccgaattctgtg 
LCMV S Antigenome Antigenome 18 cagttgcgaaatgcaatgta 
LCMV S Antigenome Antigenome 19 gcttaagtgtttcgggaaca 
LCMV S Antigenome Antigenome 20 aatggatgattcttgctgca 
LCMV S Antigenome Antigenome 21 agaatccaggtggttattgc 
LCMV S Antigenome Antigenome 22 acattcacctggactttgtc 
LCMV S Antigenome Antigenome 23 tcttcactaggagactagcg 
LCMV S Antigenome Antigenome 24 tctcctttcccaagagaaga 
LCMV S Antigenome Antigenome 25 acatatgcaggtccttttgg 
LCMV S Antigenome Antigenome 26 atagaacctgggaaaaccac 
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LCMV S Antigenome Antigenome 27 gccagacgagttaccaatac 
LCMV S Antigenome Antigenome 28 atgtttagaactgccttcgg 
LCMV S Antigenome Antigenome 29 agtgtagaaccttcagaggt 
LCMV S Antigenome Antigenome 30 ctcagatcgacaaagtgctc 
LCMV S Antigenome Antigenome 31 cagtatcctgcgacttcaac 
LCMV S Antigenome Antigenome 32 tcagagggaactccaactat 
LCMV S Antigenome Antigenome 33 tagtttcgagcctacacctc 
LCMV S Antigenome Antigenome 34 tttgaccacacactcatgag 
LCMV S Antigenome Antigenome 35 ttttgcaatctgacctctgc 
LCMV S Antigenome Antigenome 36 agaattgaccttcaccaatg 
LCMV S Antigenome Antigenome 37 acatcagtatggggacttct 
LCMV S Antigenome Antigenome 38 gcatgttcagccaacaactc 
LCMV S Antigenome Antigenome 39 cacatctgaacctgaccatg 
LCMV S Antigenome Antigenome 40 ccaatttaagtcagtggagt 
LCMV S Antigenome Antigenome 41 acccgacatttacaaaggag 
LCMV S Antigenome Antigenome 42 gtggcatgtacggtcttaag 
LCMV S Antigenome Antigenome 43 cagtttcctacttctggctg 
LCMV S Antigenome Antigenome 44 cctgtgggatattcgcattg 
LCMV S Antigenome Antigenome 45 aaggctgtctacaattttgc 
LCMV S Antigenome Antigenome 46 ttgtgcttatcgtgatcacg 
LCMV S Antigenome Antigenome 47 ctcacatcatcgatgaggtg 
LCMV S Antigenome Antigenome 48 gtgacaatgtttgaggctct 
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4.1. Abstract 
Arenaviruses are enveloped negative-strand RNA viruses that cause significant 
human disease. Encoding only four proteins to accomplish the viral life cycle, each 
arenavirus protein likely plays unappreciated accessory roles during infection. Here, we 
used immunoprecipitation and mass spectrometry to identify human proteins that interact 
with the nucleoprotein (NP) of the Old World arenavirus lymphocytic choriomeningitis 
(LCMV) and the New World arenavirus Junín Candid #1 (JUNV). Bioinformatic analysis 
of the identified protein partners of NP revealed that host translation appears to be a key 
biological process engaged during infection. In particular, NP associates with the dsRNA-
activated protein kinase (PKR), a well-characterized antiviral protein that inhibits cap-
dependent protein translation initiation via phosphorylation of eIF2α. JUNV infection leads 
to increased expression of PKR as well as its redistribution to viral replication and 
transcription factories. Further, phosphorylation of PKR, which is a prerequisite for its 
ability to phosphorylate eIF2α, is readily induced by JUNV. However, JUNV prevents this 
pool of activated PKR from phosphorylating eIF2α, even following exposure to the 
synthetic dsRNA poly(I:C), a potent PKR agonist. This blockade of PKR function was 
highly specific as LCMV was unable to similarly inhibit eIF2α phosphorylation. JUNV’s 
ability to antagonize the antiviral activity of PKR appears to be complete as silencing of 
PKR expression had no impact on viral propagation. In summary, we have provided a 
detailed map of the host machinery engaged by the arenavirus NP and identified an 
antiviral pathway that is subverted by JUNV. 
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4.2. Importance 
Arenaviruses are important human pathogens for which FDA-approved vaccines 
do not exist and effective antiviral therapeutics are needed. Design of antiviral treatment 
options and elucidation of the mechanistic basis of disease pathogenesis will depend on an 
increased basic understanding of these viruses and, in particular, their interactions with 
host cell machinery. Identifying host proteins critical for the viral life cycle and/or 
pathogenesis represents a useful strategy to uncover new drug targets. This study, for the 
first time, reveals the extensive human protein interactome of the arenavirus nucleoprotein 
and uncovers a potent antiviral host protein that is neutralized during Junín virus infection. 
In so doing, we have gained further insight into the interplay between the virus and the host 
innate immune response and provided an important dataset for the field. 
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4.3. Introduction 
The arenaviruses are a family of enveloped RNA viruses that can cause severe 
human disease. In particular, several family members, including Lassa virus (LASV) and 
Junín virus (JUNV), cause hemorrhagic fever syndromes (Buchmeier et al., 2007). 
Additionally, lymphocytic choriomeningitis virus (LCMV), which has a global 
distribution, is an underappreciated human pathogen that represents a significant 
teratogenic threat to developing fetuses and is a danger to immunosuppressed populations 
(Buchmeier et al., 2007; Fischer et al., 2006). There are currently no FDA-approved 
vaccines to prevent arenavirus infection and effective antiviral treatments are limited (Enria 
et al., 2008; McCormick et al., 1986). Several of the arenaviruses require biosafety level 
(BSL)-4 containment and are designated as Select Agents and potential bioterrorism threats 
(Botten et al., 2013). This highlights the critical need for new prevention and treatment 
options for these dangerous viruses, and the successful development of a next generation 
antiviral therapeutic will depend on an improved understanding of the basic biology of the 
arenavirus life cycle. 
Arenaviruses have a single-stranded, bisegmented negative-sense RNA genome. 
Each genomic RNA segment contains 2 open reading frames arranged in an ambisense 
fashion (Buchmeier et al., 2001). The virus encodes only 4 proteins: the nucleoprotein (NP) 
and glycoprotein (GPC) on the S genomic segment and the RNA-dependent RNA 
polymerase (L) and viral matrix protein (Z) on the L genomic segment (Buchmeier et al., 
2001). These four viral proteins are sufficient to achieve all of the steps of the viral life 
cycle. Nevertheless, it is likely that each is highly multifunctional and relies upon 
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interactions with multiple host proteins to facilitate key steps of the viral life cycle and/or 
to subvert an effective host immune response. 
The canonical role of the arenavirus NP is to encapsidate the viral genomic RNA 
and aid the viral polymerase in the process of genome replication (Buchmeier et al., 2001). 
NP also acts to prevent the induction of type I IFN via its ability to degrade dsRNA 
substrates that could activate cytoplasmic RIG-I like receptors (Hastie et al., 2011a; Qi et 
al., 2010). Work by other groups has already demonstrated the ability of the arenavirus NP 
to engage in protein-protein interactions with host cellular proteins. However, only a few 
host factors engaged by NP are known and the functional importance of these interactions 
necessitates further investigation. Among the Old World arenaviruses, it was demonstrated 
that ALIX/AIP1, an endosomal sorting complex required for transport (ESCRT) associated 
protein, associates with NP and is necessary for the efficient recruitment of NP into Z-
induced virus like particles (Shtanko et al., 2011). LCMV NP has been shown to interact 
with IKKε, which contributes to its repression of type I IFN induction (Pythoud et al., 
2012). Keratin 1, also an interacting partner of LCMV NP, is important for the virus’s 
ability to spread from cell to cell (Labudova et al., 2009). The New World arenavirus JUNV 
NP was shown to associate with eIF4A and eIF4GI, and these interactions were important 
for translation of viral mRNAs (Linero et al., 2013). Last, JUNV NP was shown to interact 
with hnRNP A/B proteins, which were required for viral propagation (Maeto et al., 2011). 
While a small number of cellular proteins have been shown to interact and/or colocalize 
with the arenavirus NP, a large-scale mapping of the host cellular interactome of NP is 
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necessary to fully appreciate the multifunctional role that this viral protein plays during the 
viral life cycle. 
Besides our appreciation of NP’s role in interfering with type I IFN induction and 
its interaction with a handful of cellular proteins, little is known about the additional 
accessory role(s) NP may play in the infected cells and how these may be affected by its 
interaction with host proteins. To address this gap in our knowledge, we mapped the 
cellular protein interactome of the arenavirus NP using LCMV, an Old World arenavirus 
member, and the New World JUNV strain Candid #1 (Goni et al., 2006). Our studies 
revealed that the arenavirus NP interacts with an extensive array of cellular proteins. In 
particular, host protein translation appears to be a major cellular function targeted by the 
arenavirus NP. We identified that the double-stranded RNA-activated protein kinase 
(PKR), an important antiviral effector, interacts with both the JUNV and LCMV NP. We 
show that, despite becoming highly activated during JUNV infection, PKR is unable to 
carry out its canonical antiviral function, which is to phosphorylate eIF2α and trigger a 
global shutdown of cap-dependent translation. LCMV similarly activates PKR but, unlike 
JUNV, appears unable to fully suppress PKR’s kinase activity as transient eIF2α 
phosphorylation occurs during LCMV infection. Nevertheless, the replication of both 
viruses was unaffected by PKR silencing suggesting that arenaviruses have developed 
strategies to neutralize this critical arm of the host innate immune response. 
 144 
 
4.4. Results 
4.4.1.  Identification of human proteins that associate with the arenavirus 
nucleoprotein.  
Viruses hijack cellular factors to complete necessary steps of their life cycle and/or 
to evade the host immune response. Thus, discovering these host factors has the potential 
to identify drug targets or help illuminate cellular pathways targeted by the virus. To 
identify the cellular protein partners of the arenavirus NP, we employed a strategy in which 
human cells (A549 or HEK 293T) were first infected with either the Old World arenavirus 
LCMV strain Armstrong 53b or the New World arenavirus JUNV strain Candid #1 
(hereafter referred to as JUNV) (Figure 4.1A). Following establishment of acute infection, 
each NP and its associated cellular protein partners were immunoprecipitated from cell 
lysates using an NP-specific monoclonal antibody. The immune complexes were separated 
by SDS-PAGE, and stained with Coomassie blue to allow visualization of the captured NP 
(bait) as well as its interacting host proteins (the prey) (Figure 4.1B to E). The stained SDS-
PAGE gels were cut into sections, and the proteins contained in each section were digested 
with trypsin and extracted for subsequent liquid chromatography tandem mass 
spectrometry (LC-MS/MS). Identified proteins were considered valid interactors in a given 
run when i) 2 or more unique tryptic peptides were detected from a particular protein in the 
infected sample but not the mock control or ii) when a minimum of five-fold more total 
tryptic peptides was detected from a particular protein in the infected sample compared to 
the mock control. Using these criteria, we identified 509 human proteins that associated 
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with JUNV NP and 348 that associated with LCMV NP in at least one experiment (Figure 
4.1F and Table S4.1). Of these proteins, 275 had a conserved interaction with JUNV NP 
and LCMV NP (Figure 4.1F). Additionally, there was a high degree of reproducibility 
when comparing the interacting host proteins between the 2 human cell lines, HEK 293T 
and A549, where 83% of interacting proteins identified in HEK 293T cells were also 
observed in A549 cells (Figure 4.1G). Thus, this data set represents the first large-scale 
map of the arenavirus NP-human protein interactome. 
4.4.2.  Cellular processes targeted by the arenavirus NP.  
We were especially interested in the 275 proteins that exhibited a conserved 
interaction with both JUNV NP and LCMV NP as these could represent fundamental and 
highly conserved aspects of arenavirus biology. Indeed, conserved hits for both viruses 
were, on average, identified by more spectral counts than those of JUNV NP or LCMV NP 
alone (Figure 4.2A). Because the strongest interactors were likely those identified by 
multiple tryptic peptides, we examined in greater detail the “strong interactors” which were 
in the top 25% of all interacting host proteins by spectral counts (Figure 4.2A and Table 
4.1). However, it should be noted that the mass spectrometry approach used in this study 
is semi-quantitative. It is possible that a strong, specific interacting cellular protein may 
not be detected at all or only at very low levels for technical reasons. Nevertheless, to better 
characterize the subset of proteins detected by the highest number spectral counts, we used 
the NIH DAVID functional annotation and gene-enrichment tool (Huang et al., 2009a, b) 
to identify functional groups of proteins that may be over-represented in our dataset. Of 
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the annotation clusters identified within this group, protein translation was the top process 
engaged by the arenavirus NP (Figure 4.2B), suggesting that this may be a key cellular 
process regulated by the virus during infection. Two important host protein partners 
involved in translation were eukaryotic translation initiation factor 2 subunit alpha, eIF2α, 
a translation initiation factor critical for the cap-dependent assembly of the 43S ribosomal 
preinitiation complex (Garcia et al., 2007), and the double-stranded RNA-activated protein 
kinase, PKR, which can lead to arrest of cellular translation in response to viral infection 
via phosphorylation of eIF2α (Garcia et al., 2007) (Table 4.1 and S4.1). In addition, NIH 
DAVID analysis on the subset of proteins interacting with only the JUNV NP or the LCMV 
NP revealed functional processes of nucleotide binding or organelle/nuclear lumen being 
engaged by the respective NPs (Figure 4.2D and E). Functional categories enriched in this 
“strong interactor” subset were very similar to those categories represented by the dataset 
as a whole (Figure 4.2B and C).  
4.4.3.  Biochemical validation of the interaction between cellular proteins and 
arenavirus NPs.  
We next chose a subset of the identified host proteins and attempted to further 
validate their association with a particular arenavirus NP via immunoprecipitation and 
Western blot. This subset of proteins included PKR, eIF2α, and Ras GTPase-activating 
protein-binding protein 1 (G3BP1) (proteins involved in translation); splicing factor, 
proline- and glutamine-rich (SFPQ) (part of several top clusters identified by the DAVID 
analysis including RNA processing, binding, and stability); and apoptosis-inducing factor 
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1, mitochondrial (AIFM1) (the most abundantly detected interacting partner of JUNV NP 
and identified as being part of the organelle/nuclear lumen cluster by the DAVID analysis). 
Each protein, with the exception of AIFM1, co-immunoprecipitated as prey with NP (bait) 
from cells infected with JUNV or LCMV (Figure 4.3A, lane 3; Figure 4.3B, lane 3). 
AIFM1 interacted specifically with JUNV NP but not LCMV NP while eIF2α interacted 
weakly with LCMV NP compared to JUNV NP. Reciprocally, PKR, G3BP1, and AIFM1, 
when serving as bait for immunoprecipitation from JUNV or LCMV-infected lysates, were 
each able to co-precipitate both viral NPs, but JUNV NP interacted more strongly with 
both AIFM1 and PKR when compared to LCMV NP (Figure 4.3C to H). Finally, we 
addressed whether this subset of host proteins could associate with an arenavirus NP in the 
absence of other viral proteins or the full viral genome. G3BP1, eIF2α, AIFM1, and SFPQ 
interact with Lassa virus, LCMV, and JUNV NP (expressed via plasmid in HEK 293T 
cells) while PKR only associates with JUNV NP (Figure 4.4A). Notably, the strength of 
interaction between each host protein and a particular NP was variable (Figure 4.4A). 
Additionally, immunoprecipitation of PKR and AIFM1 from transfected HEK 293T cells 
was able to co-precipitate each of arenaviral NPs tested (Figure 4.4B and C). 
4.4.4.  PKR and G3BP1 colocalize with JUNV NP.  
We next used fluorescence microscopy to determine whether PKR and G3BP1 were 
recruited to the replication and transcription factories of JUNV or LCMV. In JUNV-
infected cells, at 72 hours post-infection (hpi), the majority of the cells were infected, and 
NP formed large, perinuclear puncta in most cells (Figure 4.5A). At 48 hpi in LCMV-
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infected cells, most cells were infected and displayed a variable pattern of cytoplasmic NP 
staining. LCMV NP concentrated into puncta that were either small and scattered through 
the cytoplasm or large and located near the nucleus (Figure 4.5B). In the setting of JUNV 
infection, total PKR signal increased compared to mock cells (Figure 4.5A). While PKR 
staining was cytoplasmic in both infected and uninfected cells, JUNV infection resulted in 
a relocalization and concentration of PKR in JUNV NP-containing puncta (Figure 4.5A, 
see fluorescence intensity profiles). This was specific to JUNV as PKR protein levels were 
not upregulated in LCMV-infected cells and PKR remained diffusely localized, without 
specifically colocalizing with LCMV NP (Figure 4.5B, see fluorescence intensity profiles). 
This finding is consistent with biochemical evidence suggesting that PKR has a stronger 
association with JUNV NP compared to LCMV NP (Figure 4.3C and D and 4.4A).  
G3BP1 generally displayed a diffuse cytoplasmic staining pattern in uninfected 
cells (Figure 4.6), although some minority of uninfected cells spontaneously displayed 
distinct cytoplasmic puncta of G3BP1 staining in presumed stress granule structures 
(Figure 4.6A). Similar to PKR, a portion of the cytoplasmic G3BP1 concentrated in JUNV 
NP puncta (Figure 4.6A, see fluorescence intensity profiles). In LCMV-infected cells, 
G3BP1 maintained a predominantly diffuse cytoplasmic staining pattern with slight 
enrichment at NP puncta (Figure 4.6B, see fluorescence intensity profiles). 
Collectively, these experiments further validate the biological interaction of PKR 
and G3BP1 with JUNV NP and define these host proteins as components/markers of 
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presumptive viral replication and transcription factories. Further, they show the specificity 
of the NP-PKR interaction for JUNV. 
4.4.5.  PKR is activated following JUNV infection but does not phosphorylate eIF2α.  
Because of the importance of PKR as an antiviral innate immune mediator (Garcia 
et al., 2007) and the specificity of the interaction with the JUNV NP (Figure 4.3C and D, 
4.4A, and 4.5), we next sought to functionally characterize the importance of this 
interaction in the context of both New World and Old World arenavirus infections. Over a 
time course of acute infection, cellular protein lysates were probed for phospho-PKR 
(T446), a phosphorylation site in the activation loop and a marker of activated PKR. We 
also probed for phospho-eIF2α (S51), the target of PKR’s kinase activity and a marker of 
global translational shutdown. Both expression and phosphorylation of PKR were strongly 
induced late in infection with JUNV, yet there was no concomitant increase in the 
phosphorylation of PKR’s target, eIF2α, at these time points (Figure 4.7A to C). In LCMV-
infected cells, overall PKR levels did not increase but there was an induction of 
phosphorylation of PKR at 36 and 48 hpi. However, in contrast to JUNV, there was a small 
yet significant increase in the phosphorylation of eIF2α at these time points (Figure 4.7D 
to F). This suggested an ability of JUNV to prevent activated PKR from phosphorylating 
its target eIF2α.  
4.4.6.  JUNV infection blocks poly(I:C)-induced phosphorylation of eIF2α.  
The observation that PKR was highly activated (phosphorylated) in JUNV-infected 
cells, yet this activated PKR failed to phosphorylate eIF2α, suggested that the virus was 
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evading this innate surveillance pathway. To determine whether we could overcome the 
ability of the virus to block active PKR from phosphorylating eIF2α, we transfected cells 
with poly(I:C), a synthetic dsRNA analog that strongly activates PKR (Garcia et al., 2007). 
When comparing mock-cells that had been transfected with lipofectamine but no poly(I:C) 
(vehicle control) to those transfected with increasing quantities of poly(I:C), 
phosphorylation of PKR was effectively induced by increasing concentrations of poly(I:C) 
(Figure 4.8A, B, E, and F). In JUNV-infected cells, there were already high levels of 
phospho-PKR (Figure 4.8A and B). However, transfection with poly(I:C) further increased 
the induction of PKR phosphorylation (Figure 4.8A and B). In mock-infected cells, the 
increased PKR phosphorylation following poly(I:C) transfection led to increased 
phosphorylation of eIF2α (Figure 4.8A, C, E, and G). However, there was no increase in 
the phosphorylation of eIF2α in JUNV-infected cells (Figure 4.8A and C). In LCMV-
infected cells, phosphorylation of PKR could be further induced following poly(I:C) 
transfection (Figure 4.8E and F). However, this active PKR was able to phosphorylate 
eIF2α and there was no difference between phospho-eIF2α in mock-infected and LCMV-
infected cells following poly(I:C) transfection (Figure 4.8E and G). Thus, JUNV appears 
to specifically block activated PKR from phosphorylating its downstream target, eIF2α. 
4.4.7.  JUNV selectively blocks PKR’s functionality.  
Though activated PKR’s canonical target is eIF2α, PKR can also activate alternate 
signaling pathways. Among these alternate pathways is the activation of NF-κB signaling 
(Zamanian-Daryoush et al., 2000), through an incompletely defined pathway. While the 
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exact mechanism is unclear, it is known that IκB is degraded following PKR activation and 
that this allows the nuclear translocation of the NF-κB transcription factor, and subsequent 
expression of NF-κB responsive genes (Zamanian-Daryoush et al., 2000). To determine 
whether this alternate PKR signaling pathway remained functional in cells expressing 
arenavirus NPs, we also probed cellular protein lysates for IκB to see if it was degraded 
following poly(I:C) transfection as would be expected. We saw that whether cells were 
uninfected or infected with JUNV or LCMV, they were able to efficiently degrade IκB 
following transfection with poly(I:C), suggesting that this alternate PKR signaling function 
remains intact (Figure 4.8A, D, E, and H). An alternate possibility is that the observed IκB 
degradation could be the result of signaling downstream of other innate immune sensors 
capable of responding to dsRNA such as TLR3, RIG-I, or MDA5 (Kawai and Akira, 2008). 
4.4.8.  Translational profile of cells infected with JUNV or LCMV.  
We wanted to examine whether eIF2α phosphorylation observed in LCMV- but not 
JUNV-infected cells (Figure 4.7 and 4.8) was functionally correlated with repression of 
global translation in these cells. To assess rates of active translation, we utilized a newly 
described assay to examine protein translation levels in individual cells infected with either 
LCMV or JUNV (David et al., 2012; Schmidt et al., 2009). At various time points 
following infection, cells were pulse-labeled with puromycin, which is covalently 
incorporated into growing peptide chains. Nascent peptides were detected with a 
puromycin-specific monoclonal antibody, and were visualized by confocal microscopy. 
Mock-infected cells were labeled with puromycin to determine normal translation rates 
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whereas mock-infected cells that were pre-treated with sodium arsenite were labeled to 
determine protein production levels in a repressed translational state (Figure 4.9A to D). 
While cells infected with either LCMV or JUNV exhibited reduced rates of translation 
compared to uninfected cells, the biological importance of this subtle decrease is unclear 
as the majority of cells maintained translation rates that were in the “normal range” 
observed in mock-infected cells (Figure 4.9A to D). However, at intermediate time points 
following infection with LCMV (24-36 hpi), there was a significant increase in cells 
exhibiting translation rates that were highly reduced compared to mock-infected cells 
(Figure 4.9A, C, and E). A similar pattern was not observed in JUNV-infected cells (Figure 
4.9B, D, and E). These data further support the observations shown in Figures 4.7 and 4.8 
that LCMV is more sensitive than JUNV to PKR-dependent phosphorylation of eIF2α. 
Importantly, these experiments demonstrate that, in most instances, JUNV and LCMV are 
capable of infecting host cells without inducing a potent global shutdown of translation, 
despite highly activating PKR. 
4.4.9.  Replication of influenza A virus lacking expression of the NS1 protein is 
rescued by siRNA knockdown of PKR.  
We wanted to examine whether arenavirus growth would be affected by the 
knockdown of PKR by siRNA. In order to validate our siRNA knockdowns, we infected 
siRNA treated cells with an influenza A virus (strain Pan-delNS1) lacking expression of 
the nonstructural protein NS1, a well-documented PKR antagonist (Bergmann et al., 2000; 
Hatada et al., 1999), to demonstrate that we were able to effectively knockdown PKR 
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expression to a level that could functionally rescue the replication of this highly PKR-
sensitive virus. Protein levels of PKR were greatly reduced in cells transfected with a PKR-
specific siRNA compared to a scrambled, non-targeting control siRNA (Figure 4.10A). As 
expected, the level of viral nucleoprotein in cells and the quantity of released infectious 
virus by cells infected with the wild type parental strain Pan/99 were unaffected by PKR 
knockdown (Figure 4.10A to C). However, when cells were infected with the mutant Pan-
delNS1, viral nucleoprotein was expressed at higher levels (~eight fold) and significantly 
more (~six-fold) infectious virus was released from cells where PKR had been knocked 
down following siRNA transfection (Figure 4.10A to C). Together these results show that 
our knockdown of PKR by siRNA is sufficient to rescue a PKR-sensitive virus. 
4.4.10.  JUNV’s antagonism of PKR’s antiviral activity is complete.  
We next wished to test whether PKR, which appears unable to phosphorylate its 
downstream substrate, eIF2α, during JUNV infection (Figure 4.7A and C), could still exert 
an antiviral effect on the propagation of JUNV. Additionally, we were curious if 
knockdown of PKR could improve the replication of LCMV by preventing the activation 
of eIF2α (Figure 4.7 and 4.8) and the transient translation repression (Figure 4.9) observed 
during LCMV infection. To do so, we measured the levels of NP produced in infected cells 
(Figure 4.11A, B, D, and E) and infectious virus released from cells (Figure 4.11C and F) 
treated with siRNAs to silence PKR expression. Despite nearly complete knockdown of 
PKR with either of two distinct PKR-specific siRNAs (Figure 4.11A and D), release of 
infectious JUNV and LCMV virus was not impacted when compared to cells treated with 
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a scrambled, nonspecific siRNA (Figure 4.11C and F). Levels of JUNV NP were similarly 
unaffected by the knockdown of PKR (Figure 4.11B). LCMV NP levels were slightly 
increased when PKR was knocked down with one of the two PKR specific siRNAs (Figure 
4.11E). This result suggests that JUNV is capable of completely neutralizing the antiviral 
actions of PKR and further that PKR is not fundamentally required for the efficient 
propagation of JUNV. On the other hand, while eIF2α is activated and translation is 
repressed during LCMV infection, knockdown of PKR had no effect on the release of 
infectious LCMV virus and a modest effect on production of viral NP, which we believe 
to represent the transience of PKR’s restriction on LCMV infection. 
 
4.5. Discussion 
The small size of the arenavirus proteome suggests that each viral protein is highly 
multifunctional. One strategy to identify additional accessory roles for these proteins is to 
identify the host machinery they engage during infection. In this study, we conducted a 
large-scale mapping of the human cellular interactome of the Old World and New World 
arenavirus NP. While the identified interactome was complex, a large percentage of the 
cellular protein partners were shared among Old World and New World NPs (Figure 4.1F). 
Bioinformatic analysis revealed a significant enrichment in proteins involved in protein 
translation, including the antiviral protein PKR (Figure 4.2 and Table 4.1). Our studies 
demonstrate that JUNV, despite activating PKR during infection (Figure 4.7A and B), 
selectively and potently inhibits PKR’s ability to phosphorylate its downstream substrate, 
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eIF2α (Figure 4.7A and C and 4.8A and C), and subsequently interfere with viral 
propagation (Figure 4.11C).  
PKR is one of four cellular kinases able to phosphorylate eIF2α and thus globally 
shut down cap-dependent translation in response to viral infection (Donnelly et al., 2013). 
This type I IFN-stimulated protein consists of two domains: an N terminal domain that 
contains two double-stranded RNA binding motifs and a C terminal kinase domain. In non-
stressed cells, monomeric PKR is expressed at low basal levels. Upon exposure to a dsRNA 
ligand, the N terminal domain binds the dsRNA, PKR dimerizes, and each PKR subunit 
trans autophosphorylates at T446 and T451. Phosphorylation of these residues leads to full 
activation of PKR, which is then able to phosphorylate eIF2α at S51, leading to cap-
dependent translation shutdown (Figure 4.12) (Garcia et al., 2007; Zhang et al., 2001).  
A key finding of our proteomics studies was that both JUNV and LCMV NP 
interact with PKR. However, our follow-up biochemical validation (Figure 4.3 and 4.4) 
and immunofluorescence microscopy studies (Figure 4.5) suggest that this interaction may 
be more biologically-relevant for JUNV NP than LCMV NP. We demonstrate that PKR is 
strongly activated in cells infected with JUNV or LCMV (Figure 4.7) and even more so in 
infected cells that are transfected with the PKR agonist poly(I:C) (Figure 4.8). 
Nevertheless, this active PKR is only able to phosphorylate eIF2α in LCMV-infected cells 
as eIF2α phosphorylation by active PKR is strongly blunted in JUNV-infected cells (Figure 
4.7 and 4.8). This effect is recapitulated in experiments measuring rates of translation in 
infected cells (Figure 4.9), where the majority of cells infected with JUNV or LCMV 
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maintain normal rates of translation throughout the course of infection. However, at 36 hpi, 
a significant proportion of LCMV infected cells enter a state of translation repression 
(Figure 4.9E), which happens to coincide with the spike in observed eIF2α phosphorylation 
observed by Western blot (Figure 4.7D and F). Interestingly, this effect of translation 
repression appears transient as the proportion of LCMV-infected cells with normal levels 
of translation recovers by 48 hpi (Figure 4.9A, C, and E). The finding that siRNA silencing 
of PKR, while sufficient to rescue the PKR-sensitive virus IAV Pan-delNS1 (Figure 4.10), 
had no effect on the JUNV life cycle (Figure 4.11A to C) and minimal to no effect on that 
of LCMV (Figure 4.11D to F) suggests that these viruses are both resistant to PKR’s 
antiviral activity. The observation that LCMV remains resistant to PKR is surprising in 
light of the previous findings of this paper and could reflect both the transience of PKR’s 
ability to control LCMV infection and/or the fact that LCMV possesses complementary 
mechanisms to inhibit PKR activity. A final possibility is that PKR could play a proviral 
role in the context of arenavirus infection as has previously been described for hepatitis C 
virus (Arnaud et al., 2010; Garaigorta and Chisari, 2009). Though, we consider this 
possiblity unlikely as PKR knockdown did not reduce the fitness of JUNV or LCMV 
(Figure 4.11). 
Because protein translation is an absolutely critical process for the production of 
new viral components, many viruses, including those that rely on cap-dependent 
translation, have evolved mechanisms to interfere with the canonical antiviral role of PKR 
(Reineke and Lloyd, 2013). For example, the dsDNA poxvirus, vaccinia, expresses the E3L 
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protein, which prevents PKR from binding to dsRNA (Chang et al., 1992; Langland and 
Jacobs, 2002). The paramyxovirus measles, a negative strand RNA virus, antagonizes PKR 
activation via its nonstructural protein C, which negatively regulates the production of viral 
dsRNA intermediates during infection (Toth et al., 2009). In A549 cells, it was shown that 
the paramyxovirus respiratory syncytial virus (RSV) antagonizes PKR activity via its N 
protein, which binds PKR and decreases its ability to bind eIF2α thus shielding it from 
PKR’s kinase activity (Groskreutz et al., 2010). Another report confirmed that RSV 
infection leads to the activation of PKR but that it also leads to significant phosphorylation 
of eIF2α in HEp-2 cells (Lindquist et al., 2011). The discrepancy between these two studies 
may be due to cell type-specific expression of protein phosphatase 2 – the enzyme 
responsible for dephosphorylating eIF2α. The nonstructural protein 1 (NS1) of the 
orthomyxovirus influenza A directly interacts with PKR and appears to interfere with its 
ability to bind dsRNA and become activated (Li et al., 2006; Lu et al., 1995). A common 
theme from these examples is that PKR antagonism represents a common strategy 
employed by diverse viruses, but the means by which they accomplish this feat is similarly 
variable. Among the viruses cited herein, the ability of JUNV to prevent eIF2α 
phosphorylation is most similar to that previously described for RSV as in both cases PKR 
becomes activated but is unable to phosphorylate eIF2α (Figure 4.7, 4.8, and 4.12) 
(Groskreutz et al., 2010). 
The exact mechanism used by JUNV to antagonize PKR’s ability to phosphorylate 
eIF2α remains unclear. Our studies suggest that NP itself, as well as its ability to interact 
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with the cellular factors PKR and eIF2α, may be critical. Indeed, in a related study, Linero 
et al. demonstrated that acute JUNV infection or expression of JUNV NP alone is sufficient 
to prevent eIF2α phosphorylation and the subsequent formation of cellular stress granules 
(SGs) following exposure to the oxidative stressor sodium arsenite (Linero et al., 2011). 
Phosphorylaton of eIF2α is a key event in driving the nucleation of SGs, which contain 
stalled cellular mRNAs and their associated translation initiation factors and are associated 
with inhibition of cap-dependent translation in response to various cellular stresses, 
including virus infection (Thomas et al., 2011). Sodium arsenite is thought to induce SG 
formation via activation of PKR and/or heme-regulated inhibitor (McEwen et al., 2005; 
Patel et al., 2000), which ultimately phosphorylate eIF2α. Therefore, if sodium arsenite 
drives eIF2α phosphorylation via PKR, NP may similarly block PKR’s ability to 
phosphorylate eIF2α in response to both oxidative stress (sodium arsenite) and dsRNA 
intermediates (poly(I:C)).  
JUNV has also been shown to block SG formation in response to challenge with 
the ER stressors DTT or thapsigargin, both of which lead to the phosphorylation of eIF2α 
via activation of protein kinase-like endoplasmic reticulum kinase (PERK), but not PKR 
(Harding et al., 2000; Harding et al., 1999). Paradoxically, despite failing to drive SG 
formation in JUNV-infected cells, both DTT and thapsigargin potently induced the 
phosphorylation of eIF2α in these same cells (Linero et al., 2011). We identified G3BP1, 
another cellular protein critical for the nucleation of stress granules (Tourriere et al., 2003), 
as an interacting partner of JUNV and LCMV NP (Figure 4.3A, B, G, and H and 4.4A and 
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Table S4.1). Further, a related study demonstrated that G3BP1 colocalizes with the 
arenavirus Tacaribe NP during infection (Baird et al., 2012). It is possible that JUNV NP 
can prevent SG nucleation despite the presence of phosphorylated eIF2α by interfering 
with key SG proteins such as G3BP1. Indeed, several other SG proteins were identified as 
partners of arenavirus NPs in our study, including eIF3 components, G3BP2, PABC, and 
several small ribosomal subunit proteins (Table S4.1 and S4.2) (Anderson and Kedersha, 
2008; Buchan and Parker, 2009). 
In addition to the antagonism of PKR’s antiviral function reported here, 
arenaviruses have been shown to interfere with other innate immune pathways responsible 
for antiviral defense, including the RIG-I/MAVS pathway that drives type I IFN 
production. In particular, the arenavirus NP has been shown to associate with IKKε and 
block its ability to phosphorylate/activate IRF3, which is required for type I IFN production 
(Pythoud et al., 2012). LCMV NP has also been shown to block NFκB activition (Rodrigo 
et al., 2012). The arenavirus NP further antagonizes the type I IFN response via its 3’ to 5’ 
exonuclease activity that limits the availability of viral dsRNA replicative intermediates 
for recognition by the RIG-I/MAVS pathway (Hastie et al., 2011a; Qi et al., 2010). 
Notably, our results would suggest that NP cannot clear all of these dsRNA intermediates 
as we presume these are driving the activation of PKR during infection. Intriguingly, 
arenaviruses appear highly selective in their antagonism of these innate immune pathways. 
For example, Pythoud et al. demonstrated that despite blocking RIG-I/MAVS-dependent 
type I IFN production, LCMV leaves MAVS-dependent apoptosis fully functional 
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(Pythoud et al., 2015). Likewise, we report here that JUNV can block activated PKR from 
phosphorylating eIF2α (Figure 4.7A and C and 4.8A and C), yet leaves this phosphorylated 
form of PKR capable of inducing the degradation IκB in response to poly(I:C) (Figure 4.8A 
and D), which is a key step upstream of NFκB activation (Garcia et al., 2007; Zamanian-
Daryoush et al., 2000), though we recommend caution in the interpretation of this finding 
as other innate immune sensors are also able to the activate NFκB in response to stimulation 
with dsRNA ligands (Kawai and Akira, 2008). These examples of selective antagonism 
suggest that arenaviruses have co-evolved with their reservoir rodents so that arenavirus-
infected cells within the host, while unable to respond to the infecting arenavirus, can still 
mount an effective antimicrobial response against other enviromental pathogens to ensure 
the fitness and survival of the host.  
The cellular protein partners of the arenavirus NP identified in this study may 
provide clues to advance our understanding of how these viruses hijack host cell machinery 
to facilitate the viral life cycle. Importantly, each protein partner represents a candidate 
target for future antiviral screening. For example, several host proteins that interact with 
NP and are required for viral propagation were validated in our study, including hnRNPA1 
and hnRNPA2B1 (Maeto et al., 2011), as well as eIF4A and eIF4G, which are components 
of the eIF4F translation initiation complex (Baird et al., 2012; Linero et al., 2013) (Table 
4.1). Also consistent with these previous studies, eIF4E, the cap-binding component of the 
eIF4F complex, was not detected in our work, supporting the hypothesis that JUNV and 
other New World arenavirus NPs can replace the cap-binding function of eIF4E to facilitate 
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translation of viral mRNAs (Linero et al., 2013). Finally, 8 additional host proteins 
identified in our screen – COPA, DDX60L, EIF3A, EIF3G, FAU, FBL, HNRNPK, and 
NOP56 (Table S4.1) – had previously been shown to be required for LCMV and VSV 
replication (Panda et al., 2011). Our results suggest these proteins may be critical for viral 
propagation due to their interaction with the LCMV NP. These examples highlight the 
feasibility and the utility of using a proteomics-based approach to identify antiviral targets. 
In summary, we have provided the first detailed map of the human proteins 
engaged by the arenavirus NP and also highlighted host processes that are likely important 
for arenavirus propagation and/or pathogenesis. This information will serve as a useful 
resource to guide future studies investigating the importance of arenavirus-host interactions 
and defining additional functions of NP. By showing that JUNV can selectively block the 
canonical antiviral role of PKR, we have advanced our understanding of the seemingly 
multifaceted strategy employed by arenaviruses to curtail an effective innate immune 
response. Important questions to address in the future will include dissecting the specific 
mechanism used by JUNV to inihibit PKR’s antiviral activity as well as to fully interrogate 
the importance of the remaining cellular interacting proteins identified in the proteomics 
screen.  
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4.6. Materials and Methods 
4.6.1.  Cells and viruses.  
HEK 293T/17 cells (CRL-11268) and A549 (CCL-185) were procured from 
American Type Culture Collection (ATCC, Manassas, VA). Vero E6 cells were generously 
given by J. L. Whitton (The Scripps Research institute, La Jolla, CA). HEK 293T/17 cells 
were cultured in Dulbecco’s Modified Eagle Medium (DMEM) (11965-118) containing 
10% fetal bovine serum, 1% Penicillin-Streptomycin (15140-163), 1% MEM Non-
Essential Amino Acids Solution (11140-050), 1% HEPES Buffer Solution (15630-130), 
and 1% GlutaMAX (35050-061) purchased from Thermo Fisher Scientific (Waltham, 
MA). A549 cells were cultured in DMEM-F12 (11320-033, Thermo Fisher), supplemented 
with 10% fetal bovine serum, and 1% Penicillin-Streptomycin. Vero E6 cells were 
maintained in DMEM, containing 10% fetal bovine serum, 1% Penicillin-Streptomycin, 
and 1% HEPES Buffer Solution. JUNV strain Candid #1 was generously provided by R. 
Tesh (The University of Texas Medical Branch at Galveston) and M. J. Buchmeier 
(University of California, Irvine). LCMV Armstrong 53b was obtained from J. L. Whitton. 
Titers of LCMV and JUNV were performed by standard plaque assay on Vero E6 cells. 
Recombinant influenza A/Panama/2007/99 (Pan/99) wild type virus and recombinant 
influenza A Panama/2007/99 ΔNS1 (Pan-delNS1) virus were generously provided by T. 
Wolff (Robert Koch-Institut, Berlin) (Matthaei et al., 2013). Cells were infected with IAV 
at an MOI of 1 after being washed with serum-free media. Infected cells were cultured in 
serum-free DMEM containing 1ug/ml TPCK Trypsin (T1426, Sigma-Aldrich) and 0.14% 
 163 
 
BSA. Titers of IAV Pan/99 were determined by standard plaque assay on MDCK cells 
using a low-viscosity overlay (0.5x DMEM, 0.5ug/ml TPCK Trypsin, 0.07% BSA, 1.2% 
Avicel (RC591, FMC Biopolymer)) (Matrosovich et al., 2006). Titers of IAV Pan-delNS1 
were determined by immunological focus assay on MDCK cells essentially as described in 
(Battegay et al., 1991) using a low-viscosity overlay and an IAV NP monoclonal antibody 
(ab20343, Abcam, at 1:5,000). 
4.6.2.  Immunoprecipitations and affinity purifications.  
Cells were scraped into the media following infection or transfection, pelleted, 
washed with cold PBS, and gently lysed on ice in 25 mM Tris-HCL, pH 7.6 containing 1% 
Triton X-100 (T9284, Sigma-Aldrich, St. Louis, MO), 0.5% Nonidet P-40 IGEPAL CA-
630 (198596, MP Biomedicals, Solon, OH), 140 mM NaCl, 1 mM calcium chloride 
(21115, Sigma-Aldrich), and a Complete Mini EDTA-Free Protease Inhibitor Cocktail 
tablet (04693159001, Roche Applied Science). Cell lysates were clarified of insoluble 
material by centrifugation at 10,000 rpm at 4°C. To pre-clear proteins non-specifically 
interacting with the magnetic Protein G beads (Dynabeads Protein G beads, 10004D, 
Thermo Fisher), beads were added to lysate and incubated on a rotating platform for 15 
minutes at 4°C. Appropriate antibody was added to cell lysates and incubated for 2 hours 
at 4°C. Magnetic Protein G beads were added to lysates and incubated for 1 hour at 4°C. 
The beads were washed 4 times with ice cold lysis buffer to remove nonspecific proteins. 
Bound protein was stripped from the beads into 1x Laemmli Buffer, 5% β-mercaptoethanol 
by heating at 100°C for 5 minutes. Immunoprecipitated proteins were separated by SDS-
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PAGE as described below. Antibodies used for immunoprecipitations are as follows: 
JUNV NP (KA03-AA01, BEI Resources), LCMV NP (1.1.3 and 24A, generously provided 
by M. J. Buchmeier) (Buchmeier et al., 1981), AIF (sc-9416, Santa Cruz), G3BP1 (A302-
033A, Bethyl), and PKR (Y117, Abcam). 
Affinity purification of biotinylated viral NPs was performed as follows. Viral NPs 
were cloned into a modified pCAGGS plasmid and carried a C-terminal HA epitope tag, 
the tobacco etch virus (TEV) protease cleavage site, and a biotin acceptor peptide. Viral 
NPs were biotinylated when cotransfected with the plasmid BirA, which expresses a 
bacterial biotin ligase. As a control to validate the specificity of the protein-protein 
interaction, cells were transfected with an empty vector along with BirA. Cells were lysed 
as described above. Biotinylated proteins were captured by incubating cleared lysate with 
magnetic streptavidin beads (Dynabeads MyOne Streptavidin T1, 65602, Thermo Fisher) 
at 4°C for 2.5 hours. Beads were washed 4 times with cold lysis buffer, and interacting 
proteins were stripped from beads into 1x Laemmli buffer containing 5% β-
mercaptoethanol by heating at 100°C for 5 minutes. 
4.6.3.  Mass Spectrometry.  
To define the cellular protein interactome of JUNV NP and LCMV NP, A549 or 
HEK 293T cells were infected with either JUNV C#1 or LCMV Armstrong 53b. Following 
infection, the viral NPs were immunoprecipitated (as described above) along with 
associated cellular proteins. After denaturation, the immune complexes were separated by 
SDS-PAGE on Novex 4-20% Tris-Glycine polyacrylamide gels. Gels were Coomassie 
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stained (0.02% Brilliant Blue R (B7920, Sigma-Aldrich) in 32% methanol, 22% acetic 
acid) at room temperature overnight. Gels were destained for 6-8 hours in a solution 
containing 30% methanol and 10% acetic acid. Each lane was cut out of the gel in 13 
(JUNV NP) or 15 (LCMV NP) slices (cut maps available upon request). In-gel trypsin 
digestion of proteins was performed with Sequencing Grade Modified Trypsin (V5111, 
Promega, Madison, WI at 6 ng/μL) in 50 mM ammonium bicarbonate overnight at 37°C 
as previously reported (Ballif et al., 2006). Peptides were extracted from the digested gel 
slices with 50% acetonitrile (MeCN) and 2.5% formic acid (FA) and dried using a vacuum 
centrifuge. Dried peptides were resuspended in 2.5% MeCN and 2.5% FA and loaded onto 
a 12 cm reverse-phase Magic C18 microcapillary column (5 μm, 200 Å, Michrom 
Bioresources, Inc., Auburn, CA) utilizing a MicroAS autosampler (Thermo Scientific, 
Pittsburgh, PA). Peptides were eluted with a 5-35% MeCN (0.15% FA) gradient using a 
Surveyor Pump Plus HPLC (Thermo Scientific) over 40 min, after a 15min isocratic 
loading with 2.5% MeCN and 0.15% FA. An LTQ-XL linear ion trap mass spectrometer 
(Thermo Scientific) was used to acquire mass spectra of eluted peptides over the entire run 
using 10 MS/MS scans following each survey scan. Raw data were searched against the 
human IPI forward and reverse concatenated databases using SEQUEST software allowing 
a 2 Da mass tolerance for peptide matches. Cysteine residues were required to have a static 
increase in 71.0 Da for acylamide adduction. A 16.0 Da differential modification on 
methionine residues was permitted. Host proteins were accepted as legitimate NP protein 
partners if they were identified by 2 or more unique tryptic peptides in samples infected 
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with either JUNV or LCMV but not in the corresponding uninfected control. Alternatively, 
proteins were included if there was a 5-fold higher quantity of total tryptic peptides that 
were detected for a particular human protein from a viral infected sample compared to the 
sample from the corresponding uninfected control. Using these filters, the false discovery 
rate of peptides was less than 1%. 
Bioinformatic analysis of cellular protein partners was performed with the NIH 
DAVID functional annotation tool (Version 6.7; https://david.ncifcrf.gov/) (Huang et al., 
2009a, b). 
4.6.4.  SDS-PAGE and Western Blot.  
Novex 4-20% Tris-Glycine polyacrylamide gels or NuPAGE™ Novex™ 4-12% 
Bis-Tris Midi Protein Gels (WG1402BOX, Thermo Scientific) were used to separate 
protein lysates by SDS-PAGE. MOPS SDS Running Buffer (NP0001, Thermo Scientific) 
was used with the NuPage Bis-Tris polyacrylamide gels. Protein was transferred from gels 
onto nitrocellulose membranes using the iBlot Gel Transfer Device and the iBlot Transfer 
Stack nitrocellulose membranes (IB3010-01, Thermo Scientific). Membranes were 
blocked with 5% milk in PBS for 1 hour at room temperature. Primary antibodies and 
secondary antibodies were diluted in PBS containing 5% milk, 3% FBS, and 0.05% 
Nonidet P-40 IGEPAL CA-630). Blots were incubated in diluted primary antibody 
overnight at 4°C. Primary antibodies used for Western blot were: PKR (sc-707, Santa Cruz, 
at 1:1000), IκBα (9242, Cell Signaling, at 1:1000), rabbit anti-actin (A2066, Sigma 
Aldrich, at 1:5000), mouse anti-actin (A5441, Sigma Aldrich, at 1:5000), SFPQ (NB100-
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61044, Novus, at 1:2500), eIF2α (sc-11386, Santa Cruz, at 1:1000), p-eIF2α S51 (3398, 
Cell Signaling, at 1:1000), G3BP1 (A302-033A, Bethyl, at 1:2500), AIF (sc-9416, Santa 
Cruz, at 1:1000), p-PKR T446 (E120, Abcam, at 1:1000), anti-JUNV NP (NA05-AG12, 
BEI-Resources, at 1:200), anti-LCMV NP (2165, M. J. Buchmeier, at 1:10,000), and IAV 
NP (ab20343, Abcam, at 1:1,000). Unbound primary antibody was washed from blots by 
3 consecutive washes in Western wash solution (PBS with 0.5% Nonidet P-40 IGEPAL 
CA-630). Blots were incubated with diluted secondary antibody for 2 hours at room 
temperature: goat anti-mouse (H+L) (71045-3, Novagen, at 1:10,000), goat anti-mouse 
(light chain only) (AP200P, Millipore, at 1:10,000), goat anti-rabbit (H+L) (111-035-045, 
Jackson, at 1:10,000), mouse anti-rabbit (light chain only) (211-032-171, at 1:10,000), or 
rabbit anti-goat peroxidase (401515, Calbiochem, at 1:10,000). Finally, blots were washed 
3 more times with Western wash before developing with chemiluminescent substrate 
(either Pierce ECL Western Blotting Substrate (32109), SuperSignal West Pico (34080) or 
Femto (34096) Chemiluminescent Substrate, Thermo Scientific). Alternately, blots were 
probed with fluorescently labeled secondary antibodies: IRDye 800CW goat anti-rabbit 
IgG (H+L) (926-32211, LI-COR, at 1:20,000), IRDye 800CW goat anti-mouse IgG (H+L) 
(926- 32210, LI-COR, at 1:20,000), IRDye 680RD goat anti-mouse IgG (H+L) (926-
68070, LICOR, at 1:20,000), and IRDye 680RD goat anti-rabbit IgG (H+L) (926-68071, 
LICOR, at 1:20,000) and visualized with an Odyssey Infrared Imaging System (LI-COR 
Biosciences, Lincoln, NE). 
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4.6.5.  Plasmids and transfection.  
To validate the interaction of identified cellular proteins, the arenaviral NPs were 
subcloned into a modified pCAGGS expression vector as previously described (Cornillez-
Ty et al., 2009; Klaus et al., 2013). This vector expresses an NP fusion protein containing 
3 C-terminal elements: a hemagglutinin (HA) epitope tag (YPYDVPDYA), the tobacco 
etch virus (TEV) protease cleavage site (ENLYFQG), and a 23 amino acid biotin acceptor 
peptide (BAP) (MASSLRQILDSQKMEWRSNAGGS). The BAP sequence can be 
biotinylated when cells are cotransfected with a plasmid that encodes the bacterial biotin 
ligase BirA, and the biotinylated NP can be affinity purified as described (Cornillez-Ty et 
al., 2009; Klaus et al., 2013). The NP sequences subcloned into the pCAGGS expression 
vector were (for each NP, an NCBI Gene Identifier number and a Protein Locus number 
are listed): LASV strain Josiah (NC_004296, NP_694869), LCMV Armstrong 53b 
(DQ408671, ABD73126), and JUNV strain Candid 1 (HQ126699, AEB32437). 
Transfection of HEK 293T cells was done using Polyethylenimine (PEI) (23966, 
Polysciences, Inc., Warrington, PA) (5 µg of PEI (10010049, Thermo Fisher) per 1 µg 
DNA).  
4.6.6.  Confocal Microscopy.  
The localization of the viral NP and cellular proteins in JUNV- or LCMV-infected 
A549 cells was visualized by confocal microscopy. A549 cells were seeded onto #1.5 12 
mm glass cover slips (12-545-81, Thermo Scientific). The day after seeding, cells were 
infected or not (mock) with JUNV at an MOI of 0.1 or LCMV at an MOI of 0.01. Cells 
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were fixed 48 or 72 hr after infection with 4% PFA (15714, Electron Microscopy Sciences) 
in 1x PBS. Cells were permeabilized in PBS with 0.1% Triton X-100 and 1% BSA and 
then blocked in PBS containing 3% BSA for 30 minutes at room temperature.  
Cells were incubated with a primary antibody diluted in 1% BSA in 1x PBS at room 
temperature for 1 hour. NA05-AG12 (mouse) to detect JUNV NP was diluted at 1:100, 
1.1.3 (mouse) for LCMV NP was diluted 1:500, anti-PKR antibody (rabbit monoclonal, 
Y117, Abcam) was diluted 1:100, and anti-G3BP1 (A302-033A, Bethyl) was diluted 
1:100. Coverslips were washed 4 times in 1x PBS at room temperature. Coverslips were 
incubated with secondary antibody diluted in 1% BSA in 1x PBS for 30 minutes at room 
temperature. Secondary antibodies were Alexa Fluor 488-conjugated goat anti-mouse IgG 
(H+L) (A-11029, Thermo Scientific) (1:800) and Alexa Fluor 647-conjugated goat anti-
rabbit IgG (H+L) (A-21245, Thermo Scientific) (1:800). Coverslips were washed 3 times 
in PBS, stained with 4’, 6-diamidino-2-phenylindole hydrochloride 30 (DAPI) (D9542, 
Sigma Aldrich), and washed a final time in PBS, and mounted onto glass slides using 
ProLong Gold Antifade Reagent (P36934, Thermo Fisher). Confocal microscopy was 
performed with a Zeiss LSM 510 Laser Scanning Confocal Microscope. Images were 
acquired with a 63X objective lens with a numerical aperture of 1.4. Images were acquired 
at 1.0 Airy unit for the Alexa Fluor 647 dye. Pinhole diameter for the DAPI and Alexa 
Fluor 488 channels were set accordingly. 
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4.6.7.  Puromycylation of nascent polypeptides.  
To label newly-synthesized peptides in infected cells growing on glass coverslips, 
cells were incubated for 5 minutes at 37°C in puromycylation media: DMEM/F12, 10% 
FBS, 1% Pen-Strep supplemented with 91 µM puromycin (P8833, Sigma-Aldrich) and 208 
µM emetine (E2375, Sigma-Aldrich) as previously described (David et al., 2012). As a 
negative control, some cells were pretreated with complete media containing 500 µM 
Sodium Arsenite (1.06277, Sigma-Aldrich) for 15 minutes at 37°C before labeling with 
puromycylation media. Following the labeling reaction, cells were briefly washed with 
cold DPBS (with calcium and magnesium) (14040133, Thermo Fisher). Cells were washed 
with cold permeabilization buffer (50 mM Tris HCl, 5 mM MgCl2, 25 mM KCl, 0.015% 
Digitonin (D141, Sigma-Aldrich)) to remove free puromycin before being fixed in 3% PFA 
in 1x PBS for 15 minutes at room temperature. Cells were prepared for confocal 
microscopy as described above. LCMV NP was labeled with the 1.1.3 antibody (at 6.8 
µg/ml), and JUNV NP was labeled with the NA05 antibody (at 10 µg/ml), with both 
antibodies directly conjugated to Alexa Fluor 488 (Thermo Fisher).Puromycin was 
detected with the monoclonal antibody 12D10 directly conjugated to Alexa Fluor® 647 (at 
1 ug/ml, MABE343-AF647, Sigma-Aldrich). Puromycin levels were quantitated in 
individual cells with a customized image analysis pipeline in CellProfiler (Broad Institute) 
(Kamentsky et al., 2011).  
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4.6.8.  Poly(I:C) transfections.  
For a single well in a six well plate, 0 µg, 0.5 µg, or 5 µg of poly(I:C) (P0913, 
Sigma Aldrich) was added to 125 µL Opti-Mem Media (31985070, Thermo Fisher) and 
mixed well. 3 µL of Lipofectamine 2000 (11668019, Thermo Fisher) was added to a second 
tube containing 125 µL Opti-Mem and mixed gently. The solution containing poly(I:C) 
was added to the solution containing Lipofectamine 2000, mixed gently, and incubated at 
room temperature for 10 minutes. Media was aspirated from the wells and replaced with 2 
ml of fresh warm complete A549 media. The poly(I:C)/Lipofetamine transfection mix was 
added dropwise to the well. The transfected cells were incubated at 37°C for 6 hours at 
which time cells were lysed and analyzed by Western blot. 
4.6.9.  siRNA.  
siRNAs were reverse transfected in A549 cells in a 12 well plate format as follows. 
To 100 µL of Opti-Mem, 2 µL of Lipofectamine RNAi Max (13778075, Thermo Fisher) 
was added and mixed gently. To another 100 µL of Opti-Mem, 12 pmoles of siRNA was 
added and mixed. The siRNA-containing solution was added to the lipofectamine-
containing solution and allowed to incubate at room temperature for 5 minutes. 200 µL of 
this mixture were added to an empty well of a 12 well plate. Next, 40,000 A549 cells in 1 
ml of complete A549 media were added to the Opti-MEM/siRNA-containing well and 
incubated at 37°C. Two days post-transfection, the media was replaced with fresh 
prewarmed complete A549 media. siRNA-transfected A549 cells were infected 72 hours 
post-siRNA transfection. Silencer Select siRNAs were used for knockdown experiments: 
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Silencer Select Negative Control No. 1 siRNA: “siSCR” (4390843, Thermo Fisher), 
“siPKR-1” (s11185, 4390824, Thermo Fisher) (Figure 4.10 and 4.11), and “siPKR-2” 
(s229501, 4392420, Thermo Fisher) (Figure 4.11). 
4.6.10.  Statistics.  
Statistical analyses were performed in GraphPad software. Two-way ANOVA 
with post-hoc Tukey’s multiple comparisons test was used for Figure 4.8. One-way 
ANOVA with Dunnett’s multiple comparisons test was used for Figures 4.7, 4.9C, 4.9D, 
and 4.11. One-way ANOVA with Tukey’s multiple comparisons test was used for Figure 
4.9E. Unpaired two-tailed Student’s T-test was used for Figure 4.10. 
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4.9. Tables 
Table 4.1.  The top 25% most abundantly detected conserved protein partners of JUNV C#1 and 
LCMV Armstrong 53b NP.  
Gene symbol, description, and IPI ID for the most abundantly detected host protein partners of the arenavirus 
NP are listed below. The most abundant interactors were defined as those having the highest average number 
of spectral counts (total peptides) from the JUNV (n=8 independent experiments) or LCMV (n=4 independent 
experiments) mass spectrometry. 
 
Gene symbol Gene Description IPI ID 
Peptide 
spectral counts 
JUNV LCMV 
AIFM1 programmed cell death 8 (apoptosis-inducing factor) IPI00000690 89 3 
ASPH aspartate beta-hydroxylase IPI00294834 23 8 
CCT6A chaperonin containing TCP1, subunit 6A (zeta 1) IPI00027626 43 3 
CCT7 chaperonin containing TCP1, subunit 7 (eta) IPI00018465 40 4 
CKAP4 cytoskeleton-associated protein 4 IPI00141318 22 9 
CKAP5 cytoskeleton associated protein 5 IPI00028275 13 12 
CLTC clathrin, heavy polypeptide (Hc) IPI00024067 19 18 
DDX3X DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked IPI00215637 18 18 
DDX5 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 IPI00017617 12 24 
DHX9 DEAH-Box Helicase 9 IPI00844578 32 27 
EEF1A2 eukaryotic translation elongation factor 1 alpha 2 IPI00014424 16 8 
FLNA filamin A, alpha (actin binding protein 280) IPI00302592 16 77 
FLNB filamin B, beta (actin binding protein 278) IPI00289334 13 21 
HADHA hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme 
A thiolase/enoyl-Coenzyme A hydratase (trifunctional protein), 
alpha subunit 
IPI00031522 22 15 
HIST2H2BE histone 2, H2be IPI00003935 8 39 
HNRNPA1 heterogeneous nuclear ribonucleoprotein A1 IPI00215965 13 16 
HNRNPA2B1 heterogeneous nuclear ribonucleoprotein A2/B1 IPI00396378 17 12 
HNRNPA2B1 heterogeneous nuclear ribonucleoprotein A2/B1 IPI00386854 3 27 
HNRNPK heterogeneous nuclear ribonucleoprotein K IPI00216049 24 15 
HNRNPM heterogeneous nuclear ribonucleoprotein M IPI00171903 25 32 
HNRNPU heterogeneous nuclear ribonucleoprotein U (scaffold attachment 
factor A) 
IPI00479217 15 12 
HSPA8 heat shock 70kDa protein 8 IPI00003865 31 18 
IGF2BP1 insulin-like growth factor 2 mRNA binding protein 1 IPI00008557 20 19 
ILF2 interleukin enhancer binding factor 2, 45kDa IPI00005198 12 19 
IQGAP1 IQ motif containing GTPase activating protein 1 IPI00009342 14 20 
KIAA1618 chromosome 17 open reading frame 27 IPI00642126 76 3 
LMNA lamin A/C IPI00021405 31 105 
MAP1B microtubule-associated protein 1B IPI00008868 14 10 
MATR3 matrin 3 IPI00017297 12 20 
MOV10 Mov10, Moloney leukemia virus 10, homolog (mouse) IPI00444452 17 16 
MYBBP1A MYB binding protein (P160) 1a IPI00005024 28 6 
MYO1B myosin IB IPI00376344 10 30 
MYO1C myosin IC IPI00010418 27 55 
MYO6 myosin VI IPI00008455 9 18 
NCL nucleolin IPI00183526 22 17 
NCL nucleolin IPI00444262 22 13 
NPM1 anaplastic lymphoma kinase (Ki-1) IPI00220740 14 26 
PABPC1 poly(A) binding protein, cytoplasmic 1 IPI00008524 29 39 
PARP1 poly (ADP-ribose) polymerase family, member 1 IPI00449049 24 30 
PLEC1 plectin 1, intermediate filament binding protein 500kDa IPI00014898 55 307 
PKR Double Stranded RNA Activated Protein Kinase (eukaryotic 
translation initiation factor 2-alpha kinase 2) 
IPI00019463 18 7 
PRKDC protein kinase, DNA-activated, catalytic polypeptide IPI00296337 60 46 
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RPL10A ribosomal protein L10a IPI00412579 15 12 
RPL12 ribosomal protein L12 IPI00024933 15 11 
RPL13P12 ribosomal Protein L13 pseudogene 12 IPI00397611 13 13 
RPL23 ribosomal protein L23 IPI00010153 14 19 
RPL23A ribosomal protein L23a IPI00021266 12 15 
RPL3 ribosomal protein L3 IPI00550021 19 14 
RPL4 ribosomal protein L4 IPI00003918 20 9 
RPL5 ribosomal protein L5 IPI00000494 22 17 
RPL6 ribosomal protein L6 IPI00329389 25 28 
RPL7 ribosomal protein L7 IPI00030179 14 18 
RPL7A ribosomal protein L7a IPI00299573 16 17 
RPLP0 ribosomal protein, large, P0 IPI00008530 39 31 
RPLP2 ribosomal protein, large, P2 IPI00008529 22 15 
RPS18 ribosomal protein S18 IPI00013296 12 14 
RPS19 ribosomal protein S19 IPI00215780 9 21 
RPS3 ribosomal protein S3 IPI00011253 14 31 
RPS3A ribosomal protein S3A IPI00419880 11 20 
RPS4X ribosomal protein S4, X-linked IPI00217030 13 22 
RRBP1 ribosome binding protein 1 homolog 180kDa (dog) IPI00215743 40 6 
SFPQ splicing factor proline/glutamine-rich (polypyrimidine tract binding 
protein associated) 
IPI00010740 17 16 
SLC25A5 solute carrier family 25 (mitochondrial carrier; adenine nucleotide 
translocator), member 5 
IPI00007188 27 27 
TMPO thymopoietin IPI00030131 9 43 
TMPO thymopoietin IPI00216230 4 34 
TUBB2C tubulin, beta 2C IPI00007752 14 8 
XRCC5 X-ray repair complementing defective repair in Chinese hamster 
cells 5 (double-strand-break rejoining; Ku autoantigen, 80kDa) 
IPI00220834 14 13 
XRCC6 X-ray repair complementing defective repair in Chinese hamster 
cells 6 (Ku autoantigen, 70kDa) 
IPI00644712 15 18 
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4.10. Figures 
 
 
Figure 4.1.  Identification of human proteins that associate with the arenavirus nucleoprotein. 
(A) Overview of experimental approach to identify human cellular protein partners of the arenavirus 
nucleoprotein in the context of infected cells. A549 or HEK 293T cells were infected with either JUNV 
Candid #1, LCMV Armstrong 53b, or uninfected (mock). Cells were lysed and NP was immunoprecipitated 
with monoclonal antibodies. The immunoprecipitated fractions were separated by SDS-PAGE and lanes were 
cut into multiple slices. Proteins were digested with trypsin, peptides were extracted from each slice, and 
proteins were identified by tandem-mass spectrometry. (B-E) Representative Coomassie-stained gels of 
immunoprecipitated NP from (B) JUNV- or mock-infected A549 cells (C) LCMV- or mock-infected A549 
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cells (D) JUNV- or mock-infected HEK 293T cells, or (E) LCMV- or mock-infected HEK 293T cells. 
Immunoprecipitated NP is indicated by an arrowhead in each gel. Background bands composed of IgG heavy 
and light chains are denoted with asterisks. (F) Venn diagram representing the number of host proteins 
interacting with JUNV NP, LCMV NP, or both. (G) Venn diagram representing the number of host protein 
partners (of either JUNV or LCMV NP) identified in A549 cells, HEK 293T cells, or both. The Coomassie 
gels shown in panels (B-E) are representative of 2 independent experiments. 
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Figure 4.2.  Bioinformatic analysis of host protein partners of the arenavirus NP. 
(A) A frequency distribution histogram showing the number of individually identified peptides per protein 
for host proteins interacting with JUNV NP only, LCMV NP only, or both viral NPs (conserved). Vertical 
dashed line indicates the threshold above which the 25% most abundant conserved interacting proteins were 
detected. (B) A bioinformatics NIH DAVID functional annotation clustering analysis showing the most 
highly enriched biological function categories represented in the list of the 25% most abundantly detected 
and conserved interacting proteins (n= 69) displayed in Table 4.1. (C) A bioinformatics NIH DAVID 
functional annotation clustering analysis showing the most highly enriched biological function categories 
represented in the entire list of interacting proteins (n= 582). (D) NIH DAVID analysis on the subset of 
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proteins displaying specific interactions with only the JUNV NP (n=234). (E) NIH DAVID analysis on the 
subset of proteins displaying specific interactions with only the LCMV NP (n=73). For panels (A-E), 
interacting human proteins that were detected in at least 1 of the 2 independent experiments for JUNV in 
either A549 or HEK 293T cells and/or 1 of the 2 independent experiments for LCMV in either A549 or HEK 
293T cells were used for bioinformatic analysis. 
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Figure 4.3.  Biochemical validation of the interaction between cellular proteins and arenavirus NPs in 
infected cells. 
(A) JUNV NP (bait) was immunoprecipitated from lysates of A549 cells infected (JUNV) or not (mock) with 
JUNV, and associated cellular proteins (prey) were detected by Western blot. (B) LCMV NP (bait) was 
immunoprecipitated from lysates of A549 cells infected (LCMV) or not (mock) with LCMV Armstrong 53b, 
and associated cellular proteins (prey) were detected by Western blot. (C and D) A549 cells were infected 
with JUNV (C) or LCMV (D), or uninfected (mock); at 72 hpi (JUNV) or 48 hpi (LCMV), 
immunoprecipitations from infected lysates were performed using either a monoclonal antibody to the C 
terminus of PKR (bait) or a species-matched control IgG, and associated JUNV NP (C) or LCMV NP (D) 
prey were detected by Western blot. (E and F) AIFM1 (bait) was immunoprecipitated from lysates of A549 
cells infected or not (mock) with JUNV (E) or LCMV Armstrong 53b (F) using an AIFM1-specific 
polyclonal antibody and AIFM1 (bait) and associated NP (prey) were detected by Western blot. (G and H) 
G3BP1 (bait) was immunoprecipitated from lysates of A549 cells infected with JUNV (72 hpi) (G) or LCMV 
Armstrong 53b (48 hpi) (H) using either a polyclonal antibody to G3BP1 (bait) or a control rabbit IgG, and 
G3BP1 (bait) and associated NP (prey) were detected by Western blot. Protein bands composed of the IgG 
heavy chain in (D, E, F, and H) are denoted with an asterisk. Data are representative of 2 (A and B)), 4 (C), 
5 (D), or 1 (E-H) independent experiments. 
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Figure 4.4.  Biochemical validation of interactions between arenavirus NPs expressed from plasmid 
and endogenous host proteins. 
(A) HEK 293T cells were co-transfected with a plasmid encoding each respective arenavirus NP with a C-
terminal HA epitope tag, the TEV cleavage site, and a biotin acceptor peptide, along with a second plasmid 
that encodes BirA, a bacterial biotin ligase, to ensure biotinylation of the viral NPs. As a control, cells were 
co-transfected with the BirA plasmid and an empty vector (p0). Biotinylated NPs and associated host proteins 
were affinity purified from cell lysates (input) using magnetic streptavidin beads and captured proteins were 
detected by Western blot. (B and C) HEK 293T cells were transfected with a plasmid encoding each 
respective arenavirus NP with a C-terminal HA epitope tag, the TEV cleavage site, and a biotin acceptor 
peptide or, as a control, an empty vector (p0). (B) PKR (bait) was immunoprecipitated with a monoclonal 
antibody to the C terminus of PKR or with an irrelevant rabbit IgG. PKR (bait) and associated viral NP (prey) 
were detected by Western blot. (C) AIFM1 (bait) was immunoprecipitated with a polyclonal antibody. 
AIFM1 (bait) and associated viral NP (prey) were detected by Western blot. Data are representative of 2 (A), 
3 (B), or 2 (C) independent experiments. 
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Figure 4.5.  PKR colocalizes with JUNV but not LCMV NP. 
A549 cells were (A) infected (JUNV) or not (mock) with JUNV and fixed at 72 hpi (n=5) or (B) infected 
(LCMV) or not (mock) with LCMV Arm53b and fixed at 48 hpi (n=4). Cells were stained for NP (green) 
and PKR (red) and visualized by confocal immunofluorescence microscopy. Inset shows higher 
magnification of the boxed areas. A fluorescence plot profile is included to show NP and PKR signal intensity 
along the white line indicated in the magnified region in the merge panel from either JUNV or LCMV infected 
cells. Scale bar = 10µm. 
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Figure 4.6.  G3BP1 colocalizes with JUNV and LCMV NP. 
A549 cells were (A) infected (JUNV) or not (mock) with JUNV and fixed at 72 hpi (n=1) or (B) infected 
(LCMV) or not (mock) with LCMV Arm53b and fixed at 48 hpi (n=1). Cells were stained for NP (green) 
and G3BP1 (red) and visualized by confocal immunofluorescence microscopy. Inset shows higher 
magnification of the boxed areas. A fluorescence plot profile is included to show NP and G3BP1 signal 
intensity along the white line indicated in the magnified region in the merge panel from either JUNV or 
LCMV infected cells. Scale bar = 10µm. 
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Figure 4.7.  PKR is activated following JUNV infection but cannot phosphorylate eIF2α. 
A549 cells were infected with JUNV (A-C) or LCMV (D-F). Infected cell lysates were collected during a 
time course of acute infection. Viral NPs, phosphorylated PKR (T446), total PKR, phosphorylated eIF2α 
(S51), total eIF2α, and β-actin were visualized by Western blot (A and D). Phosphorylated PKR (B and E) 
and phosphorylated eIF2α (C and F) were quantified, and compared using one-way ANOVA. Data are 
presented as mean fold change ± SEM from 2 independent experiments featuring 3 technical replicates per 
experiment. ns – not significant, P>0.05; *, P≤0.05; **, P≤0.01; ***, P≤0.001; ****, P≤0.0001 
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Figure 4.8.  JUNV infection blocks poly(I:C)-induced phosphorylation of eIF2α. 
A549 cells infected with either JUNV (A-D) or LCMV (E-H) or uninfected (mock) were transfected with the 
indicated quantities of poly(I:C) to induce PKR activation. Viral NPs, phosphorylated PKR (T446), total 
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PKR, phosphorylated eIF2α (S51), total eIF2α, IκB, and β-actin were visualized by Western blot (A and E). 
Phosphorylated PKR (B and F), phosphorylated eIF2α (C and G), and IκB (D and H) were quantified, and 
compared using two-way ANOVA. Data are presented as mean fold change ± SEM from 2 independent 
experiments featuring 3 technical replicates per experiment. ns – not significant, P>0.05; *, P≤0.05; **, 
P≤0.01; ***, P≤0.001; ****, P≤0.0001 
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Figure 4.9.  Translational profile of cells infected with JUNV or LCMV. 
(A and B) Cells were either infected with LCMV (A) (n=2) or JUNV (B) (n=2), mock-infected, or treated 
with 500 µM Sodium Arsenite, and rates of translation were assessed by labeling newly synthesized peptides 
with puromycin. (C and D) Puromycin levels were quantitated in individual cells receiving no puromycin, 
mock-infected cells labeled with puromycin, mock-infected cells treated with Sodium Arsenite prior to 
puromycin labeling, or in cells infected with LCMV(C) or JUNV (D) at different time points following 
infection. Each individual cell was normalized to the mean level of puromycylation of mock-infected cells. 
The puromycin labeling of individual cells is represented by single dots, the mean puromycin labeling is 
represented by a solid red horizontal line in each condition, red error bars represent ± SD and were compared 
between mock and each time point by one-way ANOVA. A red dashed line, which represents the threshold 
for translational repression, was set as the mean level of puromycylation in mock-infected cells labeled with 
puromycin minus (1.96*SD). (C) No Puro, n=44 cells; Arsenite, n=194 cells; Mock, n=191 cells; LCMV 
12h, n=113 cells; LCMV 24h, n=276 cells; LCMV 36h, n=260 cells; LCMV 48h, n=269 cells. (D) No Puro, 
n=40 cells; Arsenite, n=205 cells; Mock, n=215 cells; JUNV 24h, n=161 cells; JUNV 48h, n=198 cells; 
JUNV 72h, n=205 cells. (E) The proportion of individual cells that fall below the translational repression 
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threshold in each condition were compared with one-way ANOVA. Though all possible comparisons 
between LCMV-infected cultures at different times post-infection in panel (E) were made, for clarity, only 
significant differences are shown. In panels (A) and (B), the borders between adjacent cells are represented 
by dashed white lines. Scale bar = 10µm. ns – not significant, P>0.05; *, P≤0.05; ****, P≤0.0001. 
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Figure 4.10.  Loss of functional PKR enhances growth of mutant delNS1 but not WT influenza A virus. 
A549 cells were transfected with a non-targeting scrambled siRNA (siSCR) or with a PKR-specific siRNA. 
Three days following siRNA transfection, cells were infected with either WT influenza A virus (IAV) Pan/99, 
a mutant IAV that does not express NS1 (Pan-delNS1), or mock-infected, and supernatants and cellular 
protein lysates were collected at 16 hpi. Protein levels of IAV nucleoprotein (NP) were detected by Western 
blot (A) and quantified, normalized to β-actin levels, and normalized to the mean of levels of NP in siSCR 
transfected cells (B). PKR expression in mock-infected cells was visualized by Western blot to confirm 
knockdown (A). The quantities of infectious virus in the supernatants was determined by plaque assay (for 
IAV Pan/99) or by focus assay (for IAV Pan-delNS1) (C). The effect of PKR knockdown on viral NP levels 
as well as released infectious virus was determined using a two-tailed, unpaired T-test (B and C). Data are 
presented as mean plaque forming units (PFU)/ml ± SEM or mean focus forming units (FFU)/ml ± SEM 
from 2 independent experiments featuring 2 technical replicates per experiment. ns – not significant, P>0.05; 
**, P≤0.01 
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Figure 4.11.  Loss of functional PKR does not impact arenavirus propagation. 
A549 cells were transfected with a non-targeting scrambled siRNA (siSCR) or with one of two PKR-specific 
siRNAs (siPKR #1, siPKR #2). Three days after siRNA transfection, cells were infected with JUNV (A-C) 
or LCMV (D-F), and supernatants and cellular protein lysates were collected at 48 (JUNV and LCMV) and 
72 hpi (JUNV only). Protein levels of PKR and viral NP were visualized by Western blot (A and D). NP 
protein levels were quantified, normalized to β-actin levels, and normalized to the mean of levels of NP in 
siSCR transfected cells at 48hpi and were compared by one-way ANOVA (B and E). The quantities of 
infectious virus in the supernatants were determined by plaque assay and were compared by one-way 
ANOVA (C and F). Data are presented as mean ± SEM from 2 independent experiments featuring 3 technical 
replicates per experiment. Data are presented as mean PFU/ml ± SEM from 2 independent experiments 
featuring 3 technical replicates per experiment in panels A to C (JUNV) or 3 independent experiments 
featuring 3 technical replicates per experiment in panels D to F (LCMV). ns – not significant, P>0.05; **, 
P≤0.01 
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Figure 4.12.  JUNV infection blocks PKR’s antiviral activity. 
Inactive PKR exists in an unphosphorylated, monomeric form. Upon binding a dsRNA ligand with its N-
terminal dsRNA binding domains, PKR dimerizes and undergoes an autophosphorylation event (at T446 and 
T451). This activated form of PKR phosphorylates eIF2α at serine 51, which leads to a global cap-dependent 
translation shutdown. The results of this study show that PKR is able to become phosphorylated in cells 
infected with JUNV but is deficient in its ability to phosphorylate its target eIF2α. We hypothesize that the 
viral NP may be responsible for blocking this step as it was shown to interact with both PKR and eIF2α. 
Other functions of active PKR such as the activation of NF-κB (as assayed by IκB degradation) remain intact. 
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4.12. Supplemental Tables 
Table S4.1.  Complete list of cellular proteins that were detected as interacting with the JUNV or 
LCMV NP.  
The average number of spectral counts (total peptides) detected by mass spectrometry from host proteins that 
associated with the JUNV NP in A549 cells (n=4) or HEK 293T cells (n=4); or with the LCMV NP in A549 
cells (n=2) or HEK 293T cells (n=2).  
      
Gene symbol Gene Description IPI id  
Peptide Spectral Count 
JUNV LCMV 
A549 
HEK 
293T 
A549 
HEK 
293T 
ABCF1 
ATP-binding cassette, sub-family F (GCN20), 
member 1 
IPI00013495 5.3 0.0 0.0 4.0 
ABCF2 
ATP-binding cassette, sub-family F (GCN20), 
member 2 
IPI00005045 3.0 1.0 0.0 3.5 
ACAD11 
acyl-Coenzyme A dehydrogenase family, member 
11 
IPI00420065 0.0 1.8 0.0 0.0 
ACIN1 apoptotic chromatin condensation inducer 1 IPI00007334 0.0 0.5 0.0 0.0 
ACTA2 actin, alpha 2, smooth muscle, aorta IPI00008603 0.0 3.5 0.0 0.0 
ACTB actin, beta IPI00021439 20.0 0.0 0.0 0.0 
ACTBL2 similar to RIKEN cDNA 4732495G21 gene IPI00003269 3.8 1.0 0.0 0.0 
ADAR adenosine deaminase, RNA-specific IPI00025057 6.3 2.8 4.0 0.0 
AGRN agrin IPI00374563 4.0 0.0 0.0 0.0 
AHNAK AHNAK nucleoprotein (desmoyokin) IPI00021812 1.8 0.0 13.0 0.0 
AIFM1 
programmed cell death 8 (apoptosis-inducing 
factor) 
IPI00000690 75.8 101.5 0.0 1.5 
AIMP1 
small inducible cytokine subfamily E, member 1 
(endothelial monocyte-activating) 
IPI00006252 0.0 2.5 0.0 1.5 
AIMP2 JTV1 gene IPI00011916 0.0 0.0 3.0 0.0 
AK2 adenylate kinase 2 IPI00172460 0.0 1.5 0.0 0.0 
AKR1B10 
aldo-keto reductase family 1, member B10 (aldose 
reductase) 
IPI00105407 2.0 0.0 0.0 0.0 
AKR1C2 
aldo-keto reductase family 1, member C2 
(dihydrodiol dehydrogenase 2; bile acid binding 
protein; 3-alpha hydroxysteroid dehydrogenase, 
type III) 
IPI00005668 2.5 0.0 5.0 0.0 
ANXA1 annexin A1 IPI00218918 11.5 0.0 0.0 0.0 
ANXA2 annexin A2 IPI00418169 9.3 0.0 0.0 0.0 
ANXA2P2 Putative annexin A2-like protein IPI00334627 20.5 0.0 0.0 0.0 
AP1B1 adaptor-related protein complex 1, beta 1 subunit IPI00328257 5.8 0.0 1.5 1.5 
AP2A1 adaptor-related protein complex 2, alpha 1 subunit IPI00256684 5.5 0.0 1.5 0.0 
AP2A2 adaptor-related protein complex 2, alpha 2 subunit IPI00016621 3.8 0.0 3.5 0.0 
AP2B1 adaptor related protein complex 2, beta 1 subunit IPI00784156 4.3 0.0 0.0 0.0 
ASPH aspartate beta-hydroxylase IPI00294834 11.3 0.0 7.5 0.0 
ATAD3A ATPase family, AAA domain containing 3A IPI00295992 0.0 2.3 1.5 2.0 
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ATAD3B ATPase family, AAA domain containing 3B IPI00045921 1.3 2.0 0.0 4.0 
ATAD3B ATPase family, AAA domain containing 3B IPI00178879 0.0 1.3 0.0 0.0 
ATP1A1 
ATPase, Na+/K+ transporting, alpha 1 
polypeptide 
IPI00006482 0.0 0.5 0.0 0.0 
ATP2A2 
ATPase, Ca++ transporting, cardiac muscle, slow 
twitch 2 
IPI00177817 5.0 0.0 0.0 0.0 
ATP5A1 
ATP synthase, H+ transporting, mitochondrial F1 
complex, alpha subunit 1, cardiac muscle 
IPI00440493 1.8 0.0 0.0 0.0 
ATP5C1 
ATP synthase, H+ transporting, mitochondrial F1 
complex, gamma polypeptide 1 
IPI00395769 5.5 0.0 3.5 0.0 
ATP5J2 
ATP synthase, H+ transporting, mitochondrial F0 
complex, subunit F2 
IPI00219291 2.3 0.0 0.0 0.0 
ATP5L 
ATP synthase, H+ transporting, mitochondrial F0 
complex, subunit G 
IPI00027448 2.8 0.0 0.0 0.0 
ATXN2L ataxin 2-like IPI00456359 1.3 0.8 3.5 2.0 
BANF1 barrier to autointegration factor 1 IPI00026087 2.0 0.0 0.0 1.5 
BAT2 HLA-B associated transcript 2 IPI00010700 0.0 6.0 0.0 0.0 
BAT2D1 BAT2 domain containing 1 IPI00083708 1.0 3.8 2.0 0.0 
BRI3BP BRI3 binding protein IPI00103599 2.0 0.0 0.0 0.0 
BUB3 
BUB3 budding uninhibited by benzimidazoles 3 
homolog (yeast) 
IPI00013468 3.8 0.0 2.5 0.0 
BXDC2 brix domain containing 2 IPI00181728 2.8 0.0 0.0 0.0 
C14orf156 chromosome 14 open reading frame 156 IPI00009922 0.0 0.0 1.5 0.0 
C14orf166 chromosome 14 open reading frame 166 IPI00006980 0.8 0.0 10.5 5.0 
C16orf80 gene trap locus 3 (mouse) IPI00001655 0.0 0.0 2.5 0.0 
C19orf66 hypothetical protein FLJ11286 IPI00167592 1.8 0.0 0.0 0.0 
C1orf57 chromosome 1 open reading frame 57 IPI00031570 0.0 3.8 0.0 0.0 
C1QBP 
complement component 1, q subcomponent 
binding protein 
IPI00014230 1.5 2.8 5.0 0.0 
C22orf28 hypothetical protein HSPC117 IPI00550689 2.8 0.0 2.0 0.0 
CAD 
carbamoyl-phosphate synthetase 2, aspartate 
transcarbamylase, and dihydroorotase 
IPI00301263 6.8 1.0 0.0 0.0 
CALM1;CAL
M3;CALM2 
calmodulin 2 (phosphorylase kinase, delta) IPI00075248 0.0 0.0 1.5 0.0 
CAPRIN1 cell cycle associated protein 1 IPI00783872 7.3 14.5 11.5 9.5 
CAPZA1 
capping protein (actin filament) muscle Z-line, 
alpha 1 
IPI00005969 0.5 0.0 0.0 0.0 
CBX1 
chromobox homolog 1 (HP1 beta homolog 
Drosophila ) 
IPI00010320 0.0 0.0 2.0 0.0 
CCDC124 hypothetical protein BC013949 IPI00060627 0.0 0.0 1.5 3.5 
CCT2 chaperonin containing TCP1, subunit 2 (beta) IPI00297779 27.8 12.8 0.0 0.0 
CCT3 chaperonin containing TCP1, subunit 3 (gamma) IPI00290770 66.8 29.5 0.0 0.0 
CCT5 chaperonin containing TCP1, subunit 5 (epsilon) IPI00010720 54.5 19.3 0.0 0.0 
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CCT6A chaperonin containing TCP1, subunit 6A (zeta 1) IPI00027626 52.8 23.0 1.5 0.0 
CCT7 chaperonin containing TCP1, subunit 7 (eta) IPI00018465 56.0 24.3 2.0 0.0 
CCT8 chaperonin containing TCP1, subunit 8 (theta) IPI00302925 54.0 21.5 0.0 0.0 
CENPV proline rich 6 IPI00376481 0.0 0.0 3.0 0.0 
CEP170 centrosomal protein 170kDa IPI00186194 1.5 1.0 0.0 0.0 
CHCHD4 
coiled-coil-helix-coiled-coil-helix domain 
containing 4 
IPI00177428 9.8 7.0 0.0 0.0 
CIRBP cold inducible RNA binding protein IPI00180954 0.0 0.0 0.0 1.5 
CKAP4 cytoskeleton-associated protein 4 IPI00141318 25.3 1.8 9.0 0.0 
CKAP5 cytoskeleton associated protein 5 IPI00028275 11.5 11.0 11.5 0.0 
CLASP1 cytoplasmic linker associated protein 1 IPI00396279 1.5 1.3 0.0 0.0 
CLASP2 cytoplasmic linker associated protein 2 IPI00024382 1.3 0.8 2.0 0.0 
CLTC clathrin, heavy polypeptide (Hc) IPI00024067 9.3 0.0 9.0 0.0 
CNOT1 CCR4-NOT transcription complex, subunit 1 IPI00166010 0.0 5.3 0.0 0.0 
CNP 2',3'-cyclic nucleotide 3' phosphodiesterase IPI00220993 2.3 0.0 0.0 0.0 
COL18A1 collagen, type XVIII, alpha 1 IPI00022822 0.8 0.0 0.0 0.0 
COL1A2 collagen, type I, alpha 2 IPI00304962 0.0 3.8 0.0 0.0 
COPA coatomer protein complex, subunit alpha IPI00295857 0.8 0.0 0.0 0.0 
CORO1C coronin 1C IPI00798401 0.0 0.0 10.5 0.0 
CPSF6 
cleavage and polyadenylation specific factor 6, 
68kDa 
IPI00012998 3.0 0.0 0.0 0.0 
CROP 
cisplatin resistance-associated overexpressed 
protein 
IPI00107745 0.0 0.0 2.5 0.0 
CSDA cold shock domain protein A IPI00031801 5.5 0.0 6.0 0.0 
CSDE1 cold shock domain containing E1, RNA-binding IPI00470891 1.3 0.0 0.0 0.0 
CSNK1A1L casein kinase 1, alpha 1-like IPI00167096 0.0 0.0 2.0 0.0 
CTNND1 catenin (cadherin-associated protein), delta 1 IPI00182469 2.5 0.0 0.0 0.0 
DAP3 death associated protein 3 IPI00018120 3.3 0.0 0.0 0.0 
DDX1 DEAD (Asp-Glu-Ala-Asp) box polypeptide 1 IPI00293655 8.0 2.5 15.0 15.5 
DDX17 DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 IPI00023785 8.0 7.3 0.0 7.0 
DDX21 DEAD (Asp-Glu-Ala-Asp) box polypeptide 21 IPI00015953 10.3 7.3 6.5 4.0 
DDX23 DEAD (Asp-Glu-Ala-Asp) box polypeptide 23 IPI00006725 2.8 1.0 0.0 0.0 
DDX24 DEAD (Asp-Glu-Ala-Asp) box polypeptide 24 IPI00006987 2.5 0.0 0.0 0.0 
DDX3X 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-
linked 
IPI00215637 19.0 3.3 17.0 9.5 
DDX3Y;LOC1
00130220 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-
linked 
IPI00293616 1.5 0.0 0.0 0.0 
DDX46 DEAD (Asp-Glu-Ala-Asp) box polypeptide 46 IPI00329791 1.3 0.0 2.5 0.0 
DDX5 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 IPI00017617 14.5 8.5 13.0 10.5 
DDX50 DEAD (Asp-Glu-Ala-Asp) box polypeptide 50 IPI00031554 0.0 0.0 0.0 2.0 
DDX54 DEAD (Asp-Glu-Ala-Asp) box polypeptide 54 IPI00152510 2.3 0.0 0.0 0.0 
DDX6 DEAD (Asp-Glu-Ala-Asp) box polypeptide 6 IPI00030320 0.0 0.0 0.0 1.5 
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DDX60 hypothetical protein FLJ20035 IPI00217606 6.0 0.0 0.0 0.0 
DDX60L DEAD-Box Helicase 60-Like IPI00853133 2.5 0.0 0.0 0.0 
DECR1 2,4-dienoyl CoA reductase 1, mitochondrial IPI00003482 3.3 2.0 3.5 0.0 
DERA 
2-deoxyribose-5-phosphate aldolase homolog (C. 
elegans) 
IPI00219677 9.3 0.0 0.0 0.0 
DHX15 DEAH (Asp-Glu-Ala-His) box polypeptide 15 IPI00396435 8.8 4.3 2.5 2.5 
DHX29 DEAH (Asp-Glu-Ala-His) box polypeptide 29 IPI00217413 5.3 5.5 3.0 0.0 
DHX30 DEAH (Asp-Glu-Ala-His) box polypeptide 30 IPI00164906 0.0 0.5 0.0 0.0 
DHX30 DEAH (Asp-Glu-Ala-His) box polypeptide 30 IPI00411733 4.0 8.0 8.5 6.5 
DHX36 DEAH (Asp-Glu-Ala-His) box polypeptide 36 IPI00027415 4.8 2.8 2.0 4.5 
DHX57 
DEAH (Asp-Glu-Ala-Asp/His) box polypeptide 
57 
IPI00168885 1.8 0.0 0.0 0.0 
DHX9 DEAH (Asp-Glu-Ala-His) box polypeptide 9 IPI00844578 34.5 28.8 20.5 6.0 
DIMT1L dimethyladenosine transferase IPI00004459 0.0 0.0 2.0 1.5 
DNAJA1 DnaJ (Hsp40) homolog, subfamily A, member 1 IPI00012535 0.0 0.0 0.0 1.5 
DNAJA3 DnaJ (Hsp40) homolog, subfamily A, member 3 IPI00179187 1.0 0.0 1.5 1.5 
DNAJC13 DnaJ (Hsp40) homolog, subfamily C, member 13 IPI00307259 4.5 0.8 2.5 0.0 
DOCK6 dedicator of cytokinesis 6 IPI00184772 1.5 0.0 0.0 0.0 
DOCK7 dedicator of cytokinesis 7 IPI00183572 0.0 0.8 0.0 0.0 
DPM1 
dolichyl-phosphate mannosyltransferase 
polypeptide 1, catalytic subunit 
IPI00022018 0.0 0.0 0.0 2.0 
DRG1 developmentally regulated GTP binding protein 1 IPI00031836 8.3 0.0 4.5 5.0 
DSP desmoplakin IPI00013933 4.8 2.8 0.0 0.0 
DYNC1H1 dynein, cytoplasmic 1, heavy chain 1 IPI00456969 4.5 2.5 0.0 0.0 
EBNA1BP2 EBNA1 binding protein 2 IPI00745955 0.5 0.0 0.0 0.0 
ECT2 epithelial cell transforming 2  IPI00748143 1.3 0.0 0.0 0.0 
EDC4 autoantigen IPI00376317 0.0 1.0 0.0 0.0 
EEF1A1 chemokine (C-C motif) receptor 5 IPI00025447 6.5 2.0 0.0 0.0 
EEF1A2 eukaryotic translation elongation factor 1 alpha 2 IPI00014424 11.8 0.0 4.0 0.0 
EEF1E1 
eukaryotic translation elongation factor 1 epsilon 
1 
IPI00003588 0.0 0.0 0.0 2.5 
EFTUD2 
elongation factor Tu GTP binding domain 
containing 2 
IPI00003519 1.8 1.0 7.0 0.0 
EIF2AK2 
eukaryotic translation initiation factor 2-alpha 
kinase 2 
IPI00019463 17.0 1.3 7.0 3.0 
EIF2S1 
eukaryotic translation initiation factor 2, subunit 1 
alpha, 35kDa 
IPI00219678 12.0 2.3 10.5 3.5 
EIF2S2 
eukaryotic translation initiation factor 2, subunit 2 
beta, 38kDa 
IPI00021728 0.0 0.0 2.5 2.0 
EIF3A 
eukaryotic translation initiation factor 3, subunit 
10 theta, 150/170kDa 
IPI00029012 2.5 1.5 5.5 0.0 
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EIF3B 
eukaryotic translation initiation factor 3, subunit 9 
eta, 116kDa 
IPI00396370 0.0 0.0 2.0 0.0 
EIF3CL;EIF3
C 
eukaryotic translation initiation factor 3, subunit 
8, 110kDa 
IPI00016910 0.0 0.0 2.0 0.0 
EIF3F 
eukaryotic translation initiation factor 3, subunit 5 
epsilon, 47kDa 
IPI00654777 0.8 0.0 0.0 3.0 
EIF3G 
eukaryotic translation initiation factor 3, subunit 4 
delta, 44kDa 
IPI00290460 0.8 0.0 0.0 0.0 
EIF3L 
eukaryotic translation initiation factor 3, subunit 6 
interacting protein 
IPI00465233 0.0 1.3 0.0 2.5 
EIF4A1;SNOR
A67 
eukaryotic translation initiation factor 4A, isoform 
1 
IPI00025491 0.0 0.0 1.5 0.0 
EIF4A3 DEAD (Asp-Glu-Ala-Asp) box polypeptide 48 IPI00009328 0.0 0.0 0.0 2.0 
EIF4B eukaryotic translation initiation factor 4B IPI00012079 1.3 0.0 0.0 0.0 
EIF4G1 eukaryotic translation initiation factor 4 gamma, 1 IPI00220365 0.8 0.8 5.5 0.0 
EIF4G1 eukaryotic translation initiation factor 4 gamma, 1 IPI00386533 2.5 1.3 2.5 0.0 
EIF4G3 eukaryotic translation initiation factor 4 gamma, 3 IPI00328268 0.0 0.5 0.0 0.0 
EIF5A2 eukaryotic translation initiation factor 5A2 IPI00006935 1.0 0.0 0.0 0.0 
EIF5B eukaryotic translation initiation factor 5B IPI00299254 10.0 10.5 6.5 0.0 
ELAVL1 
ELAV (embryonic lethal, abnormal vision, 
Drosophila)-like 1 (Hu antigen R) 
IPI00301936 4.0 3.8 14.0 10.0 
EMD emerin (Emery-Dreifuss muscular dystrophy) IPI00032003 1.8 2.5 14.5 2.0 
EMG1 EMG1 nucleolar protein homolog (S. cerevisiae) IPI00025347 0.0 0.0 2.5 0.0 
EPPK1 epiplakin 1 IPI00010951 0.8 0.0 9.5 0.0 
EPRS glutamyl-prolyl-tRNA synthetase IPI00013452 9.3 11.3 5.5 2.5 
ERLIN1 SPFH domain family, member 1 IPI00007940 2.3 0.0 0.0 0.0 
EWSR1 Ewing sarcoma breakpoint region 1 IPI00009841 0.0 0.0 0.0 1.5 
EXOSC10 exosome component 10 IPI00009464 2.8 0.8 1.5 0.0 
EXOSC6 exosome component 6 IPI00073602 0.0 1.8 0.0 0.0 
EXOSC9 exosome component 9 IPI00029697 1.0 0.0 0.0 0.0 
FAM120A chromosome 9 open reading frame 10 IPI00039626 6.3 0.0 11.5 4.0 
FAM164A chromosome 8 open reading frame 70 IPI00329753 0.5 0.0 0.0 0.0 
FAM83H family with sequence similarity 83 member H IPI00784320 0.0 0.0 4.0 0.0 
FAM91A1 family with sequence similarity 91, member A1 IPI00152671 1.0 0.0 0.0 0.0 
FARSA 
phenylalanine-tRNA synthetase-like, alpha 
subunit 
IPI00031820 0.0 1.8 0.0 0.0 
FARSB phenylalanine-tRNA synthetase-like, beta subunit IPI00300074 3.3 2.5 1.5 3.0 
FASN fatty acid synthase IPI00026781 1.5 0.0 0.0 0.0 
FAU 
Finkel-Biskis-Reilly murine sarcoma virus (FBR-
MuSV) ubiquitously expressed (fox derived); 
ribosomal protein S30 
IPI00019770 3.3 0.0 0.0 0.0 
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FBL fibrillarin IPI00025039 1.5 0.0 3.5 0.0 
FLNA filamin A, alpha (actin binding protein 280) IPI00302592 11.8 0.0 38.5 0.0 
FLNB filamin B, beta (actin binding protein 278) IPI00289334 6.5 0.0 10.5 0.0 
FLNC filamin C, gamma (actin binding protein 280) IPI00178352 3.8 0.0 0.0 0.0 
FMR1 fragile X mental retardation 1 IPI00215720 3.3 5.8 0.0 6.5 
FUS 
fusion (involved in t(12;16) in malignant 
liposarcoma) 
IPI00221354 0.0 1.3 0.0 0.0 
FXR1 
fragile X mental retardation, autosomal homolog 
1 
IPI00016249 4.8 2.0 4.0 3.5 
FXR2 
fragile X mental retardation, autosomal homolog 
2 
IPI00016250 0.0 5.0 0.0 4.5 
G3BP1 
Ras-GTPase-activating protein SH3-domain-
binding protein 
IPI00012442 8.3 6.8 10.5 12.0 
G3BP2 
Ras-GTPase activating protein SH3 domain-
binding protein 2 
IPI00009057 1.5 3.5 0.0 6.0 
G6PD glucose-6-phosphate dehydrogenase IPI00216008 2.8 0.0 0.0 0.0 
GCN1L1 
GCN1 general control of amino-acid synthesis 1-
like 1 (yeast) 
IPI00001159 3.3 0.8 0.0 0.0 
GIGYF2 trinucleotide repeat containing 15 IPI00647635 0.0 0.5 0.0 0.0 
GNB2L1 
guanine nucleotide binding protein (G protein), 
beta polypeptide 2-like 1 
IPI00641950 1.3 3.3 0.0 0.0 
GNL3 
guanine nucleotide binding protein-like 3 
(nucleolar) 
IPI00003886 2.0 4.5 0.0 5.0 
GRWD1 glutamate-rich WD repeat containing 1 IPI00027831 3.0 0.0 0.0 0.0 
GTF2I general transcription factor II, i IPI00054042 2.8 0.0 2.0 0.0 
GTF3C1 
general transcription factor IIIC, polypeptide 1, 
alpha 220kDa 
IPI00414481 0.5 0.0 0.0 0.0 
GTPBP1 GTP binding protein 1 IPI00010463 0.0 1.3 0.0 0.0 
GTPBP4 GTP binding protein 4 IPI00385042 4.3 0.0 0.0 2.0 
H1FX H1 histone family, member X IPI00021924 5.5 0.0 4.5 2.0 
H2AFV H2A histone family, member V IPI00018278 3.8 0.0 0.0 5.0 
H2AFY H2A histone family, member Y IPI00059366 3.0 0.0 8.0 0.0 
HADHA 
hydroxyacyl-Coenzyme A dehydrogenase/3-
ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme 
A hydratase (trifunctional protein), alpha subunit 
IPI00031522 24.3 8.0 15.0 0.0 
HADHB 
hydroxyacyl-Coenzyme A dehydrogenase/3-
ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme 
A hydratase (trifunctional protein), beta subunit 
IPI00022793 2.0 0.0 0.0 0.0 
HDLBP high density lipoprotein binding protein (vigilin) IPI00022228 3.8 1.0 5.5 0.0 
HERC5 hect domain and RLD 5 IPI00008821 1.3 1.3 0.0 0.0 
HIST1H1C histone 1, H1c IPI00217465 3.3 1.5 0.0 0.0 
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HIST1H4J;HIS
T1H4E;HIST1
H4H;HIST1H4
K;HIST2H4A;
HIST1H4D;HI
ST1H4F;HIST
2H4B;HIST1H
4C;HIST1H4B;
HIST1H4I;HIS
T1H4L;HIST1
H4A;HIST4H4 
histone 2, H4 IPI00453473 8.3 0.0 0.0 0.0 
HIST2H2BE histone 2, H2be IPI00003935 0.0 2.0 32.5 6.0 
HNRNPA0 heterogeneous nuclear ribonucleoprotein A0 IPI00011913 2.3 0.0 8.5 2.0 
HNRNPA1 heterogeneous nuclear ribonucleoprotein A1 IPI00215965 14.0 8.5 10.0 5.5 
HNRNPA2B1 heterogeneous nuclear ribonucleoprotein A2/B1 IPI00386854 0.8 1.8 15.5 11.0 
HNRNPA2B1 heterogeneous nuclear ribonucleoprotein A2/B1 IPI00396378 5.5 11.0 7.0 4.5 
HNRNPA3 heterogeneous nuclear ribonucleoprotein A3 IPI00419373 7.5 5.8 12.0 4.0 
HNRNPAB heterogeneous nuclear ribonucleoprotein A/B IPI00106509 4.5 3.5 4.0 0.0 
HNRNPC 
heterogeneous nuclear ribonucleoprotein C 
(C1/C2) 
IPI00216592 9.3 2.8 10.5 3.0 
HNRNPCL1 heterogeneous nuclear ribonucleoprotein C-like 1 IPI00027569 4.5 0.0 0.0 3.0 
HNRNPD 
heterogeneous nuclear ribonucleoprotein D (AU-
rich element RNA binding protein 1, 37kDa) 
IPI00028888 3.8 4.0 2.0 3.5 
HNRNPF heterogeneous nuclear ribonucleoprotein F IPI00003881 2.8 0.0 8.5 3.0 
HNRNPH1 heterogeneous nuclear ribonucleoprotein H1 (H) IPI00013881 0.0 0.0 2.5 0.0 
HNRNPH3 
heterogeneous nuclear ribonucleoprotein H3 
(2H9) 
IPI00013877 2.0 0.0 7.5 0.0 
HNRNPK heterogeneous nuclear ribonucleoprotein K IPI00216049 23.5 6.0 19.5 3.5 
HNRNPL heterogeneous nuclear ribonucleoprotein L IPI00027834 2.5 1.8 7.5 4.0 
HNRNPM heterogeneous nuclear ribonucleoprotein M IPI00171903 30.0 7.8 12.5 19.0 
HNRNPR heterogeneous nuclear ribonucleoprotein R IPI00012074 6.8 2.0 6.5 4.5 
HNRNPU 
heterogeneous nuclear ribonucleoprotein U 
(scaffold attachment factor A) 
IPI00479217 19.5 11.3 9.0 9.0 
HNRNPUL1 heterogeneous nuclear ribonucleoprotein U-like 1 IPI00013070 11.3 2.8 4.5 2.5 
HNRNPUL2 heterogeneous nuclear ribonucleoprotein U-like 2 IPI00456887 3.3 0.0 0.0 0.0 
HNRPDL heterogeneous nuclear ribonucleoprotein D-like IPI00011274 2.3 2.3 3.5 2.0 
HP1BP3 heterochromatin protein 1, binding protein 3 IPI00640417 2.0 0.0 0.0 0.0 
HRNR hornerin IPI00398625 2.0 0.0 0.0 0.0 
HSD17B12 hydroxysteroid (17-beta) dehydrogenase 12 IPI00007676 3.0 2.3 0.0 0.0 
HSP90AA1 
heat shock protein 90kDa alpha (cytosolic), class 
A member 1 
IPI00382470 3.0 1.5 0.0 0.0 
HSPA1A;HSP
A1B 
heat shock 70kDa protein 1A IPI00304925 7.8 0.0 0.0 5.0 
HSPA1L heat shock 70kDa protein 7 (HSP70B) IPI00301277 4.8 2.3 4.0 5.5 
HSPA2 heat shock 70kDa protein 2 IPI00007702 1.5 0.0 0.0 0.0 
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HSPA5 
heat shock 70kDa protein 5 (glucose-regulated 
protein, 78kDa) 
IPI00003362 0.0 0.0 4.0 4.0 
HSPA8 heat shock 70kDa protein 8 IPI00003865 31.0 0.0 19.5 8.0 
HSPD1 heat shock protein family D (Hsp60) member 1 IPI00784154 2.8 0.0 0.0 0.0 
IARS isoleucine-tRNA synthetase IPI00644127 3.3 2.0 5.5 2.5 
IFI16 interferon, gamma-inducible protein 16 IPI00003443 2.8 0.0 0.0 0.0 
IFIT3 
interferon-induced protein with tetratricopeptide 
repeats 3 
IPI00024254 1.0 0.0 0.0 0.0 
IGF2BP1 
insulin-like growth factor 2 mRNA binding 
protein 1 
IPI00008557 19.8 21.0 17.0 21.5 
IGF2BP2 
insulin-like growth factor 2 mRNA binding 
protein 2 
IPI00179713 4.0 2.5 0.0 4.0 
IGF2BP3 
insulin-like growth factor 2 mRNA binding 
protein 3 
IPI00165467 3.0 1.0 3.0 6.5 
IGF2BP3 
insulin-like growth factor 2 mRNA binding 
protein 3 
IPI00658000 7.3 6.3 10.0 9.5 
IGLC1;IGLV1
-44;IGLV1-
40;IGLV3-
21;IGLV2-
11;IGLV2-
14;IGL@;IGL
C2;IGLC3 
immunoglobulin lambda constant 1 (Mcg marker) IPI00154742 3.8 0.0 0.0 0.0 
ILF2 interleukin enhancer binding factor 2, 45kDa IPI00005198 12.8 11.3 7.5 11.5 
ILF3 interleukin enhancer binding factor 3, 90kDa IPI00219330 14.5 8.5 10.5 16.0 
ILK-2;CCT4 chaperonin containing TCP1, subunit 4 (delta) IPI00302927 44.0 17.0 0.0 0.0 
IMMT inner membrane protein, mitochondrial (mitofilin) IPI00009960 2.5 1.3 1.5 0.0 
IMP3 
IMP3, U3 small nucleolar ribonucleoprotein, 
homolog (yeast) 
IPI00019488 0.0 0.0 2.0 0.0 
IPO7 importin 7 IPI00007402 2.5 1.0 0.0 0.0 
IQGAP1 IQ motif containing GTPase activating protein 1 IPI00009342 13.8 0.0 19.5 0.0 
ISG15 
interferon, alpha-inducible protein (clone IFI-
15K) 
IPI00375631 14.0 0.0 0.0 0.0 
KARS lysyl-tRNA synthetase IPI00014238 1.5 1.8 0.0 3.0 
KHDRBS1 
KH domain containing, RNA binding, signal 
transduction associated 1 
IPI00008575 0.8 1.8 0.0 4.0 
KIAA0020 pumilio RNA binding family member 3 IPI00791325 0.8 0.0 4.0 0.0 
KIAA1618 KIAA1618 IPI00217287 22.0 0.0 0.0 0.0 
KIAA1618 KIAA1618 IPI00218094 19.5 0.0 0.0 0.0 
KIAA1618 chromosome 17 open reading frame 27 IPI00642126 76.3 0.0 1.5 0.0 
KIAA1967 KIAA1967 IPI00182757 3.0 0.0 0.0 0.0 
KIF2A kinesin heavy chain member 2 IPI00010368 3.0 0.0 0.0 0.0 
KIFC1 kinesin family member C1 IPI00306400 0.0 2.5 0.0 0.0 
KPNB1 karyopherin (importin) beta 1 IPI00001639 4.3 1.5 4.0 0.0 
KTN1 kinectin 1 (kinesin receptor) IPI00328753 2.0 0.0 0.0 0.0 
LACTB lactamase, beta IPI00294186 5.8 0.0 2.5 0.0 
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LAMA5 laminin subunit alpha 5 IPI00783665 5.3 0.0 0.0 0.0 
LAMB1 laminin, beta 1 IPI00013976 3.0 0.0 0.0 0.0 
LAMC1 laminin, gamma 1 (formerly LAMB2) IPI00298281 2.5 0.0 0.0 0.0 
LARP1 La ribonucleoprotein domain family, member 1 IPI00185919 11.0 7.8 14.5 8.0 
LARP4 La ribonucleoprotein domain family, member 4 IPI00043638 0.0 0.0 0.0 1.5 
LARP4B La ribonucleoprotein domain family member 4B IPI00827634 1.0 0.0 0.0 3.5 
LARS leucyl-tRNA synthetase IPI00103994 0.0 2.5 2.0 1.5 
LBA1 
tetratricopeptide repeat and ankyrin repeat 
containing 1 
IPI00847543 1.8 0.0 0.0 0.0 
LEMD2 LEM domain containing 2 IPI00168336 0.0 0.0 8.5 0.0 
LIG3 ligase III, DNA, ATP-dependent IPI00000156 0.0 1.0 7.0 0.0 
LMNA lamin A/C IPI00021405 23.0 0.0 52.5 0.0 
LMNB1 lamin B1 IPI00217975 1.3 0.8 13.0 0.0 
LOC26010 DNA polymerase-transactivated protein 6 IPI00023532 4.8 0.0 0.0 0.0 
LOC442497;SL
C3A2 
solute carrier family 3 (activators of dibasic and 
neutral amino acid transport), member 2 
IPI00027493 6.0 0.0 0.0 0.0 
LOC652595   IPI00183920 1.3 0.0 0.0 1.5 
LRPPRC leucine rich pentatricopeptide repeat containing IPI00783271 7.8 2.8 15.5 0.0 
LRRC59 leucine rich repeat containing 59 IPI00396321 8.3 2.3 10.0 4.5 
LUC7L2 LUC7-like 2 (S. cerevisiae) IPI00006932 1.5 0.0 0.0 2.0 
MACF1 microtubule-actin crosslinking factor 1 IPI00256861 3.0 0.0 0.0 0.0 
MAP1B microtubule-associated protein 1B IPI00008868 13.8 0.0 5.0 0.0 
MAP4 microtubule-associated protein 4 IPI00220113 0.0 3.5 5.0 3.0 
MAP4 microtubule-associated protein 4 IPI00396171 2.5 0.0 0.0 0.0 
MAP7 microtubule-associated protein 7 IPI00020771 8.5 0.0 0.0 0.0 
MARS methionine-tRNA synthetase IPI00008240 0.0 2.0 0.0 5.0 
MATR3 matrin 3 IPI00017297 7.5 7.8 13.0 7.0 
MCM3 
MCM3 minichromosome maintenance deficient 3 
(S. cerevisiae) 
IPI00013214 1.0 0.0 0.0 0.0 
MDN1 MDN1, midasin homolog (yeast) IPI00167941 0.0 0.8 0.0 0.0 
MKI67 antigen identified by monoclonal antibody Ki-67 IPI00004233 0.0 0.0 2.5 0.0 
MKI67IP 
MKI67 (FHA domain) interacting nucleolar 
phosphoprotein 
IPI00154590 0.0 0.0 3.5 0.0 
MOV10 
Mov10, Moloney leukemia virus 10, homolog 
(mouse) 
IPI00444452 14.0 20.8 10.5 21.5 
MPRIP myosin phosphatase-Rho interacting protein IPI00166518 2.3 1.5 6.5 0.0 
MRPL11 mitochondrial ribosomal protein L11 IPI00007001 0.0 0.0 1.5 0.0 
MRPS22 mitochondrial ribosomal protein S22 IPI00013146 0.0 0.0 1.5 0.0 
MRPS27 mitochondrial ribosomal protein S27 IPI00022002 1.3 0.0 0.0 0.0 
MRPS9 mitochondrial ribosomal protein S9 IPI00641924 2.8 0.0 0.0 0.0 
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MRTO4 chromosome 1 open reading frame 33 IPI00106491 0.0 0.0 2.0 1.5 
MSH2 
mutS homolog 2, colon cancer, nonpolyposis type 
1 (E. coli) 
IPI00017303 1.5 0.0 0.0 0.0 
MSH6 mutS homolog 6 (E. coli) IPI00106847 3.3 0.5 3.0 0.0 
MSI2 musashi homolog 2 (Drosophila) IPI00073713 0.0 0.0 0.0 2.0 
MTDH metadherin IPI00328715 1.8 0.0 0.0 0.0 
MTUS1 mitochondrial tumor suppressor 1 IPI00428447 1.8 0.0 0.0 0.0 
MVP major vault protein IPI00000105 1.3 0.0 0.0 0.0 
MX1 
myxovirus (influenza virus) resistance 1, 
interferon-inducible protein p78 (mouse) 
IPI00167949 2.8 0.0 0.0 0.0 
MYBBP1A MYB binding protein (P160) 1a IPI00005024 32.5 22.5 7.5 2.0 
MYH10 myosin, heavy polypeptide 10, non-muscle IPI00397526 12.5 5.3 0.0 0.0 
MYH9 myosin, heavy polypeptide 9, non-muscle IPI00019502 144.8 2.0 0.0 0.0 
MYL12B myosin regulatory light chain MRLC2 IPI00033494 6.8 0.0 0.0 0.0 
MYL6;MYL6B 
myosin, light polypeptide 6, alkali, smooth muscle 
and non-muscle 
IPI00335168 6.5 0.0 0.0 0.0 
MYL9 myosin, light polypeptide 9, regulatory IPI00030929 5.3 0.0 0.0 0.0 
MYO1B myosin IB IPI00376344 10.0 0.0 29.5 0.0 
MYO1C myosin IC IPI00010418 27.5 6.5 27.5 0.0 
MYO1D myosin ID IPI00329719 0.0 3.0 1.5 0.0 
MYO1E myosin IE IPI00329672 3.0 0.0 3.5 0.0 
MYO6 myosin VI IPI00008455 0.0 2.3 9.0 0.0 
MYO9B myosin IXB IPI00306933 0.5 0.0 0.0 0.0 
NACA 
nascent-polypeptide-associated complex alpha 
polypeptide 
IPI00023748 3.3 0.0 0.0 0.0 
NAT10 N-acetyltransferase 10 IPI00300127 0.0 0.0 2.0 0.0 
NCBP1 nuclear cap binding protein subunit 1, 80kDa IPI00019380 4.3 1.0 4.5 9.0 
NCL nucleolin IPI00183526 29.8 15.0 19.0 14.5 
NCL nucleolin IPI00444262 25.3 12.8 9.5 16.5 
NME4 non-metastatic cells 4, protein expressed in IPI00012972 2.3 0.0 0.0 0.0 
NMNAT1 nicotinamide nucleotide adenylyltransferase 1 IPI00009726 0.0 0.8 0.0 0.0 
NOL6 nucleolar protein family 6 (RNA-associated) IPI00152890 0.0 0.0 2.0 0.0 
NOM1 nucleolar protein with MIF4G domain 1 IPI00145593 1.8 0.0 0.0 0.0 
NONO non-POU domain containing, octamer-binding IPI00304596 2.5 6.8 5.5 0.0 
NOP2 nucleolar protein 1, 120kDa IPI00294891 8.8 2.3 5.0 0.0 
NOP56 nucleolar protein 5A (56kDa with KKE/D repeat) IPI00411937 0.0 0.0 3.5 0.0 
NOP58 nucleolar protein NOP5/NOP58 IPI00006379 2.5 0.0 2.0 0.0 
NPM1 anaplastic lymphoma kinase (Ki-1) IPI00220740 12.0 5.3 15.5 10.5 
NSUN2 NOL1/NOP2/Sun domain family, member 2 IPI00306369 5.3 0.0 0.0 0.0 
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NUFIP2 
nuclear fragile X mental retardation protein 
interacting protein 2 
IPI00002349 0.0 0.0 2.0 3.0 
NUMA1 nuclear mitotic apparatus protein 1 IPI00006196 0.5 0.0 0.0 0.0 
NUP133 nucleoporin 133kDa IPI00291200 0.0 0.0 2.0 0.0 
OAS2 2'-5'-oligoadenylate synthetase 2, 69/71kDa IPI00217049 2.0 0.0 0.0 0.0 
OAS3 2'-5'-oligoadenylate synthetase 3, 100kDa IPI00002405 16.8 0.0 0.0 0.0 
OGDH 
oxoglutarate (alpha-ketoglutarate) dehydrogenase 
(lipoamide) 
IPI00098902 3.8 0.0 0.0 0.0 
PA2G4 proliferation-associated 2G4, 38kDa IPI00299000 0.0 1.3 0.0 0.0 
PABPC1 poly(A) binding protein, cytoplasmic 1 IPI00008524 35.8 21.5 39.5 38.5 
PABPC4 
poly(A) binding protein, cytoplasmic 4 (inducible 
form) 
IPI00012726 6.3 3.5 7.0 13.5 
PARP1 poly (ADP-ribose) polymerase family, member 1 IPI00449049 20.0 15.5 24.0 20.5 
PARP9 poly (ADP-ribose) polymerase family, member 9 IPI00027803 0.5 0.0 0.0 0.0 
PCBP2 poly(rC) binding protein 2 IPI00012066 0.0 0.0 0.0 3.5 
PDCD11 programmed cell death 11 IPI00400922 0.0 0.0 3.0 0.0 
PELP1 proline, glutamic acid and leucine rich protein 1 IPI00006702 0.8 3.0 0.0 0.0 
PFDN2 prefoldin subunit 2 IPI00006052 2.5 0.0 0.0 0.0 
PFKP phosphofructokinase, platelet IPI00009790 0.0 0.0 2.0 0.0 
PGAM5 phosphoglycerate mutase family member 5 IPI00063242 3.3 1.8 5.5 3.0 
PGAM5 phosphoglycerate mutase family member 5 IPI00788907 2.5 0.0 0.0 0.0 
PHB2 prohibitin 2 IPI00027252 1.0 0.0 0.0 0.0 
PLEC1 
plectin 1, intermediate filament binding protein 
500kDa 
IPI00014898 67.5 1.5 153.5 0.0 
PNO1 putatative 28 kDa protein IPI00024524 0.0 0.0 1.5 0.0 
POLRMT polymerase (RNA) mitochondrial (DNA directed) IPI00298738 2.5 0.0 2.0 0.0 
PPIB peptidylprolyl isomerase B (cyclophilin B) IPI00646304 0.0 0.0 2.0 0.0 
PPP1CC 
protein phosphatase 1, catalytic subunit, gamma 
isoform 
IPI00005705 0.0 0.8 0.0 0.0 
PPP1R12A 
protein phosphatase 1, regulatory (inhibitor) 
subunit 12A 
IPI00183002 0.0 0.0 1.5 0.0 
PRDX1 peroxiredoxin 1 IPI00000874 0.0 0.0 4.0 0.0 
PRIC285 
peroxisomal proliferator-activated receptor A 
interacting complex 285 
IPI00249304 24.0 2.5 0.0 0.0 
PRKDC 
protein kinase, DNA-activated, catalytic 
polypeptide 
IPI00296337 76.5 43.0 46.0 0.0 
PRKRA 
protein kinase, interferon-inducible double 
stranded RNA dependent activator 
IPI00021167 0.0 1.8 0.0 0.0 
PRPF40A pre-mRNA processing factor 40 homolog A IPI00337385 0.0 0.5 0.0 0.0 
PRPF8 
PRP8 pre-mRNA processing factor 8 homolog 
(yeast) 
IPI00007928 1.8 2.0 3.5 0.0 
PRPH peripherin IPI00013164 0.0 0.0 2.5 0.0 
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PSMC5 
proteasome (prosome, macropain) 26S subunit, 
ATPase, 5 
IPI00023919 1.3 0.0 0.0 0.0 
PSPC1 paraspeckle component 1 IPI00103525 0.0 1.0 0.0 0.0 
PTBP1 polypyrimidine tract binding protein 1 IPI00179964 6.3 8.3 10.5 0.0 
PTCD3 pentatricopeptide repeat domain 3 IPI00783302 0.5 0.0 0.0 0.0 
PTK2 PTK2 protein tyrosine kinase 2 IPI00012885 1.0 0.0 0.0 0.0 
PTPLAD1 
protein tyrosine phosphatase-like A domain 
containing 1 
IPI00008998 4.0 0.0 3.0 0.0 
PTRF polymerase I and transcript release factor IPI00176903 6.3 0.0 0.0 0.0 
PURA purine-rich element binding protein A IPI00023591 0.0 0.5 3.0 2.5 
PYGM 
phosphorylase, glycogen; muscle (McArdle 
syndrome, glycogen storage disease type V) 
IPI00218130 1.3 0.0 0.0 0.0 
QARS glutaminyl-tRNA synthetase IPI00026665 1.0 0.0 1.5 3.5 
RAI14 retinoic acid induced 14 IPI00292953 2.8 2.0 11.0 0.0 
RALY 
RNA binding protein, autoantigenic (hnRNP-
associated with lethal yellow homolog (mouse)) 
IPI00011268 0.5 0.0 3.5 0.0 
RANBP2 RAN binding protein 2 IPI00221325 0.0 0.0 2.5 0.0 
RARS arginyl-tRNA synthetase IPI00004860 2.8 3.5 1.5 2.5 
RBM14;RBM4 RNA binding motif protein 14 IPI00013174 0.0 5.0 3.0 4.5 
RBM25 RNA binding motif protein 25 IPI00004273 0.5 0.0 0.0 0.0 
RBM28 RNA binding motif protein 28 IPI00304187 2.5 0.0 0.0 0.0 
RBM39 RNA-binding region (RNP1, RRM) containing 2 IPI00163505 3.5 1.8 0.0 3.0 
RBMX RNA binding motif protein, X-linked IPI00304692 0.8 0.0 0.0 0.0 
RECQL RecQ protein-like (DNA helicase Q1-like) IPI00178431 1.3 0.0 0.0 0.0 
RFC1 replication factor C (activator 1) 1, 145kDa IPI00375358 0.0 1.5 0.0 0.0 
RFC2 replication factor C (activator 1) 2, 40kDa IPI00017412 0.0 0.0 2.0 0.0 
RFC4 replication factor C (activator 1) 4, 37kDa IPI00017381 3.3 0.0 2.5 0.0 
RFC5 replication factor C (activator 1) 5, 36.5kDa IPI00031514 1.5 0.0 0.0 0.0 
RIF1 RAP1 interacting factor homolog (yeast) IPI00293845 0.0 0.0 3.5 0.0 
RNF213 ring finger protein 213 IPI00470478 12.8 0.0 0.0 0.0 
RPA1 replication protein A1, 70kDa IPI00020127 0.0 2.5 13.0 2.5 
RPA2 replication protein A2, 32kDa IPI00013939 0.0 0.0 5.5 0.0 
RPL10A ribosomal protein L10a IPI00412579 6.8 20.0 6.0 5.5 
RPL10L ribosomal protein L10-like IPI00064765 0.0 0.0 3.0 0.0 
RPL10P16 ribosomal protein L10 pseudogene 16 IPI00374260 2.0 0.0 0.0 0.0 
RPL11 ribosomal protein L11 IPI00376798 5.5 2.5 0.0 0.0 
RPL12 ribosomal protein L12 IPI00024933 18.8 10.5 5.0 11.0 
RPL13 ribosomal protein L13 IPI00465361 7.3 1.0 6.5 4.5 
RPL13A ribosomal protein L13a IPI00304612 5.8 1.0 2.0 3.5 
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RPL13P12 ribosomal protein L13 pseudogene 12 IPI00397611 9.0 9.8 9.5 9.5 
RPL14 ribosomal protein L14 IPI00555744 3.0 0.0 0.0 0.0 
RPL15 ribosomal protein L15 IPI00470528 0.0 6.0 8.0 4.0 
RPL18 ribosomal protein L18 IPI00215719 13.5 11.3 9.0 7.5 
RPL18A ribosomal protein L18a IPI00026202 5.8 1.8 9.5 3.0 
RPL19 ribosomal protein L19 IPI00025329 6.8 2.5 4.5 0.0 
RPL21P19;RP
L21;RPL21P16 
ribosomal protein L21 IPI00247583 10.0 8.3 8.5 6.0 
RPL22 ribosomal protein L22 IPI00219153 0.0 1.3 0.0 0.0 
RPL23 ribosomal protein L23 IPI00010153 7.3 6.8 15.5 12.5 
RPL23A ribosomal protein L23a IPI00021266 14.3 8.8 11.0 12.0 
RPL24 ribosomal protein L24 IPI00306332 6.3 7.5 7.5 4.5 
RPL26L1 ribosomal protein L26-like 1 IPI00007144 6.0 4.8 8.0 7.0 
RPL27 ribosomal protein L27 IPI00219155 10.3 2.8 4.0 4.0 
RPL27A ribosomal protein L27a IPI00456758 5.3 4.0 0.0 0.0 
RPL28 ribosomal protein L28 IPI00182533 5.0 2.3 0.0 0.0 
RPL3 ribosomal protein L3 IPI00550021 19.3 18.0 15.0 13.0 
RPL30 ribosomal protein L30 IPI00219156 12.8 6.0 11.0 13.5 
RPL31 ribosomal protein L31 IPI00026302 5.5 4.0 0.0 0.0 
RPL34 ribosomal protein L34 IPI00219160 4.3 1.5 5.5 4.0 
RPL35 ribosomal protein L35 IPI00412607 2.0 3.3 3.5 3.0 
RPL35A ribosomal protein L35a IPI00029731 7.8 6.3 3.5 4.0 
RPL36 ribosomal protein L36 IPI00216237 6.8 1.8 5.5 5.5 
RPL36AL ribosomal protein L36a-like IPI00056494 1.0 0.0 0.0 0.0 
RPL37A ribosomal protein L37a IPI00414860 0.0 1.8 0.0 0.0 
RPL38 ribosomal protein L38 IPI00215790 6.3 0.0 0.0 0.0 
RPL4 ribosomal protein L4 IPI00003918 27.8 12.3 9.0 9.0 
RPL5 ribosomal protein L5 IPI00000494 15.5 11.8 13.5 11.5 
RPL6 ribosomal protein L6 IPI00329389 22.8 27.8 26.5 29.0 
RPL7;RPL7P3
2 
ribosomal protein L7 IPI00030179 15.5 11.8 17.5 18.5 
RPL7A ribosomal protein L7a IPI00299573 17.5 15.0 17.5 8.5 
RPL7AP27   IPI00075558 2.5 1.8 0.0 0.0 
RPL7L1 ribosomal protein L7-like 1 IPI00456940 0.0 0.0 2.5 0.0 
RPL8 ribosomal protein L8 IPI00012772 8.0 3.8 8.5 6.0 
RPL9 ribosomal protein L9 IPI00031691 1.8 3.8 14.5 7.0 
RPLP0 ribosomal protein, large, P0 IPI00008530 40.3 37.0 29.0 32.0 
RPLP1 ribosomal protein, large, P1 IPI00008527 7.0 2.5 0.0 4.0 
RPLP2 ribosomal protein, large, P2 IPI00008529 22.8 20.8 6.5 8.0 
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RPN1 ribophorin I IPI00025874 2.3 0.0 2.0 0.0 
RPS10 ribosomal protein S10 IPI00008438 4.3 1.8 0.0 7.0 
RPS11 ribosomal protein S11 IPI00025091 5.3 0.0 4.5 3.0 
RPS13 ribosomal protein S13 IPI00221089 12.0 6.3 11.5 6.5 
RPS14 ribosomal protein S14 IPI00026271 7.5 2.3 9.5 6.0 
RPS15 ribosomal protein S15 IPI00479058 1.0 0.0 2.0 0.0 
RPS15A ribosomal protein S15a IPI00221091 6.0 3.5 6.5 4.0 
RPS16 ribosomal protein S16 IPI00221092 9.0 4.8 16.5 15.5 
RPS17 ribosomal protein S17 IPI00221093 5.8 1.8 10.5 0.0 
RPS18;LOC10
0130553 
ribosomal protein S18 IPI00013296 16.8 5.0 16.0 11.0 
RPS19 ribosomal protein S19 IPI00215780 10.8 5.5 22.0 19.5 
RPS2 ribosomal protein S2 IPI00013485 7.3 4.3 14.5 14.0 
RPS20 ribosomal protein S20 IPI00012493 0.8 0.0 5.5 6.0 
RPS23 ribosomal protein S23 IPI00218606 8.0 0.0 9.0 5.0 
RPS24 ribosomal protein S24 IPI00029750 8.8 4.8 12.5 5.5 
RPS25 ribosomal protein S25 IPI00012750 3.8 0.0 0.0 8.0 
RPS27 ribosomal protein S27 IPI00397358 0.5 0.0 3.5 0.0 
RPS27 ribosomal protein S27 (metallopanstimulin 1) IPI00513971 0.0 0.0 2.5 0.0 
RPS28 ribosomal protein S28 IPI00719622 0.0 0.0 3.5 0.0 
RPS3 ribosomal protein S3 IPI00011253 20.3 7.3 33.5 28.5 
RPS3A ribosomal protein S3A IPI00419880 15.3 4.5 22.0 8.5 
RPS4X ribosomal protein S4, X-linked IPI00217030 18.0 8.3 25.5 17.5 
RPS5 ribosomal protein S5 IPI00008433 0.0 0.5 4.0 0.0 
RPS6 ribosomal protein S6 IPI00021840 8.0 4.0 9.0 6.0 
RPS7 ribosomal protein S7 IPI00013415 1.3 6.8 8.5 5.5 
RPS7P4   IPI00008293 1.5 0.0 3.5 1.5 
RPS8 ribosomal protein S8 IPI00216587 10.3 7.3 8.0 4.5 
RPS9 ribosomal protein S9 IPI00221088 3.0 5.5 19.5 8.0 
RPSAP12 ribosomal protein SA pseudogene 12 IPI00398958 3.3 0.0 2.0 0.0 
RRBP1 
ribosome binding protein 1 homolog 180kDa 
(dog) 
IPI00215743 55.3 4.8 6.0 0.0 
RRP12 KIAA0690 IPI00101186 1.8 0.0 0.0 0.0 
RSL1D1 ribosomal L1 domain containing 1 IPI00008708 0.5 0.0 0.0 0.0 
S100A10 
S100 calcium binding protein A10 (annexin II 
ligand, calpactin I, light polypeptide (p11)) 
IPI00183695 2.8 0.0 0.0 0.0 
SAMD9 sterile alpha motif domain containing 9 IPI00217018 1.5 0.0 0.0 0.0 
SAMHD1 SAM domain and HD domain 1 IPI00294739 2.3 0.5 0.0 0.0 
SEMG1 semenogelin I IPI00023020 7.0 0.0 0.0 0.0 
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SEMG2 semenogelin II IPI00025415 2.5 0.0 0.0 0.0 
SERBP1 SERPINE1 mRNA binding protein 1 IPI00410693 4.8 5.0 4.5 0.0 
SF3A1 splicing factor 3a, subunit 1, 120kDa IPI00017451 0.5 1.0 1.5 0.0 
SF3B1 splicing factor 3b, subunit 1, 155kDa IPI00026089 2.8 0.0 3.5 0.0 
SF3B2 splicing factor 3b, subunit 2, 145kDa IPI00221106 2.8 0.0 1.5 0.0 
SFPQ 
splicing factor proline/glutamine-rich 
(polypyrimidine tract binding protein associated) 
IPI00010740 9.8 23.5 8.0 8.0 
SFRS1 
splicing factor, arginine/serine-rich 1 (splicing 
factor 2, alternate splicing factor) 
IPI00215884 9.8 5.0 13.0 7.0 
SFRS2 splicing factor, arginine/serine-rich 2 IPI00005978 3.0 0.0 0.0 1.5 
SFRS3 splicing factor, arginine/serine-rich 3 IPI00010204 2.3 0.0 0.0 2.5 
SFRS5 splicing factor, arginine/serine-rich 5 IPI00012341 2.5 0.0 0.0 0.0 
SFRS6 splicing factor, arginine/serine-rich 6 IPI00012345 0.0 1.5 0.0 0.0 
SFRS7 splicing factor, arginine/serine-rich 7, 35kDa IPI00003377 3.5 2.5 4.0 4.0 
SFXN1 sideroflexin 1 IPI00009368 0.0 2.5 0.0 0.0 
SGPL1 sphingosine-1-phosphate lyase 1 IPI00099463 1.0 0.0 0.0 0.0 
SKIV2L2 
superkiller viralicidic activity 2-like 2 (S. 
cerevisiae) 
IPI00647217 2.3 0.0 0.0 1.5 
SLC25A1 
solute carrier family 25 (mitochondrial carrier; 
citrate transporter), member 1 
IPI00294159 1.3 0.0 0.0 0.0 
SLC25A11 
solute carrier family 25 (mitochondrial carrier; 
oxoglutarate carrier), member 11 
IPI00219729 1.5 6.0 2.0 2.5 
SLC25A12 
solute carrier family 25 (mitochondrial carrier, 
Aralar), member 12 
IPI00386271 1.0 0.0 0.0 0.0 
SLC25A13 solute carrier family 25, member 13 (citrin) IPI00007084 2.8 5.0 1.5 1.5 
SLC25A3 
solute carrier family 25 (mitochondrial carrier; 
phosphate carrier), member 3 
IPI00022202 7.0 4.0 2.0 0.0 
SLC25A5 
solute carrier family 25 (mitochondrial carrier; 
adenine nucleotide translocator), member 5 
IPI00007188 30.8 17.0 27.0 0.0 
SLC25A6 
solute carrier family 25 (mitochondrial carrier; 
adenine nucleotide translocator), member 4 
IPI00291467 7.3 0.0 7.5 0.0 
SLC2A1 
solute carrier family 2 (facilitated glucose 
transporter), member 1 
IPI00220194 0.8 0.0 0.0 0.0 
SMARCA1 
SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily a, 
member 1 
IPI00216046 0.0 0.0 4.5 0.0 
SMARCA5 
SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily a, 
member 5 
IPI00297211 0.0 0.0 1.5 0.0 
SMC1A 
SMC1 structural maintenance of chromosomes 1-
like 1 (yeast) 
IPI00291939 0.0 1.3 2.0 0.0 
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SMC2 
SMC2 structural maintenance of chromosomes 2-
like 1 (yeast) 
IPI00007927 2.0 1.0 0.0 0.0 
SMC3 chondroitin sulfate proteoglycan 6 (bamacan) IPI00219420 0.0 0.0 6.5 0.0 
SMC4 
SMC4 structural maintenance of chromosomes 4-
like 1 (yeast) 
IPI00328298 1.8 1.3 0.0 0.0 
SMCHD1 
structural maintenance of chromosomes flexible 
hinge domain containing 1 
IPI00465022 1.0 0.0 0.0 0.0 
SND1 staphylococcal nuclease domain containing 1 IPI00140420 0.5 0.0 0.0 1.5 
SNORA7A;RP
L32 
ribosomal protein L32 IPI00395998 5.0 0.0 0.0 0.0 
SNRNP200 
activating signal cointegrator 1 complex subunit 
3-like 1 
IPI00168235 0.0 2.5 0.0 0.0 
SNRNP200 
activating signal cointegrator 1 complex subunit 
3-like 1 
IPI00420014 2.3 1.3 3.0 0.0 
SNRPD1 
small nuclear ribonucleoprotein D1 polypeptide 
16kDa 
IPI00302850 0.0 0.0 0.0 2.5 
SNRPD2 
small nuclear ribonucleoprotein D2 polypeptide 
16.5kDa 
IPI00017963 2.8 0.0 0.0 3.5 
SNRPE small nuclear ribonucleoprotein polypeptide E IPI00029266 1.5 0.0 0.0 0.0 
SNRPG small nuclear ribonucleoprotein polypeptide G IPI00016572 1.5 0.0 2.0 0.0 
SPATS2 spermatogenesis associated, serine-rich 2 IPI00329345 2.3 0.0 0.0 0.0 
SPTAN1 spectrin, alpha, non-eythrocytic 1 IPI00744706 2.3 0.0 12.0 0.0 
SPTBN1 spectrin, beta, non-erythrocytic 1 IPI00005614 1.8 0.0 13.5 0.0 
SQRDL sulfide quinone reductase-like (yeast) IPI00009634 1.8 0.0 0.0 0.0 
SRP14 
signal recognition particle 14kDa (homologous 
Alu RNA binding protein) 
IPI00293434 3.3 0.0 6.5 2.0 
SRP9;SRP9L1 signal recognition particle 9kDa IPI00216125 0.5 0.0 0.0 0.0 
SRPK1 SFRS protein kinase 1 IPI00290439 0.0 0.0 0.0 3.5 
SRPK2 SFRS protein kinase 2 IPI00333420 0.8 0.0 0.0 0.0 
SRRM1 serine/arginine repetitive matrix 1 IPI00328293 1.0 0.0 0.0 0.0 
SRRM2 serine/arginine repetitive matrix 2 IPI00782992 2.5 10.0 4.5 7.0 
SRRT ARS2 protein IPI00220038 3.0 0.0 0.0 0.0 
SSB Sjogren syndrome antigen B (autoantigen La) IPI00009032 1.8 0.0 0.0 3.0 
SSBP1 single-stranded DNA binding protein 1 IPI00029744 0.0 0.0 14.0 1.5 
SSRP1 structure specific recognition protein 1 IPI00005154 6.3 3.0 0.0 0.0 
STAT1 
signal transducer and activator of transcription 1, 
91kDa 
IPI00030781 0.8 0.0 0.0 0.0 
STAU1 
staufen, RNA binding protein, homolog 1 
(Drosophila) 
IPI00000001 1.0 0.5 0.0 0.0 
STRAP serine/threonine kinase receptor associated protein IPI00294536 1.0 0.0 0.0 0.0 
STT3B 
STT3, subunit of the oligosaccharyltransferase 
complex, homolog B (S. cerevisiae) 
IPI00152377 1.0 0.0 0.0 0.0 
SUB1 SUB1 homolog (S. cerevisiae) IPI00221222 3.0 1.8 0.0 0.0 
SUPT16H suppressor of Ty 16 homolog (S. cerevisiae) IPI00026970 8.5 7.5 0.0 0.0 
SYNCRIP 
synaptotagmin binding, cytoplasmic RNA 
interacting protein 
IPI00018140 12.3 3.3 11.5 13.5 
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TAF15 
TAF15 RNA polymerase II, TATA box binding 
protein (TBP)-associated factor, 68kDa 
IPI00020194 0.5 0.0 0.0 0.0 
TARDBP TAR DNA binding protein IPI00025815 1.8 0.0 0.0 0.0 
TBCB cytoskeleton associated protein 1 IPI00293126 1.0 0.0 0.0 0.0 
TBL2 transducin (beta)-like 2 IPI00000948 4.0 0.0 1.5 0.0 
TCOF1 Treacher Collins-Franceschetti syndrome 1 IPI00165041 4.3 0.5 0.0 0.0 
TCP1 t-complex 1 IPI00290566 70.8 36.0 0.0 0.0 
TEX10 testis expressed sequence 10 IPI00549664 0.0 0.0 0.0 2.0 
TFAM transcription factor A, mitochondrial IPI00020928 0.0 0.0 3.0 0.0 
TGM2 
transglutaminase 2 (C polypeptide, protein-
glutamine-gamma-glutamyltransferase) 
IPI00294578 5.0 0.0 0.0 0.0 
THOC2 THO complex 2 IPI00158615 0.0 0.0 1.5 0.0 
THOC4 THO complex 4 IPI00328840 2.0 0.0 0.0 2.5 
THOC6 THO complex 6 homolog (Drosophila) IPI00301252 0.0 0.0 2.0 0.0 
THRAP3 thyroid hormone receptor associated protein 3 IPI00104050 0.0 2.0 0.0 0.0 
TIMM50 
translocase of inner mitochondrial membrane 50 
homolog (yeast) 
IPI00418497 3.3 0.0 0.0 0.0 
TJP1 tight junction protein 1 (zona occludens 1) IPI00216219 2.3 0.0 9.0 0.0 
TMCO1 transmembrane and coiled-coil domains 1 IPI00026111 1.8 0.0 0.0 0.0 
TMOD3 tropomodulin 3 (ubiquitous) IPI00005087 1.3 0.0 0.0 0.0 
TMPO thymopoietin IPI00030131 4.3 0.0 43.0 0.0 
TMPO thymopoietin IPI00216230 1.8 0.0 34.0 0.0 
TNFAIP2 tumor necrosis factor, alpha-induced protein 2 IPI00304866 2.0 0.0 0.0 0.0 
TOP1 topoisomerase (DNA) I IPI00413611 5.0 1.5 0.0 3.0 
TOP2A topoisomerase (DNA) II alpha 170kDa IPI00178667 0.0 0.0 12.0 0.0 
TOP2B topoisomerase (DNA) II beta 180kDa IPI00027280 0.0 0.0 7.5 0.0 
TPM1 tropomyosin 1 (alpha) IPI00000230 5.0 0.0 0.0 0.0 
TRAM1 translocation associated membrane protein 1 IPI00219111 10.8 0.0 0.0 0.0 
TRIM21 tripartite motif-containing 21 IPI00018971 26.0 2.8 0.0 0.0 
TRIM25 tripartite motif-containing 25 IPI00029629 9.3 0.0 0.0 0.0 
TRIM28 tripartite motif-containing 28 IPI00438229 3.3 0.0 0.0 0.0 
TRIP12 thyroid hormone receptor interactor 12 IPI00032342 2.0 0.0 2.0 0.0 
TROVE2 TROVE domain family, member 2 IPI00019450 2.0 2.5 2.5 2.0 
TSR1 TSR1, 20S rRNA accumulation, homolog (yeast) IPI00292894 6.3 0.0 4.5 2.5 
TUBA1C tubulin, alpha 6 IPI00166768 10.0 0.0 0.0 0.0 
TUBA4A tubulin, alpha 1 (testis specific) IPI00007750 9.0 5.0 0.0 0.0 
TUBB tubulin, beta IPI00011654 8.5 4.5 0.0 0.0 
TUBB1 tubulin, beta 1 IPI00006510 1.8 0.8 2.5 0.0 
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TUBB2C tubulin, beta 2C IPI00007752 7.8 13.5 4.0 0.0 
TUFM Tu translation elongation factor, mitochondrial IPI00027107 7.5 0.0 2.5 1.5 
TXN thioredoxin IPI00216298 9.8 14.8 0.0 0.0 
U2AF1 U2(RNU2) small nuclear RNA auxiliary factor 1 IPI00005613 3.5 0.0 0.0 0.0 
U2AF2 U2 (RNU2) small nuclear RNA auxiliary factor 2 IPI00031556 4.3 3.8 0.0 0.0 
UBC;RPS27A;
UBB 
ribosomal protein S27a IPI00179330 7.5 1.5 13.0 0.0 
UBTF 
upstream binding transcription factor, RNA 
polymerase I 
IPI00014533 2.5 0.0 0.0 1.5 
UGDH UDP-glucose dehydrogenase IPI00031420 2.3 0.0 0.0 0.0 
UNC45B unc-45 homolog B (C. elegans) IPI00217428 0.8 0.0 0.0 0.0 
UPF1 
UPF1 regulator of nonsense transcripts homolog 
(yeast) 
IPI00034049 1.8 2.5 12.5 5.0 
UQCRC2 ubiquinol-cytochrome c reductase core protein II IPI00305383 3.5 0.0 0.0 0.0 
USP10 ubiquitin specific peptidase 10 IPI00291946 1.3 3.0 6.5 7.0 
USP39 ubiquitin specific peptidase 39 IPI00419844 0.0 0.0 0.0 2.5 
UTP20;LOC65
3877 
UTP20, small subunit (SSU) processome 
component, homolog (yeast) 
IPI00004970 0.5 0.0 1.5 0.0 
VIM vimentin IPI00418471 0.0 8.3 0.0 0.0 
VRK1 vaccinia related kinase 1 IPI00019640 0.0 0.0 2.0 0.0 
XPO1 exportin 1 (CRM1 homolog, yeast) IPI00298961 0.5 1.0 0.0 0.0 
XPOT 
exportin, tRNA (nuclear export receptor for 
tRNAs) 
IPI00306290 1.0 1.3 0.0 0.0 
XRCC1 
X-ray repair complementing defective repair in 
Chinese hamster cells 1 
IPI00002564 0.0 0.0 1.5 0.0 
XRCC5 
X-ray repair complementing defective repair in 
Chinese hamster cells 5 (double-strand-break 
rejoining; Ku autoantigen, 80kDa) 
IPI00220834 10.5 3.8 16.5 10.0 
XRCC6 
X-ray repair complementing defective repair in 
Chinese hamster cells 6 (Ku autoantigen, 70kDa) 
IPI00644712 15.0 6.8 24.0 12.0 
XRN2 5'-3' exoribonuclease 2 IPI00100151 12.8 1.5 6.5 2.0 
YBX1 Y box binding protein 1 IPI00031812 9.0 2.0 5.0 4.0 
YTHDC2 YTH domain containing 2 IPI00010200 2.5 1.0 1.5 0.0 
YWHAQ 
tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, theta 
polypeptide 
IPI00018146 2.3 0.0 0.0 0.0 
ZC3H4   IPI00187011 2.0 0.0 0.0 0.0 
ZC3HAV1 zinc finger CCCH-type, antiviral 1 IPI00332936 10.5 0.0 2.5 2.0 
ZC3HAV1 zinc finger CCCH-type, antiviral 1 IPI00410067 1.5 0.0 0.0 0.0 
ZCCHC3 zinc finger, CCHC domain containing 3 IPI00011550 0.0 0.0 0.0 5.5 
ZNFX1 zinc finger, NFX1-type containing 1 IPI00165981 3.3 0.0 0.0 0.0 
- keratin 8-like 1 IPI00017870 2.3 0.0 21.0 0.0 
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-   IPI00069693 4.3 0.0 3.5 0.0 
-   IPI00176692 3.8 0.0 0.0 4.0 
-   IPI00394699 9.3 3.0 5.0 7.0 
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Table S4.2.  Stress granule proteins that interact with arenavirus NP.  
Cellular proteins with a known association with stress granules are listed, including the multiple ribosomal 
S proteins (RPS) that are constituents of the small ribosomal subunit. 
 
Gene Symbol Gene Description IPI ID 
CAPRIN1 Cell Cycle Associated Protein 1 IPI00783872 
DDX6 DEAD (Asp-Glu-Ala-Asp) box polypeptide 6 IPI00030320 
EIF3A eukaryotic translation initiation factor 3, subunit 10 theta, 150/170kDa IPI00029012 
EIF3B eukaryotic translation initiation factor 3, subunit 9 eta, 116kDa IPI00396370 
EIF3CL;EIF3C eukaryotic translation initiation factor 3, subunit 8, 110kDa IPI00016910 
EIF3F eukaryotic translation initiation factor 3, subunit 5 epsilon, 47kDa IPI00654777 
EIF3G eukaryotic translation initiation factor 3, subunit 4 delta, 44kDa IPI00290460 
EIF3L eukaryotic translation initiation factor 3, subunit 6 interacting protein IPI00465233 
EIF4A1;SNORA67 eukaryotic translation initiation factor 4A, isoform 1 IPI00025491 
EIF4A3 DEAD (Asp-Glu-Ala-Asp) box polypeptide 48 IPI00009328 
EIF4G1 eukaryotic translation initiation factor 4 gamma, 1 IPI00220365 
EIF4G3 eukaryotic translation initiation factor 4 gamma, 3 IPI00328268 
ELAVL1 ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1 (Hu antigen R) IPI00301936 
FXR1 fragile X mental retardation, autosomal homolog 1 IPI00016249 
FXR2 fragile X mental retardation, autosomal homolog 2 IPI00016250 
G3BP1 Ras-GTPase-activating protein SH3-domain-binding protein IPI00012442 
G3BP2 Ras-GTPase activating protein SH3 domain-binding protein 2 IPI00009057 
GNB2L1 guanine nucleotide binding protein (G protein), beta polypeptide 2-like 1 IPI00641950 
PABPC1 poly(A) binding protein, cytoplasmic 1 IPI00008524 
PABPC4 poly(A) binding protein, cytoplasmic 4 (inducible form) IPI00012726 
RPS10 ribosomal protein S10 IPI00008438 
RPS11 ribosomal protein S11 IPI00025091 
RPS13 ribosomal protein S13 IPI00221089 
RPS14 ribosomal protein S14 IPI00026271 
RPS15 ribosomal protein S15 IPI00479058 
RPS15A ribosomal protein S15a IPI00221091 
RPS16 ribosomal protein S16 IPI00221092 
RPS17 ribosomal protein S17 IPI00221093 
RPS18;LOC100130553 ribosomal protein S18 IPI00013296 
RPS19 ribosomal protein S19 IPI00215780 
RPS2 ribosomal protein S2 IPI00013485 
RPS20 ribosomal protein S20 IPI00012493 
RPS23 ribosomal protein S23 IPI00218606 
RPS24 ribosomal protein S24 IPI00029750 
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RPS25 ribosomal protein S25 IPI00012750 
RPS27 ribosomal protein S27 (metallopanstimulin 1) IPI00513971 
RPS27 ribosomal protein S27 IPI00397358 
RPS28 ribosomal protein S28 IPI00719622 
RPS3 ribosomal protein S3 IPI00011253 
RPS3A ribosomal protein S3A IPI00419880 
RPS4X ribosomal protein S4, X-linked IPI00217030 
RPS5 ribosomal protein S5 IPI00008433 
RPS6 ribosomal protein S6 IPI00021840 
RPS7 ribosomal protein S7 IPI00013415 
RPS7P4 ribosomal protein S7 pseudogene 4 IPI00008293 
RPS8 ribosomal protein S8 IPI00216587 
RPS9 ribosomal protein S9 IPI00221088 
STAU1 staufen, RNA binding protein, homolog 1 (Drosophila) IPI00000001 
YBX1 Y box binding protein 1 IPI00031812 
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CHAPTER 5: SUMMARY OF FINDINGS AND FUTURE DIRECTIONS 
5.1.  Arenvirus genome transcription and replication 
How viruses establish long lived persistent infections in their rodent hosts has 
been an important question motivating researchers since the discovery of this key feature 
of arenavirus infections. The methods researchers took toward examining these questions 
evolved along with cell culture and molecular biology technologies over time. Early work 
spearheaded by Hotchin et al. during the late 1960’s and 1970’s used cell culture models 
and measured viral release from infected cells as a primary metric of active infection. 
Tracking release of infectious particles from infected cultures and from individual cells 
isolated from those cultures over time led to the emergence of a model whereby arenavirus 
persistence was hypothesized to be repeated cycles of transient infections of individual 
cells within a large population of cells (Hotchin, 1973, 1974a, b).  
During the 1980’s and 1990’s with the advent of more advanced molecular 
biology, gene cloning, and nucleic acid sequencing technologies, it became possible to 
probe the genetic events of arenavirus infection more directly. It was found that the 
arenaviruses had a bi-segmented, single-stranded, negative-sense genome (Leung et al., 
1977). Researchers discovered that the arenaviruses possessed an interesting “ambisense” 
coding strategy where each genomic RNA segment encodes two genes but in opposite 
polarity (Auperin et al., 1984b; Salvato and Shimomaye, 1989; Southern et al., 1987). This 
suggested that these viruses to control the relative timing of specific gene expression events 
based on the polarity of the viral genes on the genomic RNA that would be delivered to 
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newly infected cells, which was subsequently demonstrated in cells infected with TCRV 
(Franze-Fernandez et al., 1987). It was shown that purified virus packaged both genomic 
and antigenomic RNA (Franze-Fernandez et al., 1987). Further, it was shown that smaller 
than expected genomic RNAs appear in infected cells over time, suggesting that viral 
RNAs may accumulate deletions following the initial phase of acute infection (Francis and 
Southern, 1988a, b).  
These initial experiments led to the systematic exploration of the genetic nature 
of persistence in both in vitro and in vivo models of infection primarily by Southern et al. 
in the 1980’s and 1990’s. They observed that viral RNA is maintained in persistently 
infected mouse tissue and in persistently infected cell culture (Francis and Southern, 1988a, 
b). They suggested that the genetic signature of reduced arenavirus replication during 
persistence was due to the appearance of short deletions in the 3’ and 5’ UTR regions  of 
the viral genomic RNAs, and that these deletions selectively inhibited gene transcription 
but permitted genome replication (Meyer and Southern, 1994). Lastly, they proposed that 
terminal deletions could be repaired by the viral polymerase leading to a rescue of viral 
genome that was both transcription and replication competent, thus allowing productive 
infection of cells to reset (Meyer and Southern, 1997). With this new data, the field seems 
to have largely forgotten the original work by Hotchin et al., with more recent reviews of 
the subject making no mention of his work on persistence, and focus instead on the work 
of Southern et al. to explain the mechanism by which infected cells become persistently 
infected (Labudova et al., 2016). 
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We were not convinced that the genetic model put forth by Southern et al. told 
the whole story for two primary reasons. First, Southern et al. suggest that persistently 
infected cells maintain high levels of genomic material during persistence and the 
expression of this genetic material is regulated by the presence or absence of terminal 
deletions that can be repaired. However, this does not completely match observations from 
the work of Hotchin et al., which showed that the vast majority of individual cells cloned 
from persistently infected cultures did not produce infectious virus (Hotchin, 1973). 
Second, Southern et al. suggest a repair mechanism of the genomic terminal deletions 
(from 2-38 base pairs in length) relying solely on addition of random non-templated 
nucleotides (Meyer and Southern, 1997). While, it is possible that this method could repair 
very short deletions of just a few lost bases, the probability that a viral polymerase could 
correctly repair longer deletions becomes vanishingly improbable. We thus hypothesized 
that neither the hypotheses of Hotchin or Southern were complete and that recent 
improvements in fluorescence in situ hybridization (FISH) permitting the labeling of single 
RNA molecules could bring these two models of persistence into harmony. 
The work presented in Chapter 2 leveraged cutting-edge single-molecule RNA 
FISH (smFISH) and a high-throughput imaging and analysis pipeline to follow the kinetics 
of genome transcription and replication in single cells during a time course of infection 
from one hour to several weeks following initial infection. This work allowed us to confirm 
previous data showing the temporal separation between the expression of the viral NP and 
GPC genes providing further appreciation for the ability of this ambisense coding strategy 
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to temporally control viral gene expression programs (Franze-Fernandez et al., 1987). 
Further, though previous work indicated that S antigenomic RNA was packaged in LCMV 
virions, we never detected expression of GPC in the initial hours following infection 
suggesting that if antigenome is packaged in infectious virions, this RNA is 
transcriptionally incompetent upon initial RNP release into the cytoplasm of the newly 
infected cells (Franze-Fernandez et al., 1987). Additionally, data from Chapter 2 suggest 
that a subpopulation of viral particles do not package the L segment. This observation could 
suggest that recruitment of viral genetic material into budding virions is not a highly 
regulated process and virions packaging various suites of encapsidated RNAs could occur 
as has recently been demonstrated to be the case for Rift Valley fever virus using a similar 
smFISH approach (Wichgers Schreur and Kortekaas, 2016). 
Strikingly, when we imaged thousands of individual cells from persistently 
infected cells over time, we noted that, at some time points in the persistent phase, the 
majority of cells in the population had no detectable viral RNAs and at other time points, 
close to 100% of cells in the population had detectable viral RNAs. Moreover, the 
transition between these states occurred cyclically over time similar the cycles of release 
of infectious virus during persistence as previously reported in the literature (Lehmann-
Grube et al., 1969). This suggested to us that the model of Hotchin appears to be correct, 
and individual cells experience cyclic self-limited transient infections during persistence. 
While we do not question the veracity of the results of Southern et al., we suggest that the 
terminal deletions that occur in genomes during persistence most likely are a mechanism 
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employed by the virus to limit its own transcription and replication within a cell and to 
eventually clear active infection. We think it more likely that these cells become re-infected 
from virus produced by reservoir cells containing viral genomic RNA with intact 3’ and 5’ 
UTRs than the alternative where genomes in each persistently infected cell are repaired by 
the viral L polymerase through the addition of random non-templated bases. 
A serious limitation of the study presented in Chapter 2 was the poor signal-to-
noise ratio (SNR) of the FISH probe sets that were designed to specifically hybridize to the 
genomic (but not the viral mRNAs). This fact led us to use probe sets that targeted the viral 
mRNAs along with their respective genomic or antigenomic RNA species. The strength of 
this approach is that we can simultaneously visualize a greater range of viral RNA species 
in single infected cells. However, we lose the ability to definitively know the identity of 
the RNAs we are visualizing. Future work to improve the binding sensitivity of genome 
specific FISH probe sets would be worthwhile. We hypothesized that encapsidation of viral 
genomic and antigenomic RNA by nucleoprotein could prevent probe access and limit 
probe sensitivity. If this is the case, we believe that performing a brief protease digestion 
of fixed cells prior to FISH staining, as has previously been reported (Buxbaum et al., 
2014),  could allow us to overcome this technical barrier. The added insight gained from 
this would improve our ability to quantitatively characterize the rates of genome replication 
and even allow us to estimate rates of genome degradation. These data would be 
instrumental for the creation of a mathematical model describing the genetic events of 
arenavirus infection, a tool that could be invaluable to help predict how various mutations 
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to the viral L polymerase, Z protein, or NP (all known regulators of the viral gene 
expression program) could affect the kinetics of viral growth and/or alter the propensity of 
the virus to establish persistent infection. 
5.2.  Arenavirus Replication Complexes 
As obligate intracellular parasites, viruses are unable to replicate independently 
of a host cell. It is becoming increasingly clear that a range of viruses create specific niches 
at subcellular sites to facilitate various steps of their life cycle (den Boon et al., 2010; 
Novoa et al., 2005a). Though comparatively little is known about how negative-strand 
viruses take advantage of cellular compartments, there are a few notable recent examples 
in the literature (Bruce et al., 2010; Novoa et al., 2005b). For example, it was shown that  
Influenza A virus (IAV) is dependent on Rab11 positive recycling endosomes for optimal 
replication (Amorim et al., 2011; Eisfeld et al., 2011). Two independent groups used 
smFISH to demonstrate that the Rab11 positive recycling endosome is a site where the 
different viral genomic segments assemble and are transported to the plasma membrane 
(Chou et al., 2013; Lakdawala et al., 2014).  
We were motivated to explore what role membrane bound compartments may 
play in facilitating the life cycle of the prototypic arenavirus LCMV by several key 
findings: (i) the observation that IAV, a negative-strand virus with a segmented RNA 
genome, intimately relies upon a cellular membrane bound organelle, (ii) that the 
arenavirus NP localizes to defined punctate structures in the cytoplasm of infected cells 
(Baird et al., 2012; Knopp et al., 2015), and (iii) that arenaviral RNPs copurify with cellular 
 227 
 
membrane (Baird et al., 2012). In Chapter 3, we used smFISH probe sets to specifically 
label and visualize S segment genomic and antigenomic RNA in cells acutely infected with 
LCMV. Viral genomic RNA localized in defined cytoplasmic foci whose size, brightness, 
and subcellular localization evolved over the course of acute infection. We confirmed that 
these cytoplasmic foci were sites of active viral replication by demonstrating the 
colocalization of S genomic RNA with S antigenomic RNA, its replicative complementary 
intermediate, and nucleoprotein, which encapsidates the genomic and antigenomic RNA. 
Taking advantage of a previously published siRNA screen showing that Rab5c was 
required for optimal LCMV growth (Panda et al., 2011), we showed that LCMV S genome 
concentrates at Rab5c positive early endosomal membranes in a proportion of infected 
cells. Thus, to address the question of how the virus may benefit from concentrating its 
genetic material at this endosomal membrane, we examined whether the virus was 
recruiting other viral structural components to this site. Indeed, we showed, that in a portion 
of infected cells there was a high degree of colocalization between the viral S genome and 
viral glycoprotein, suggesting that the virus may be utilizing intracellular membrane bound 
compartments as sites for the assembly of nascent viral components before being 
transported to the plasma membrane where budding occurs, a finding that contradicts the 
current dogma of arenavirus assembly. 
Obvious next steps to confirm and extend these findings are to fully define all of 
the viral components that may be assembled at the intracellular sites identified in Chapter 
3 and to characterize the mechanisms they use to traffic to the plasma membrane. Indeed, 
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elements of this work are currently underway. We have shown that the viral Z protein 
strongly colocalizes with Rab5c positive endosomes in a subpopulation of LCMV infected 
cells (C. M. Ziegler, E. A. Bruce, B. R. King, and J. Botten, Unpublished Data) providing 
some evidence that all the viral components pre-assemble intracellularly. Additionally, we 
have observed that disruption of the microtubule cytoskeleton by treating cells with 
nocodazole results in a dramatic redistribution of viral components in infected cells (B. R. 
King and J. Botten, Unpublished Data). However, infectious viral output is unaffected 
following microtubule disruption suggesting that the virus may employ redundant 
intracellular transport mechanisms permitting intracellular viral assembly and trafficking 
as has also recently been reported for IAV (Nturibi et al., 2017). It will be important to 
further explore the role of microtubules in trafficking and, additionally, to consider actin-
dependent pathways as alternative routes the virus may take to reach the plasma membrane. 
To better understand the role played by Rab5c in promoting these processes, infection of 
cells should be performed in cells stably transduced with a drug-inducible dominant 
negative Rab5c. Imaging the localization of the different viral components following the 
disruption of Rab5c function will be highly informative and should include the Rab5a and 
Rab5b isoforms to determine the specificity of this pathway. Furthermore, immunogold 
EM studies to examine the ultrastructural detail of viral replication complexes in the 
cytoplasm of infected cells will provide additional critical insights. 
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5.3.  The NP host-protein interactome 
In addition to its canonical role of encapsidation of the viral single-stranded RNA 
genome, over the past years NP’s multifunctional nature has become clear. Structural 
investigations have yielded insight into how the viral NP is able to bind viral RNA and has 
also revealed a C terminal domain with a previously unrecognized 3’ to 5’ exonuclease 
activity (Hastie et al., 2011a; Qi et al., 2010; Zhang et al., 2013). This has provided the first 
mechanistic explanation of how the arenavirus NP is able to inhibit the activation of the 
host type I IFN response. Other documented roles played by NP in the arenavirus life cycle 
are interaction with viral Z protein (Levingston Macleod et al., 2011; Ortiz-Riano et al., 
2011), important for the recruitment of viral RNPs into budding virions (Levingston 
Macleod et al., 2011), regulation of apoptosis (Wolff et al., 2013a), modulation of innate 
immunity signaling (Pythoud et al., 2012; Rodrigo et al., 2012), and regulation of cellular 
translation by preventing the induction of stress granules in infected cells (Linero et al., 
2011). By playing such diverse roles, in the life cycle, we had hypothesized that virus must 
interact with a wide range of cellular proteins, and that these protein-protein interactions 
would facilitate these, and potentially, as yet, undescribed steps of the viral life cycle. 
 In Chapter 4, we performed tandem mass spectrometry to identify the host 
cellular protein partners of the Old World arenavirus LCVM NP and the New World 
arenavirus JUNV. Here we established the first wide-scale interactome map of the host cell 
machinery engaged by diverse arenaviruses during infection, giving us an unprecedented 
view of the diverse biological functions performed by NP. Bioinformatic analysis of this 
protein-protein interaction map suggested that host cellular translation was a major 
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biological function that was highly associated with NP. This was fascinating in view of the 
observation that JUNV NP is able to prevent the assembly of stress granules in response to 
cellular stress in viral infected cells and cells ectopically expressing NP (Linero et al., 
2011). Mining the data set for master regulators of cellular translation, we identified the 
eIF2α kinase PKR, a cytoplasmic sensor of dsRNA (most often a result of viral infection) 
that phosphorylates eIF2α and leads to global translation arrests. 
The identification of this cellular factor led us to functionally characterize the NP-
PKR interaction and the PKR signaling pathway in infected cells. We found that the NP-
PKR interaction appeared to be stronger for JUNV NP than for LCMV NP. Additionally, 
we found that while PKR was activated in JUNV infected cells, it was unable to 
phosphorylate eIF2α, and translation rates remained normal. On the other hand, the weaker 
LCMV NP-PKR interaction was not as robust at interfering with PKR’s activity. This result 
is interesting considering studies showing divergence in the ability of the Old World and 
New World NP’s ability to prevent robust induction of type I IFN. LASV and LCMV NP 
were both shown to strongly inhibit the expression of type I IFN (Hastie et al., 2011a; 
Martinez-Sobrido et al., 2009; Martinez-Sobrido et al., 2007; Qi et al., 2010). However, 
JUNV, in one study, did not exhibit the same exonuclease activity (Zhang et al., 2013) and 
poorly inhibits type I IFN induction (Huang et al., 2012). This data fits with the model of 
PKR inhibition revealed in our study. We conjecture that because JUNV NP is unable to 
prevent the induction of type I IFN, it must develop additional strategies to limit the 
antiviral activity of individual IFN stimulated genes (e.g. PKR) to promote viral growth in 
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infected cells. The imperative of Old World arenavirus (e.g. LASV or LCMV) NP to inhibit 
the activity of various interferon stimulated genes may be relaxed as the expression of these 
genes remains low. 
Moreover, the identification of PKR as a functionally important host protein 
partner of JUNV NP was interesting in light of the work showing that stress granule 
induction is inhibited in JUVN infected cells and in cells expressing JUNV NP (Linero et 
al., 2011). The large-scale map of arenavirus NP and host cellular protein interactions from 
this study has allowed us to hypothesize that the interaction between JUNV NP and PKR 
may be the mechanism utilized by the virus to maintain normal rates of translation in cells 
experiencing stress that would normally lead to the phosphorylation of eIF2α and the 
formation of stress granules. 
The conclusion of Chapter 4 that JUNV NP is able to inhibit the activity of PKR 
has also been explored recently by Huang et al. (Huang et al., 2017). They show that 
infection with wild type JUNV strain Romero leads to both activation of PKR and eIF2α 
phosphorylation, in contrast to our result showing no eIF2α phosphorylation (Huang et al., 
2017). Nevertheless, the authors demonstrated that in PKR deficient cells, WT JUNV 
replication was marginally impaired, suggesting that active PKR is not playing an antiviral 
role in New World arenavirus infections and may even be beneficial for viral growth 
(Huang et al., 2017). Additional work is needed to reconcile the results of our two studies 
and to explore the possibility that NP’s engagement with PKR may be one mechanism by 
which JUNV C#1 is attenuated. 
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Beyond the ability of arenaviruses to modulate host cellular translation, this work 
has provided an important data set to the field that will serve as an important hypothesis 
generating tool in the future. Another tantalizing question that have emerged from our data, 
but remain to be tested in more detail, is how JUNV NP is involved in the balance between 
apoptosis initiation versus its inhibition. Interestingly, the most abundantly detected 
cellular protein partner of JUNV NP was apoptosis inducing factor 1 (AIFM1), which is 
released from the mitochondria following stress and is translocated to the nucleus where it 
is involved in nuclear fragmentation during the apoptotic program (Lipton and Bossy-
Wetzel, 2002). It remains to be explored how this interaction may be critical in regulating 
the precarious balancing act between cell survival and apoptosis noted in studies of JUNV 
infected cells (Kolokoltsova et al., 2014; Wolff et al., 2013a). 
5.4. Conclusion 
In conclusion, I have had the opportunity to explore a broad range of questions 
related to the arenavirus life cycle during my dissertation. The principle that unifies the 
diverse projects described herein is how the virus utilizes specific subcellular niches and 
cellular machinery to promote effective viral transcription, replication, and additional steps 
of the virus life cycle. The work we have performed has allowed us to revisit long standing 
conflicting hypotheses of persistence, to develop new paradigms of how arenaviruses may 
rely on cellular organelles to promote assembly, and identify additional ways in which 
arenaviruses hijack cellular machinery to avoid an effective innate immune response. It is 
our hope that the conclusions of this work and the future studies it inspires will lead to the 
 233 
 
development of novel antiviral therapeutics that can be used to better treat these devastating 
infections that touch so many people around the world.  
  
 234 
 
5.5.  References 
Amorim, M.J., Bruce, E.A., Read, E.K., Foeglein, A., Mahen, R., Stuart, A.D., and Digard, 
P. (2011). A Rab11- and microtubule-dependent mechanism for cytoplasmic transport of 
influenza A virus viral RNA. Journal of virology 85, 4143-4156. 
Auperin, D.D., Romanowski, V., Galinski, M., and Bishop, D.H. (1984b). Sequencing 
studies of pichinde arenavirus S RNA indicate a novel coding strategy, an ambisense viral 
S RNA. Journal of virology 52, 897-904. 
Baird, N.L., York, J., and Nunberg, J.H. (2012). Arenavirus infection induces discrete 
cytosolic structures for RNA replication. Journal of virology 86, 11301-11310. 
Bruce, E.A., Digard, P., and Stuart, A.D. (2010). The Rab11 pathway is required for 
influenza A virus budding and filament formation. Journal of virology 84, 5848-5859. 
Buxbaum, A.R., Wu, B., and Singer, R.H. (2014). Single beta-actin mRNA detection in 
neurons reveals a mechanism for regulating its translatability. Science 343, 419-422. 
Chou, Y.Y., Heaton, N.S., Gao, Q., Palese, P., Singer, R.H., and Lionnet, T. (2013). 
Colocalization of different influenza viral RNA segments in the cytoplasm before viral 
budding as shown by single-molecule sensitivity FISH analysis. PLoS pathogens 9, 
e1003358. 
den Boon, J.A., Diaz, A., and Ahlquist, P. (2010). Cytoplasmic viral replication complexes. 
Cell host & microbe 8, 77-85. 
Eisfeld, A.J., Kawakami, E., Watanabe, T., Neumann, G., and Kawaoka, Y. (2011). 
RAB11A is essential for transport of the influenza virus genome to the plasma membrane. 
Journal of virology 85, 6117-6126. 
Francis, S.J., and Southern, P.J. (1988a). Deleted viral RNAs and lymphocytic 
choriomeningitis virus persistence in vitro. The Journal of general virology 69 ( Pt 8), 
1893-1902. 
Francis, S.J., and Southern, P.J. (1988b). Molecular analysis of viral RNAs in mice 
persistently infected with lymphocytic choriomeningitis virus. Journal of virology 62, 
1251-1257. 
Franze-Fernandez, M.T., Zetina, C., Iapalucci, S., Lucero, M.A., Bouissou, C., Lopez, R., 
Rey, O., Daheli, M., Cohen, G.N., and Zakin, M.M. (1987). Molecular structure and early 
events in the replication of Tacaribe arenavirus S RNA. Virus research 7, 309-324. 
 235 
 
Hastie, K.M., Kimberlin, C.R., Zandonatti, M.A., MacRae, I.J., and Saphire, E.O. (2011a). 
Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3' to 5' exonuclease 
activity essential for immune suppression. Proceedings of the National Academy of 
Sciences of the United States of America 108, 2396-2401. 
Hotchin, J. (1973). Transient virus infection: spontaneous recovery mechanism of 
lymphocytic choriomeningitis virrus-infected cells. Nat New Biol 241, 270-272. 
Hotchin, J. (1974a). Cyclical phenomena in persistent virus infection. J Reticuloendothel 
Soc 15, 304-311. 
Hotchin, J. (1974b). The role of transient infection in arenavirus persistence. Prog Med 
Virol 18, 81-93. 
Huang, C., Kolokoltsova, O.A., Mateer, E.J., Koma, T., and Paessler, S. (2017). Highly 
pathogenic New World arenavirus infection activates the pattern recognition receptor PKR 
without attenuating virus replication in human cells. Journal of virology. 
Huang, C., Kolokoltsova, O.A., Yun, N.E., Seregin, A.V., Poussard, A.L., Walker, A.G., 
Brasier, A.R., Zhao, Y., Tian, B., de la Torre, J.C., and Paessler, S. (2012). Junin virus 
infection activates the type I interferon pathway in a RIG-I-dependent manner. PLoS Negl 
Trop Dis 6, e1659. 
Knopp, K.A., Ngo, T., Gershon, P.D., and Buchmeier, M.J. (2015). Single nucleoprotein 
residue modulates arenavirus replication complex formation. mBio 6, e00524-00515. 
Kolokoltsova, O.A., Grant, A.M., Huang, C., Smith, J.K., Poussard, A.L., Tian, B., Brasier, 
A.R., Peters, C.J., Tseng, C.T., de la Torre, J.C., and Paessler, S. (2014). RIG-I enhanced 
interferon independent apoptosis upon Junin virus infection. PloS one 9, e99610. 
Labudova, M., Pastorek, J., and Pastorekova, S. (2016). Lymphocytic choriomeningitis 
virus: ways to establish and maintain non-cytolytic persistent infection. Acta Virol 60, 15-
26. 
Lakdawala, S.S., Wu, Y., Wawrzusin, P., Kabat, J., Broadbent, A.J., Lamirande, E.W., 
Fodor, E., Altan-Bonnet, N., Shroff, H., and Subbarao, K. (2014). Influenza a virus 
assembly intermediates fuse in the cytoplasm. PLoS pathogens 10, e1003971. 
Lehmann-Grube, F., Slenczka, W., and Tees, R. (1969). A persistent and inapparent 
infection of L cells with the virus of lymphocytic choriomeningitis. The Journal of general 
virology 5, 63-81. 
Leung, W.C., Ghosh, H.P., and Rawls, W.E. (1977). Strandedness of Pichinde virus RNA. 
Journal of virology 22, 235-237. 
 236 
 
Levingston Macleod, J.M., D'Antuono, A., Loureiro, M.E., Casabona, J.C., Gomez, G.A., 
and Lopez, N. (2011). Identification of two functional domains within the arenavirus 
nucleoprotein. Journal of virology 85, 2012-2023. 
Linero, F.N., Thomas, M.G., Boccaccio, G.L., and Scolaro, L.A. (2011). Junin virus 
infection impairs stress-granule formation in Vero cells treated with arsenite via inhibition 
of eIF2alpha phosphorylation. The Journal of general virology 92, 2889-2899. 
Lipton, S.A., and Bossy-Wetzel, E. (2002). Dueling activities of AIF in cell death versus 
survival: DNA binding and redox activity. Cell 111, 147-150. 
Martinez-Sobrido, L., Emonet, S., Giannakas, P., Cubitt, B., Garcia-Sastre, A., and de la 
Torre, J.C. (2009). Identification of amino acid residues critical for the anti-interferon 
activity of the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis 
virus. Journal of virology 83, 11330-11340. 
Martinez-Sobrido, L., Giannakas, P., Cubitt, B., Garcia-Sastre, A., and de la Torre, J.C. 
(2007). Differential inhibition of type I interferon induction by arenavirus nucleoproteins. 
Journal of virology 81, 12696-12703. 
Meyer, B.J., and Southern, P.J. (1994). Sequence heterogeneity in the termini of 
lymphocytic choriomeningitis virus genomic and antigenomic RNAs. Journal of virology 
68, 7659-7664. 
Meyer, B.J., and Southern, P.J. (1997). A novel type of defective viral genome suggests a 
unique strategy to establish and maintain persistent lymphocytic choriomeningitis virus 
infections. Journal of virology 71, 6757-6764. 
Novoa, R.R., Calderita, G., Arranz, R., Fontana, J., Granzow, H., and Risco, C. (2005a). 
Virus factories: associations of cell organelles for viral replication and morphogenesis. 
Biology of the cell / under the auspices of the European Cell Biology Organization 97, 147-
172. 
Novoa, R.R., Calderita, G., Cabezas, P., Elliott, R.M., and Risco, C. (2005b). Key Golgi 
factors for structural and functional maturation of bunyamwera virus. Journal of virology 
79, 10852-10863. 
Nturibi, E., Bhagwat, A.R., Coburn, S., Myerburg, M.M., and Lakdawala, S.S. (2017). 
Intracellular Colocalization of Influenza Viral RNA and Rab11A Is Dependent upon 
Microtubule Filaments. Journal of virology 91. 
Ortiz-Riano, E., Cheng, B.Y., de la Torre, J.C., and Martinez-Sobrido, L. (2011). The C-
Terminal Region of Lymphocytic Choriomeningitis Virus Nucleoprotein Contains Distinct 
 237 
 
and Segregable Functional Domains Involved in NP-Z Interaction and Counteraction of 
the Type I Interferon Response. Journal of virology 85, 13038-13048. 
Panda, D., Das, A., Dinh, P.X., Subramaniam, S., Nayak, D., Barrows, N.J., Pearson, J.L., 
Thompson, J., Kelly, D.L., Ladunga, I., and Pattnaik, A.K. (2011). RNAi screening reveals 
requirement for host cell secretory pathway in infection by diverse families of negative-
strand RNA viruses. Proceedings of the National Academy of Sciences of the United States 
of America 108, 19036-19041. 
Pythoud, C., Rodrigo, W.W., Pasqual, G., Rothenberger, S., Martinez-Sobrido, L., de la 
Torre, J.C., and Kunz, S. (2012). Arenavirus nucleoprotein targets interferon regulatory 
factor-activating kinase IKKepsilon. Journal of virology 86, 7728-7738. 
Qi, X., Lan, S., Wang, W., Schelde, L.M., Dong, H., Wallat, G.D., Ly, H., Liang, Y., and 
Dong, C. (2010). Cap binding and immune evasion revealed by Lassa nucleoprotein 
structure. Nature 468, 779-783. 
Rodrigo, W.W., Ortiz-Riano, E., Pythoud, C., Kunz, S., de la Torre, J.C., and Martinez-
Sobrido, L. (2012). Arenavirus nucleoproteins prevent activation of nuclear factor kappa 
B. Journal of virology 86, 8185-8197. 
Salvato, M.S., and Shimomaye, E.M. (1989). The completed sequence of lymphocytic 
choriomeningitis virus reveals a unique RNA structure and a gene for a zinc finger protein. 
Virology 173, 1-10. 
Southern, P.J., Singh, M.K., Riviere, Y., Jacoby, D.R., Buchmeier, M.J., and Oldstone, 
M.B. (1987). Molecular characterization of the genomic S RNA segment from lymphocytic 
choriomeningitis virus. Virology 157, 145-155. 
Wichgers Schreur, P.J., and Kortekaas, J. (2016). Single-Molecule FISH Reveals Non-
selective Packaging of Rift Valley Fever Virus Genome Segments. PLoS pathogens 12, 
e1005800. 
Wolff, S., Becker, S., and Groseth, A. (2013a). Cleavage of the Junin virus nucleoprotein 
serves a decoy function to inhibit the induction of apoptosis during infection. Journal of 
virology 87, 224-233. 
Zhang, Y., Li, L., Liu, X., Dong, S., Wang, W., Huo, T., Guo, Y., Rao, Z., and Yang, C. 
(2013). Crystal structure of Junin virus nucleoprotein. The Journal of general virology 94, 
2175-2183. 
 
  
 238 
 
 
COMPREHENSIVE BIBLIOGRAPHY 
Ambrosio, A., Saavedra, M., Mariani, M., Gamboa, G., and Maiza, A. (2011). Argentine 
hemorrhagic fever vaccines. Hum Vaccin 7, 694-700. 
Amorim, M.J., Bruce, E.A., Read, E.K., Foeglein, A., Mahen, R., Stuart, A.D., and Digard, 
P. (2011). A Rab11- and microtubule-dependent mechanism for cytoplasmic transport of 
influenza A virus viral RNA. Journal of virology 85, 4143-4156. 
Anderson, P., and Kedersha, N. (2008). Stress granules: the Tao of RNA triage. Trends 
Biochem Sci 33, 141-150. 
Armstrong, C., and Dickens, P.F. (1935). Benign Lymphocytic Choriomeningitis (Acute 
Aseptic Meningitis): A New Disease Entity. Public Health Reports 50, 831-842. 
Armstrong, C., and Lillie, R.D. (1934). Experimental Lymphocytic Choriomeningitis of 
Monkeys and Mice Produced by a Virus Encountered in Studies of the 1933 St. Louis 
Encephalitis Epidemic. Public Health Reports 49, 1019-1027. 
Armstrong, C., and Wooley, J.G. (1935). Studies on the Origin of a Newly Discovered 
Virus Which Causes Lymphocytic Choriomeningitis in Experimental Animals. Public 
Health Reports 50, 537-541. 
Arnaud, N., Dabo, S., Maillard, P., Budkowska, A., Kalliampakou, K.I., Mavromara, P., 
Garcin, D., Hugon, J., Gatignol, A., Akazawa, D., Wakita, T., and Meurs, E.F. (2010). 
Hepatitis C virus controls interferon production through PKR activation. PloS one 5, 
e10575. 
Auperin, D., Dimock, K., Cash, P., Rawls, W.E., Leung, W.C., and Bishop, D.H. (1982a). 
Analyses of the genomes of prototype pichinde arenavirus and a virulent derivative of 
Pichinde Munchique: evidence for sequence conservation at the 3' termini of their viral 
RNA species. Virology 116, 363-367. 
Auperin, D.D., Compans, R.W., and Bishop, D.H. (1982b). Nucleotide sequence 
conservation at the 3' termini of the virion RNA species of New World and Old World 
arenaviruses. Virology 121, 200-203. 
Auperin, D.D., Galinski, M., and Bishop, D.H. (1984a). The sequences of the N protein 
gene and intergenic region of the S RNA of pichinde arenavirus. Virology 134, 208-219. 
Auperin, D.D., Romanowski, V., Galinski, M., and Bishop, D.H. (1984b). Sequencing 
studies of pichinde arenavirus S RNA indicate a novel coding strategy, an ambisense viral 
S RNA. Journal of virology 52, 897-904. 
 239 
 
Baird, N.L., York, J., and Nunberg, J.H. (2012). Arenavirus infection induces discrete 
cytosolic structures for RNA replication. Journal of virology 86, 11301-11310. 
Ballif, B.A., Cao, Z., Schwartz, D., Carraway, K.L., 3rd, and Gygi, S.P. (2006). 
Identification of 14-3-3epsilon substrates from embryonic murine brain. J Proteome Res 5, 
2372-2379. 
Battegay, M., Cooper, S., Althage, A., Banziger, J., Hengartner, H., and Zinkernagel, R.M. 
(1991). Quantification of lymphocytic choriomeningitis virus with an immunological focus 
assay in 24- or 96-well plates. J Virol Methods 33, 191-198. 
Bausch, D.G., Hadi, C.M., Khan, S.H., and Lertora, J.J. (2010). Review of the literature 
and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa 
fever. Clin Infect Dis 51, 1435-1441. 
Bergmann, M., Garcia-Sastre, A., Carnero, E., Pehamberger, H., Wolff, K., Palese, P., and 
Muster, T. (2000). Influenza virus NS1 protein counteracts PKR-mediated inhibition of 
replication. Journal of virology 74, 6203-6206. 
Bodewes, R., Raj, V.S., Kik, M.J., Schapendonk, C.M., Haagmans, B.L., Smits, S.L., and 
Osterhaus, A.D. (2014). Updated phylogenetic analysis of arenaviruses detected in boid 
snakes. Journal of virology 88, 1399-1400. 
Bonthius, D.J. (2009). Lymphocytic choriomeningitis virus: a prenatal and postnatal threat. 
Adv Pediatr 56, 75-86. 
Bonthius, D.J. (2012). Lymphocytic choriomeningitis virus: an underrecognized cause of 
neurologic disease in the fetus, child, and adult. Semin Pediatr Neurol 19, 89-95. 
Botten, J., King, B., Klaus, J., and Ziegler, C. (2013). Pathogenic Old World Arenaviruses. 
In Viral Hemorrhagic Fevers, S.K. Singh, and D. Ruzek, eds. (Boca Raton, Florida: CRC 
Press), pp. 233-259. 
Bruce, E.A., Digard, P., and Stuart, A.D. (2010). The Rab11 pathway is required for 
influenza A virus budding and filament formation. Journal of virology 84, 5848-5859. 
Brunotte, L., Kerber, R., Shang, W., Hauer, F., Hass, M., Gabriel, M., Lelke, M., Busch, 
C., Stark, H., Svergun, D.I., Betzel, C., Perbandt, M., and Gunther, S. (2011). Structure of 
the Lassa virus nucleoprotein revealed by X-ray crystallography, small-angle X-ray 
scattering, and electron microscopy. The Journal of biological chemistry 286, 38748-
38756. 
 240 
 
Bucci, C., Lutcke, A., Steele-Mortimer, O., Olkkonen, V.M., Dupree, P., Chiariello, M., 
Bruni, C.B., Simons, K., and Zerial, M. (1995). Co-operative regulation of endocytosis by 
three Rab5 isoforms. FEBS Lett 366, 65-71. 
Buchan, J.R., and Parker, R. (2009). Eukaryotic stress granules: the ins and outs of 
translation. Molecular cell 36, 932-941. 
Buchmeier, M.J. (2002). Arenaviruses: protein structure and function. Current topics in 
microbiology and immunology 262, 159-173. 
Buchmeier, M.J., Bowen, M.D., and Peters, C.J. (2001). Arenaviridae: The viruses and 
their replication. In Fields Virology, H.P.M. Knipe D. M., Griffin D. E., Lamb R. A., 
Martin M. A., Roizman B., Straus S. E., ed. (Philadelphia, PA: Lippincott Williams & 
Wilkins), pp. 1635-1668. 
Buchmeier, M.J., de la Torre, J.C., and Peters, C.J. (2007). Arenaviridae: The Viruses and 
Their Replication. In Fields Virology, D.M. Knipe, P.M. Howley, D.E. Griffin, R.A. Lamb, 
M.A. Martin, B. Roizman, and S.E. Straus, eds. (Philadelphia: Wolters Kluwer 
Heath/Lippincott Williams & Wilkins), pp. 1791-1827. 
Buchmeier, M.J., de la Torre, J.C., and Peters, C.J. (2013). Arenaviridae. In Fields 
Virology, D.M. Knipe, P.M. Howley, J.I. Cohen, D.E. Griffin, R.A. Lamb, M.A. Martin, 
V.R. Racaniello, and B. Roizman, eds. (Philadelphia, PA: Wolters Kluwer 
Heath/Lippincott Williams & Wilkins), pp. 1283-1303. 
Buchmeier, M.J., Elder, J.H., and Oldstone, M.B. (1978). Protein structure of lymphocytic 
choriomeningitis virus: identification of the virus structural and cell associated 
polypeptides. Virology 89, 133-145. 
Buchmeier, M.J., Lewicki, H.A., Tomori, O., and Oldstone, M.B. (1981). Monoclonal 
antibodies to lymphocytic choriomeningitis and pichinde viruses: generation, 
characterization, and cross-reactivity with other arenaviruses. Virology 113, 73-85. 
Buchmeier, M.J., Welsh, R.M., Dutko, F.J., and Oldstone, M.B. (1980). The virology and 
immunobiology of lymphocytic choriomeningitis virus infection. Adv Immunol 30, 275-
331. 
Buchmeier, M.J., and Zajac, A.J. (1999). Lymphocytic choriomeningitis virus. In 
Persistent viral infections, R. Ahmed, and I. Chen, eds. (Chichester ; New York: John 
Wiley & Sons), pp. x, 725 p. 
Burns, J.W., and Buchmeier, M.J. (1991). Protein-protein interactions in lymphocytic 
choriomeningitis virus. Virology 183, 620-629. 
 241 
 
Burns, J.W., and Buchmeier, M.J. (1993). Glycoproteins of the arenaviruses. In The 
Arenaviridae, M.S. Salvato, ed. (New York: Plenum Press), pp. 17-35. 
Burri, D.J., da Palma, J.R., Kunz, S., and Pasquato, A. (2012). Envelope glycoprotein of 
arenaviruses. Viruses 4, 2162-2181. 
Buxbaum, A.R., Wu, B., and Singer, R.H. (2014). Single beta-actin mRNA detection in 
neurons reveals a mechanism for regulating its translatability. Science 343, 419-422. 
Capul, A.A., Perez, M., Burke, E., Kunz, S., Buchmeier, M.J., and de la Torre, J.C. (2007). 
Arenavirus Z-glycoprotein association requires Z myristoylation but not functional RING 
or late domains. Journal of virology 81, 9451-9460. 
Carnec, X., Baize, S., Reynard, S., Diancourt, L., Caro, V., Tordo, N., and Bouloy, M. 
(2011). Lassa virus nucleoprotein mutants generated by reverse genetics induce a robust 
type I interferon response in human dendritic cells and macrophages. Journal of virology 
85, 12093-12097. 
Carter, M.F., Biswal, N., and Rawls, W.E. (1973). Characterization of nucleic acid of 
pichinde virus. Journal of virology 11, 61-68. 
Carter, M.F., Biswal, N., and Rawls, W.E. (1974). Polymerase activity of Pichinde virus. 
Journal of virology 13, 577-583. 
Casabona, J.C., Levingston Macleod, J.M., Loureiro, M.E., Gomez, G.A., and Lopez, N. 
(2009). The RING domain and the L79 residue of Z protein are involved in both the rescue 
of nucleocapsids and the incorporation of glycoproteins into infectious chimeric 
arenavirus-like particles. Journal of virology 83, 7029-7039. 
Castelnuovo, M., Rahman, S., Guffanti, E., Infantino, V., Stutz, F., and Zenklusen, D. 
(2013). Bimodal expression of PHO84 is modulated by early termination of antisense 
transcription. Nat Struct Mol Biol 20, 851-858. 
Chan, Y.K., and Gack, M.U. (2016). Viral evasion of intracellular DNA and RNA sensing. 
Nature reviews. Microbiology 14, 360-373. 
Chang, H.W., Watson, J.C., and Jacobs, B.L. (1992). The E3L gene of vaccinia virus 
encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein 
kinase. Proceedings of the National Academy of Sciences of the United States of America 
89, 4825-4829. 
Charrel, R.N., Coutard, B., Baronti, C., Canard, B., Nougairede, A., Frangeul, A., Morin, 
B., Jamal, S., Schmidt, C.L., Hilgenfeld, R., Klempa, B., and de Lamballerie, X. (2011). 
 242 
 
Arenaviruses and hantaviruses: from epidemiology and genomics to antivirals. Antiviral 
Res 90, 102-114. 
Charrel, R.N., and de Lamballerie, X. (2003). Arenaviruses other than Lassa virus. 
Antiviral Res 57, 89-100. 
Charrel, R.N., and de Lamballerie, X. (2010). Zoonotic aspects of arenavirus infections. 
Vet Microbiol 140, 213-220. 
Charrel, R.N., de Lamballerie, X., and Emonet, S. (2008). Phylogeny of the genus 
Arenavirus. Curr Opin Microbiol 11, 362-368. 
Charrel, R.N., Lemasson, J.J., Garbutt, M., Khelifa, R., De Micco, P., Feldmann, H., and 
de Lamballerie, X. (2003). New insights into the evolutionary relationships between 
arenaviruses provided by comparative analysis of small and large segment sequences. 
Virology 317, 191-196. 
Chou, Y.Y., Heaton, N.S., Gao, Q., Palese, P., Singer, R.H., and Lionnet, T. (2013). 
Colocalization of different influenza viral RNA segments in the cytoplasm before viral 
budding as shown by single-molecule sensitivity FISH analysis. PLoS pathogens 9, 
e1003358. 
Cornillez-Ty, C.T., Liao, L., Yates, J.R., 3rd, Kuhn, P., and Buchmeier, M.J. (2009). 
Severe acute respiratory syndrome coronavirus nonstructural protein 2 interacts with a host 
protein complex involved in mitochondrial biogenesis and intracellular signaling. Journal 
of virology 83, 10314-10318. 
Cornu, T.I., and de la Torre, J.C. (2001). RING finger Z protein of lymphocytic 
choriomeningitis virus (LCMV) inhibits transcription and RNA replication of an LCMV 
S-segment minigenome. Journal of virology 75, 9415-9426. 
Cornu, T.I., and de la Torre, J.C. (2002). Characterization of the arenavirus RING finger Z 
protein regions required for Z-mediated inhibition of viral RNA synthesis. Journal of 
virology 76, 6678-6688. 
D'Antuono, A., Loureiro, M.E., Foscaldi, S., Marino-Buslje, C., and Lopez, N. (2014). 
Differential contributions of tacaribe arenavirus nucleoprotein N-terminal and C-terminal 
residues to nucleocapsid functional activity. Journal of virology 88, 6492-6505. 
David, A., Dolan, B.P., Hickman, H.D., Knowlton, J.J., Clavarino, G., Pierre, P., Bennink, 
J.R., and Yewdell, J.W. (2012). Nuclear translation visualized by ribosome-bound nascent 
chain puromycylation. The Journal of cell biology 197, 45-57. 
 243 
 
den Boon, J.A., and Ahlquist, P. (2010). Organelle-like membrane compartmentalization 
of positive-strand RNA virus replication factories. Annual review of microbiology 64, 241-
256. 
den Boon, J.A., Diaz, A., and Ahlquist, P. (2010). Cytoplasmic viral replication complexes. 
Cell host & microbe 8, 77-85. 
Donnelly, N., Gorman, A.M., Gupta, S., and Samali, A. (2013). The eIF2alpha kinases: 
their structures and functions. Cell Mol Life Sci 70, 3493-3511. 
Dutko, F.J., and Pfau, C.J. (1978). Arenavirus defective interfering particles mask the cell-
killing potential of standard virus. The Journal of general virology 38, 195-208. 
Eichler, R., Strecker, T., Kolesnikova, L., ter Meulen, J., Weissenhorn, W., Becker, S., 
Klenk, H.D., Garten, W., and Lenz, O. (2004). Characterization of the Lassa virus matrix 
protein Z: electron microscopic study of virus-like particles and interaction with the 
nucleoprotein (NP). Virus research 100, 249-255. 
Eisfeld, A.J., Kawakami, E., Watanabe, T., Neumann, G., and Kawaoka, Y. (2011). 
RAB11A is essential for transport of the influenza virus genome to the plasma membrane. 
Journal of virology 85, 6117-6126. 
Ellenberg, P., Edreira, M., Lozano, M., and Scolaro, L. (2002). Synthesis and expression 
of viral antigens in Vero cells persistently infected with Junin virus. Archives of virology 
147, 1543-1557. 
Ellenberg, P., Edreira, M., and Scolaro, L. (2004). Resistance to superinfection of Vero 
cells persistently infected with Junin virus. Archives of virology 149, 507-522. 
Emonet, S., Lemasson, J.J., Gonzalez, J.P., de Lamballerie, X., and Charrel, R.N. (2006). 
Phylogeny and evolution of old world arenaviruses. Virology 350, 251-257. 
Enria, D.A., Briggiler, A.M., and Sanchez, Z. (2008). Treatment of Argentine hemorrhagic 
fever. Antiviral Res 78, 132-139. 
Farber, F.E., and Rawls, W.E. (1975). Isolation of ribosome-like sturctures from Pichinde 
virus. The Journal of general virology 26, 21-31. 
Fehling, S.K., Lennartz, F., and Strecker, T. (2012). Multifunctional nature of the 
arenavirus RING finger protein Z. Viruses 4, 2973-3011. 
Ferron, F., Weber, F., de la Torre, J.C., and Reguera, J. (2017). Transcription and 
replication mechanisms of Bunyaviridae and Arenaviridae L proteins. Virus research 234, 
118-134. 
 244 
 
Findlay, G.M., Alcock, N.S., and Stern, R.O. (1936). The Virus Ætiology Of One Form Of 
Lymphocytic Meningitis. Lancet 227, 650-654. 
Fischer, S.A., Graham, M.B., Kuehnert, M.J., Kotton, C.N., Srinivasan, A., Marty, F.M., 
Comer, J.A., Guarner, J., Paddock, C.D., DeMeo, D.L., Shieh, W.J., Erickson, B.R., 
Bandy, U., DeMaria, A., Jr., Davis, J.P., Delmonico, F.L., Pavlin, B., Likos, A., Vincent, 
M.J., Sealy, T.K., Goldsmith, C.S., Jernigan, D.B., Rollin, P.E., Packard, M.M., Patel, M., 
Rowland, C., Helfand, R.F., Nichol, S.T., Fishman, J.A., Ksiazek, T., Zaki, S.R., and Team, 
L.i.T.R.I. (2006). Transmission of lymphocytic choriomeningitis virus by organ 
transplantation. N Engl J Med 354, 2235-2249. 
Francis, S.J., and Southern, P.J. (1988a). Deleted viral RNAs and lymphocytic 
choriomeningitis virus persistence in vitro. The Journal of general virology 69 ( Pt 8), 
1893-1902. 
Francis, S.J., and Southern, P.J. (1988b). Molecular analysis of viral RNAs in mice 
persistently infected with lymphocytic choriomeningitis virus. Journal of virology 62, 
1251-1257. 
Francis, S.J., Southern, P.J., Valsamakis, A., and Oldstone, M.B. (1987). State of viral 
genome and proteins during persistent lymphocytic choriomeningitis virus infection. 
Current topics in microbiology and immunology 133, 67-88. 
Franze-Fernandez, M.T., Zetina, C., Iapalucci, S., Lucero, M.A., Bouissou, C., Lopez, R., 
Rey, O., Daheli, M., Cohen, G.N., and Zakin, M.M. (1987). Molecular structure and early 
events in the replication of Tacaribe arenavirus S RNA. Virus research 7, 309-324. 
Fuller-Pace, F.V., and Southern, P.J. (1988). Temporal analysis of transcription and 
replication during acute infection with lymphocytic choriomeningitis virus. Virology 162, 
260-263. 
Fuller-Pace, F.V., and Southern, P.J. (1989). Detection of virus-specific RNA-dependent 
RNA polymerase activity in extracts from cells infected with lymphocytic 
choriomeningitis virus: in vitro synthesis of full-length viral RNA species. Journal of 
virology 63, 1938-1944. 
Garaigorta, U., and Chisari, F.V. (2009). Hepatitis C virus blocks interferon effector 
function by inducing protein kinase R phosphorylation. Cell host & microbe 6, 513-522. 
Garcia, M.A., Meurs, E.F., and Esteban, M. (2007). The dsRNA protein kinase PKR: virus 
and cell control. Biochimie 89, 799-811. 
Garcin, D., and Kolakofsky, D. (1990). A novel mechanism for the initiation of Tacaribe 
arenavirus genome replication. Journal of virology 64, 6196-6203. 
 245 
 
Garcin, D., and Kolakofsky, D. (1992). Tacaribe arenavirus RNA synthesis in vitro is 
primer dependent and suggests an unusual model for the initiation of genome replication. 
Journal of virology 66, 1370-1376. 
Goldberg, I.G., Allan, C., Burel, J.M., Creager, D., Falconi, A., Hochheiser, H., Johnston, 
J., Mellen, J., Sorger, P.K., and Swedlow, J.R. (2005). The Open Microscopy Environment 
(OME) Data Model and XML file: open tools for informatics and quantitative analysis in 
biological imaging. Genome Biol 6, R47. 
Goni, S.E., Iserte, J.A., Ambrosio, A.M., Romanowski, V., Ghiringhelli, P.D., and Lozano, 
M.E. (2006). Genomic features of attenuated Junin virus vaccine strain candidate. Virus 
genes 32, 37-41. 
Grant, A., Seregin, A., Huang, C., Kolokoltsova, O., Brasier, A., Peters, C., and Paessler, 
S. (2012). Junin virus pathogenesis and virus replication. Viruses 4, 2317-2339. 
Groseth, A., Wolff, S., Strecker, T., Hoenen, T., and Becker, S. (2010). Efficient budding 
of the tacaribe virus matrix protein z requires the nucleoprotein. Journal of virology 84, 
3603-3611. 
Groskreutz, D.J., Babor, E.C., Monick, M.M., Varga, S.M., and Hunninghake, G.W. 
(2010). Respiratory Syncytial Virus Limits alpha Subunit of Eukaryotic Translation 
Initiation Factor 2 (eIF alpha) Phosphorylation to Maintain Translation and Viral 
Replication. Journal of Biological Chemistry 285, 24023-24031. 
Haist, K., Ziegler, C., and Botten, J. (2015). Strand-Specific Quantitative Reverse 
Transcription-Polymerase Chain Reaction Assay for Measurement of Arenavirus Genomic 
and Antigenomic RNAs. PloS one 10, e0120043. 
Harding, H.P., Zhang, Y., Bertolotti, A., Zeng, H., and Ron, D. (2000). Perk is essential 
for translational regulation and cell survival during the unfolded protein response. 
Molecular cell 5, 897-904. 
Harding, H.P., Zhang, Y., and Ron, D. (1999). Protein translation and folding are coupled 
by an endoplasmic-reticulum-resident kinase. Nature 397, 271-274. 
Harmon, B., Kozina, C., Maar, D., Carpenter, T.S., Branda, C.S., Negrete, O.A., and 
Carson, B.D. (2013). Identification of critical amino acids within the nucleoprotein of 
Tacaribe virus important for anti-interferon activity. The Journal of biological chemistry 
288, 8702-8711. 
Harnish, D.G., Leung, W.C., and Rawls, W.E. (1981). Characterization of polypeptides 
immunoprecipitable from Pichinde virus-infected BHK-21 cells. Journal of virology 38, 
840-848. 
 246 
 
Hass, M., Westerkofsky, M., Muller, S., Becker-Ziaja, B., Busch, C., and Gunther, S. 
(2006). Mutational analysis of the lassa virus promoter. Journal of virology 80, 12414-
12419. 
Hastie, K.M., Kimberlin, C.R., Zandonatti, M.A., MacRae, I.J., and Saphire, E.O. (2011a). 
Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3' to 5' exonuclease 
activity essential for immune suppression. Proceedings of the National Academy of 
Sciences of the United States of America 108, 2396-2401. 
Hastie, K.M., Liu, T., Li, S., King, L.B., Ngo, N., Zandonatti, M.A., Woods, V.L., Jr., de 
la Torre, J.C., and Saphire, E.O. (2011b). Crystal structure of the Lassa virus nucleoprotein-
RNA complex reveals a gating mechanism for RNA binding. Proceedings of the National 
Academy of Sciences of the United States of America 108, 19365-19370. 
Hatada, E., Saito, S., and Fukuda, R. (1999). Mutant influenza viruses with a defective NS1 
protein cannot block the activation of PKR in infected cells. Journal of virology 73, 2425-
2433. 
Hotchin, J. (1973). Transient virus infection: spontaneous recovery mechanism of 
lymphocytic choriomeningitis virrus-infected cells. Nat New Biol 241, 270-272. 
Hotchin, J. (1974a). Cyclical phenomena in persistent virus infection. J Reticuloendothel 
Soc 15, 304-311. 
Hotchin, J. (1974b). The role of transient infection in arenavirus persistence. Prog Med 
Virol 18, 81-93. 
Hotchin, J., Kinch, W., Benson, L., and Sikora, E. (1975). Role of substrains in persistent 
lymphocytic choriomeningitis virus infection. Bull World Health Organ 52, 457-463. 
Howard, C.R., and Buchmeier, M.J. (1983). A protein kinase activity in lymphocytic 
choriomeningitis virus and identification of the phosphorylated product using monoclonal 
antibody. Virology 126, 538-547. 
Huang, A.S. (1973). Defective interfering viruses. Annual review of microbiology 27, 101-
117. 
Huang, A.S., and Baltimore, D. (1970). Defective viral particles and viral disease 
processes. Nature 226, 325-327. 
Huang, C., Kolokoltsova, O.A., Mateer, E.J., Koma, T., and Paessler, S. (2017). Highly 
pathogenic New World arenavirus infection activates the pattern recognition receptor PKR 
without attenuating virus replication in human cells. Journal of virology. 
 247 
 
Huang, C., Kolokoltsova, O.A., Yun, N.E., Seregin, A.V., Poussard, A.L., Walker, A.G., 
Brasier, A.R., Zhao, Y., Tian, B., de la Torre, J.C., and Paessler, S. (2012). Junin virus 
infection activates the type I interferon pathway in a RIG-I-dependent manner. PLoS Negl 
Trop Dis 6, e1659. 
Huang, D.W., Sherman, B.T., and Lempicki, R.A. (2009a). Bioinformatics enrichment 
tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids 
Res 37, 1-13. 
Huang, D.W., Sherman, B.T., and Lempicki, R.A. (2009b). Systematic and integrative 
analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4, 44-57. 
Huang, Q., Shao, J., Lan, S., Zhou, Y., Xing, J., Dong, C., Liang, Y., and Ly, H. (2015). In 
vitro and in vivo characterizations of pichinde viral nucleoprotein exoribonuclease 
functions. Journal of virology 89, 6595-6607. 
Iapalucci, S., Chernavsky, A., Rossi, C., Burgin, M.J., and Franze-Fernandez, M.T. (1994). 
Tacaribe virus gene expression in cytopathic and non-cytopathic infections. Virology 200, 
613-622. 
Iapalucci, S., Lopez, N., and Franze-Fernandez, M.T. (1991). The 3' end termini of the 
Tacaribe arenavirus subgenomic RNAs. Virology 182, 269-278. 
ICTV, A.S.G. (2014a). Create a new genus, Reptarenavirus, comprising three new species 
in the family 
Arenaviridae.  (Internation Committee on the Taxonomy of Viruses). 
ICTV, A.S.G. (2014b). Rename one (1) genus and twenty-five (25) species in the family 
Arenaviridae.  (International Committee on Taxonomy of Viruses 
). 
Iwasaki, M., Cubitt, B., Sullivan, B.M., and de la Torre, J.C. (2016). The High Degree of 
Sequence Plasticity of the Arenavirus Noncoding Intergenic Region (IGR) Enables the Use 
of a Nonviral Universal Synthetic IGR To Attenuate Arenaviruses. Journal of virology 90, 
3187-3197. 
Iwasaki, M., Ngo, N., Cubitt, B., and de la Torre, J.C. (2015). Efficient Interaction between 
Arenavirus Nucleoprotein (NP) and RNA-Dependent RNA Polymerase (L) Is Mediated by 
the Virus Nucleocapsid (NP-RNA) Template. Journal of virology 89, 5734-5738. 
Jacamo, R., Lopez, N., Wilda, M., and Franze-Fernandez, M.T. (2003). Tacaribe virus Z 
protein interacts with the L polymerase protein to inhibit viral RNA synthesis. Journal of 
virology 77, 10383-10393. 
 248 
 
Jiang, X., Huang, Q., Wang, W., Dong, H., Ly, H., Liang, Y., and Dong, C. (2013). 
Structures of arenaviral nucleoproteins with triphosphate dsRNA reveal a unique 
mechanism of immune suppression. The Journal of biological chemistry 288, 16949-
16959. 
Kamentsky, L., Jones, T.R., Fraser, A., Bray, M.A., Logan, D.J., Madden, K.L., Ljosa, V., 
Rueden, C., Eliceiri, K.W., and Carpenter, A.E. (2011). Improved structure, function and 
compatibility for CellProfiler: modular high-throughput image analysis software. 
Bioinformatics 27, 1179-1180. 
Kawai, T., and Akira, S. (2008). Toll-like receptor and RIG-I-like receptor signaling. Ann 
N Y Acad Sci 1143, 1-20. 
Kerber, R., Rieger, T., Busch, C., Flatz, L., Pinschewer, D.D., Kummerer, B.M., and 
Gunther, S. (2011). Cross-species analysis of the replication complex of old world 
arenaviruses reveals two nucleoprotein sites involved in L protein function. Journal of 
virology 85, 12518-12528. 
King, B.R., Hershkowitz, D., Eisenhauer, P.L., Weir, M.E., Ziegler, C.M., Russo, J., Bruce, 
E.A., Ballif, B.A., and Botten, J. (2017). A Map of the Arenavirus Nucleoprotein-Host 
Protein Interactome Reveals that Junin Virus Selectively Impairs the Antiviral Activity of 
Double-Stranded RNA-Activated Protein Kinase (PKR). Journal of virology 91. 
Klaus, J.P., Eisenhauer, P., Russo, J., Mason, A.B., Do, D., King, B., Taatjes, D., Cornillez-
Ty, C., Boyson, J.E., Thali, M., Zheng, C., Liao, L., Yates, J.R., 3rd, Zhang, B., Ballif, 
B.A., and Botten, J.W. (2013). The intracellular cargo receptor ERGIC-53 is required for 
the production of infectious arenavirus, coronavirus, and filovirus particles. Cell host & 
microbe 14, 522-534. 
Knopp, K.A., Ngo, T., Gershon, P.D., and Buchmeier, M.J. (2015). Single nucleoprotein 
residue modulates arenavirus replication complex formation. mBio 6, e00524-00515. 
Kolokoltsova, O.A., Grant, A.M., Huang, C., Smith, J.K., Poussard, A.L., Tian, B., Brasier, 
A.R., Peters, C.J., Tseng, C.T., de la Torre, J.C., and Paessler, S. (2014). RIG-I enhanced 
interferon independent apoptosis upon Junin virus infection. PloS one 9, e99610. 
Kranzusch, P.J., and Whelan, S.P. (2011). Arenavirus Z protein controls viral RNA 
synthesis by locking a polymerase-promoter complex. Proceedings of the National 
Academy of Sciences of the United States of America 108, 19743-19748. 
Labudova, M., Pastorek, J., and Pastorekova, S. (2016). Lymphocytic choriomeningitis 
virus: ways to establish and maintain non-cytolytic persistent infection. Acta Virol 60, 15-
26. 
 249 
 
Labudova, M., Tomaskova, J., Skultety, L., Pastorek, J., and Pastorekova, S. (2009). The 
nucleoprotein of lymphocytic choriomeningitis virus facilitates spread of persistent 
infection through stabilization of the keratin network. Journal of virology 83, 7842-7849. 
Lakdawala, S.S., Wu, Y., Wawrzusin, P., Kabat, J., Broadbent, A.J., Lamirande, E.W., 
Fodor, E., Altan-Bonnet, N., Shroff, H., and Subbarao, K. (2014). Influenza a virus 
assembly intermediates fuse in the cytoplasm. PLoS pathogens 10, e1003971. 
Lan, S., McLay, L., Aronson, J., Ly, H., and Liang, Y. (2008). Genome comparison of 
virulent and avirulent strains of the Pichinde arenavirus. Archives of virology 153, 1241-
1250. 
Langland, J.O., and Jacobs, B.L. (2002). The role of the PKR-inhibitory genes, E3L and 
K3L, in determining vaccinia virus host range. Virology 299, 133-141. 
Lee, K.J., Novella, I.S., Teng, M.N., Oldstone, M.B., and de La Torre, J.C. (2000). NP and 
L proteins of lymphocytic choriomeningitis virus (LCMV) are sufficient for efficient 
transcription and replication of LCMV genomic RNA analogs. Journal of virology 74, 
3470-3477. 
Lehmann-Grube, F. (1967). A carrier state of lymphocytic choriomeningitis virus in L cell 
cultures. Nature 213, 770-773. 
Lehmann-Grube, F. (1971). Lymphocytic choriomeningitis virus, Vol 10 (Wien: Springer-
Verlag). 
Lehmann-Grube, F., Martinez Peralta, L.M., Bruns, M., and Lohler, J. (1983). Persistent 
infection of mice with the lymphocytic choriomeningitis virus. In Virus-host interactions, 
receptors, persistence, and neurological diseases, H. Fraenkel-Conrat, and R.R. Wagner, 
eds. (New York: Plenum Press), pp. 43-103. 
Lehmann-Grube, F., Popescu, M., Schaefer, H., and Gschwender, H.H. (1975). LCM virus 
infection of cells in vitro. Bull World Health Organ 52, 443-456. 
Lehmann-Grube, F., Slenczka, W., and Tees, R. (1969). A persistent and inapparent 
infection of L cells with the virus of lymphocytic choriomeningitis. The Journal of general 
virology 5, 63-81. 
Lennartz, F., Hoenen, T., Lehmann, M., Groseth, A., and Garten, W. (2013). The role of 
oligomerization for the biological functions of the arenavirus nucleoprotein. Archives of 
virology 158, 1895-1905. 
Leung, W.C., Ghosh, H.P., and Rawls, W.E. (1977). Strandedness of Pichinde virus RNA. 
Journal of virology 22, 235-237. 
 250 
 
Leung, W.C., and Rawls, W.E. (1977). Virion-associated ribosomes are not required for 
the replication of Pichinde virus. Virology 81, 174-176. 
Levingston Macleod, J.M., D'Antuono, A., Loureiro, M.E., Casabona, J.C., Gomez, G.A., 
and Lopez, N. (2011). Identification of two functional domains within the arenavirus 
nucleoprotein. Journal of virology 85, 2012-2023. 
Li, S., Min, J.Y., Krug, R.M., and Sen, G.C. (2006). Binding of the influenza A virus NS1 
protein to PKR mediates the inhibition of its activation by either PACT or double-stranded 
RNA. Virology 349, 13-21. 
Lindquist, M.E., Mainou, B.A., Dermody, T.S., and Crowe, J.E., Jr. (2011). Activation of 
protein kinase R is required for induction of stress granules by respiratory syncytial virus 
but dispensable for viral replication. Virology 413, 103-110. 
Linero, F., Welnowska, E., Carrasco, L., and Scolaro, L. (2013). Participation of eIF4F 
complex in Junin virus infection: blockage of eIF4E does not impair virus replication. 
Cellular microbiology 15, 1766-1782. 
Linero, F.N., Thomas, M.G., Boccaccio, G.L., and Scolaro, L.A. (2011). Junin virus 
infection impairs stress-granule formation in Vero cells treated with arsenite via inhibition 
of eIF2alpha phosphorylation. The Journal of general virology 92, 2889-2899. 
Lipton, S.A., and Bossy-Wetzel, E. (2002). Dueling activities of AIF in cell death versus 
survival: DNA binding and redox activity. Cell 111, 147-150. 
Lopez, N., and Franze-Fernandez, M.T. (2007). A single stem-loop structure in Tacaribe 
arenavirus intergenic region is essential for transcription termination but is not required for 
a correct initiation of transcription and replication. Virus research 124, 237-244. 
Lopez, N., Jacamo, R., and Franze-Fernandez, M.T. (2001). Transcription and RNA 
replication of tacaribe virus genome and antigenome analogs require N and L proteins: Z 
protein is an inhibitor of these processes. Journal of virology 75, 12241-12251. 
Lu, Y., Wambach, M., Katze, M.G., and Krug, R.M. (1995). Binding of the influenza virus 
NS1 protein to double-stranded RNA inhibits the activation of the protein kinase that 
phosphorylates the elF-2 translation initiation factor. Virology 214, 222-228. 
Macneil, A., Stroher, U., Farnon, E., Campbell, S., Cannon, D., Paddock, C.D., Drew, C.P., 
Kuehnert, M., Knust, B., Gruenenfelder, R., Zaki, S.R., Rollin, P.E., Nichol, S.T., and 
Team, L.T.I. (2012). Solid organ transplant-associated lymphocytic choriomeningitis, 
United States, 2011. Emerg Infect Dis 18, 1256-1262. 
 251 
 
Maeto, C.A., Knott, M.E., Linero, F.N., Ellenberg, P.C., Scolaro, L.A., and Castilla, V. 
(2011). Differential effect of acute and persistent Junin virus infections on the nucleo-
cytoplasmic trafficking and expression of heterogeneous nuclear ribonucleoproteins type 
A and B. The Journal of general virology 92, 2181-2190. 
Marq, J.B., Kolakofsky, D., and Garcin, D. (2010). Unpaired 5' ppp-nucleotides, as found 
in arenavirus double-stranded RNA panhandles, are not recognized by RIG-I. The Journal 
of biological chemistry 285, 18208-18216. 
Martinez-Sobrido, L., Emonet, S., Giannakas, P., Cubitt, B., Garcia-Sastre, A., and de la 
Torre, J.C. (2009). Identification of amino acid residues critical for the anti-interferon 
activity of the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis 
virus. Journal of virology 83, 11330-11340. 
Martinez-Sobrido, L., Giannakas, P., Cubitt, B., Garcia-Sastre, A., and de la Torre, J.C. 
(2007). Differential inhibition of type I interferon induction by arenavirus nucleoproteins. 
Journal of virology 81, 12696-12703. 
Martinez-Sobrido, L., Zuniga, E.I., Rosario, D., Garcia-Sastre, A., and de la Torre, J.C. 
(2006). Inhibition of the type I interferon response by the nucleoprotein of the prototypic 
arenavirus lymphocytic choriomeningitis virus. Journal of virology 80, 9192-9199. 
Martinez, M.G., Forlenza, M.B., and Candurra, N.A. (2009). Involvement of cellular 
proteins in Junin arenavirus entry. Biotechnology journal 4, 866-870. 
Matrosovich, M., Matrosovich, T., Garten, W., and Klenk, H.D. (2006). New low-viscosity 
overlay medium for viral plaque assays. Virol J 3, 63. 
Matthaei, M., Budt, M., and Wolff, T. (2013). Highly pathogenic H5N1 influenza A virus 
strains provoke heterogeneous IFN-alpha/beta responses that distinctively affect viral 
propagation in human cells. PloS one 8, e56659. 
McCormick, J.B., King, I.J., Webb, P.A., Scribner, C.L., Craven, R.B., Johnson, K.M., 
Elliott, L.H., and Belmont-Williams, R. (1986). Lassa fever. Effective therapy with 
ribavirin. N Engl J Med 314, 20-26. 
McEwen, E., Kedersha, N., Song, B., Scheuner, D., Gilks, N., Han, A., Chen, J.J., 
Anderson, P., and Kaufman, R.J. (2005). Heme-regulated inhibitor kinase-mediated 
phosphorylation of eukaryotic translation initiation factor 2 inhibits translation, induces 
stress granule formation, and mediates survival upon arsenite exposure. The Journal of 
biological chemistry 280, 16925-16933. 
 252 
 
Meyer, B.J., de la Torre, J.C., and Southern, P.J. (2002). Arenaviruses: genomic RNAs, 
transcription, and replication. Current topics in microbiology and immunology 262, 139-
157. 
Meyer, B.J., and Southern, P.J. (1993). Concurrent sequence analysis of 5' and 3' RNA 
termini by intramolecular circularization reveals 5' nontemplated bases and 3' terminal 
heterogeneity for lymphocytic choriomeningitis virus mRNAs. Journal of virology 67, 
2621-2627. 
Meyer, B.J., and Southern, P.J. (1994). Sequence heterogeneity in the termini of 
lymphocytic choriomeningitis virus genomic and antigenomic RNAs. Journal of virology 
68, 7659-7664. 
Meyer, B.J., and Southern, P.J. (1997). A novel type of defective viral genome suggests a 
unique strategy to establish and maintain persistent lymphocytic choriomeningitis virus 
infections. Journal of virology 71, 6757-6764. 
Momose, F., Sekimoto, T., Ohkura, T., Jo, S., Kawaguchi, A., Nagata, K., and Morikawa, 
Y. (2011). Apical transport of influenza A virus ribonucleoprotein requires Rab11-positive 
recycling endosome. PloS one 6, e21123. 
Morin, B., Coutard, B., Lelke, M., Ferron, F., Kerber, R., Jamal, S., Frangeul, A., Baronti, 
C., Charrel, R., de Lamballerie, X., Vonrhein, C., Lescar, J., Bricogne, G., Gunther, S., and 
Canard, B. (2010). The N-terminal domain of the arenavirus L protein is an RNA 
endonuclease essential in mRNA transcription. PLoS pathogens 6, e1001038. 
Mueller, F., Senecal, A., Tantale, K., Marie-Nelly, H., Ly, N., Collin, O., Basyuk, E., 
Bertrand, E., Darzacq, X., and Zimmer, C. (2013). FISH-quant: automatic counting of 
transcripts in 3D FISH images. Nature methods 10, 277-278. 
Murphy, F.A. (1975). Arenavirus taxonomy: a review. Bull World Health Organ 52, 389-
391. 
Nielsen, E., Severin, F., Backer, J.M., Hyman, A.A., and Zerial, M. (1999). Rab5 regulates 
motility of early endosomes on microtubules. Nature cell biology 1, 376-382. 
Novoa, R.R., Calderita, G., Arranz, R., Fontana, J., Granzow, H., and Risco, C. (2005a). 
Virus factories: associations of cell organelles for viral replication and morphogenesis. 
Biology of the cell / under the auspices of the European Cell Biology Organization 97, 147-
172. 
Novoa, R.R., Calderita, G., Cabezas, P., Elliott, R.M., and Risco, C. (2005b). Key Golgi 
factors for structural and functional maturation of bunyamwera virus. Journal of virology 
79, 10852-10863. 
 253 
 
Nturibi, E., Bhagwat, A.R., Coburn, S., Myerburg, M.M., and Lakdawala, S.S. (2017). 
Intracellular Colocalization of Influenza Viral RNA and Rab11A Is Dependent upon 
Microtubule Filaments. Journal of virology 91. 
Oldstone, M.B. (1998). Viral persistence: mechanisms and consequences. Curr Opin 
Microbiol 1, 436-441. 
Oldstone, M.B., and Buchmeier, M.J. (1982). Restricted expression of viral glycoprotein 
in cells of persistently infected mice. Nature 300, 360-362. 
Ortiz-Riano, E., Cheng, B.Y., de la Torre, J.C., and Martinez-Sobrido, L. (2011). The C-
Terminal Region of Lymphocytic Choriomeningitis Virus Nucleoprotein Contains Distinct 
and Segregable Functional Domains Involved in NP-Z Interaction and Counteraction of 
the Type I Interferon Response. Journal of virology 85, 13038-13048. 
Ortiz-Riano, E., Cheng, B.Y., de la Torre, J.C., and Martinez-Sobrido, L. (2012). Self-
association of Lymphocytic Choriomeningitis Virus Nucleoprotein is mediated by its N-
terminal region and is not required for its anti-interferon function. Journal of virology. 
Panda, D., Das, A., Dinh, P.X., Subramaniam, S., Nayak, D., Barrows, N.J., Pearson, J.L., 
Thompson, J., Kelly, D.L., Ladunga, I., and Pattnaik, A.K. (2011). RNAi screening reveals 
requirement for host cell secretory pathway in infection by diverse families of negative-
strand RNA viruses. Proceedings of the National Academy of Sciences of the United States 
of America 108, 19036-19041. 
Pannetier, D., Faure, C., Georges-Courbot, M.C., Deubel, V., and Baize, S. (2004). Human 
macrophages, but not dendritic cells, are activated and produce alpha/beta interferons in 
response to Mopeia virus infection. Journal of virology 78, 10516-10524. 
Pannetier, D., Reynard, S., Russier, M., Carnec, X., and Baize, S. (2014). Production of 
CXC and CC chemokines by human antigen-presenting cells in response to Lassa virus or 
closely related immunogenic viruses, and in cynomolgus monkeys with lassa fever. PLoS 
Negl Trop Dis 8, e2637. 
Parisi, G., Echave, J., Ghiringhelli, D., and Romanowski, V. (1996). Computational 
characterisation of potential RNA-binding sites in arenavirus nucleocapsid proteins. Virus 
genes 13, 247-254. 
Patel, C.V., Handy, I., Goldsmith, T., and Patel, R.C. (2000). PACT, a stress-modulated 
cellular activator of interferon-induced double-stranded RNA-activated protein kinase, 
PKR. The Journal of biological chemistry 275, 37993-37998. 
 254 
 
Perez, M., and de la Torre, J.C. (2003). Characterization of the genomic promoter of the 
prototypic arenavirus lymphocytic choriomeningitis virus. Journal of virology 77, 1184-
1194. 
Pinschewer, D.D., Perez, M., and de la Torre, J.C. (2003). Role of the virus nucleoprotein 
in the regulation of lymphocytic choriomeningitis virus transcription and RNA replication. 
Journal of virology 77, 3882-3887. 
Pinschewer, D.D., Perez, M., and de la Torre, J.C. (2005). Dual role of the lymphocytic 
choriomeningitis virus intergenic region in transcription termination and virus propagation. 
Journal of virology 79, 4519-4526. 
Polyak, S.J., Zheng, S., and Harnish, D.G. (1995a). 5' termini of Pichinde arenavirus S 
RNAs and mRNAs contain nontemplated nucleotides. Journal of virology 69, 3211-3215. 
Polyak, S.J., Zheng, S., and Harnish, D.G. (1995b). Analysis of Pichinde arenavirus 
transcription and replication in human THP-1 monocytic cells. Virus research 36, 37-48. 
Pythoud, C., Rodrigo, W.W., Pasqual, G., Rothenberger, S., Martinez-Sobrido, L., de la 
Torre, J.C., and Kunz, S. (2012). Arenavirus nucleoprotein targets interferon regulatory 
factor-activating kinase IKKepsilon. Journal of virology 86, 7728-7738. 
Pythoud, C., Rothenberger, S., Martinez-Sobrido, L., de la Torre, J.C., and Kunz, S. (2015). 
Lymphocytic Choriomeningitis Virus Differentially Affects the Virus-Induced Type I 
Interferon Response and Mitochondrial Apoptosis Mediated by RIG-I/MAVS. Journal of 
virology 89, 6240-6250. 
Qi, X., Lan, S., Wang, W., Schelde, L.M., Dong, H., Wallat, G.D., Ly, H., Liang, Y., and 
Dong, C. (2010). Cap binding and immune evasion revealed by Lassa nucleoprotein 
structure. Nature 468, 779-783. 
Raj, A., van den Bogaard, P., Rifkin, S.A., van Oudenaarden, A., and Tyagi, S. (2008). 
Imaging individual mRNA molecules using multiple singly labeled probes. Nature 
methods 5, 877-879. 
Raju, R., Raju, L., Hacker, D., Garcin, D., Compans, R., and Kolakofsky, D. (1990). 
Nontemplated bases at the 5' ends of Tacaribe virus mRNAs. Virology 174, 53-59. 
Rawls, W.E., Chan, M.A., and Gee, S.R. (1981). Mechanisms of persistence in arenavirus 
infections: a brief review. Can J Microbiol 27, 568-574. 
Reineke, L.C., and Lloyd, R.E. (2013). Diversion of stress granules and P-bodies during 
viral infection. Virology 436, 255-267. 
 255 
 
Rivers, T.M., and McNair Scott, T.F. (1935). Meningitis in Man Caused by a Filterable 
Virus. Science 81, 439-440. 
Rivers, T.M., and Scott, T.F. (1936). Meningitis in Man Caused by a Filterable Virus : Ii. 
Identification of the Etiological Agent. J Exp Med 63, 415-432. 
Rodrigo, W.W., Ortiz-Riano, E., Pythoud, C., Kunz, S., de la Torre, J.C., and Martinez-
Sobrido, L. (2012). Arenavirus nucleoproteins prevent activation of nuclear factor kappa 
B. Journal of virology 86, 8185-8197. 
Rojek, J.M., and Kunz, S. (2008). Cell entry by human pathogenic arenaviruses. Cellular 
microbiology 10, 828-835. 
Rojek, J.M., Sanchez, A.B., Nguyen, N.T., de la Torre, J.C., and Kunz, S. (2008). Different 
mechanisms of cell entry by human-pathogenic Old World and New World arenaviruses. 
Journal of virology 82, 7677-7687. 
Rowe, W.P., Murphy, F.A., Bergold, G.H., Casals, J., Hotchin, J., Johnson, K.M., 
Lehmann-Grube, F., Mims, C.A., Traub, E., and Webb, P.A. (1970). Arenoviruses: 
proposed name for a newly defined virus group. Journal of virology 5, 651-652. 
Russier, M., Pannetier, D., and Baize, S. (2012). Immune responses and Lassa virus 
infection. Viruses 4, 2766-2785. 
Russier, M., Reynard, S., Carnec, X., and Baize, S. (2014). The exonuclease domain of 
Lassa virus nucleoprotein is involved in antigen-presenting-cell-mediated NK cell 
responses. Journal of virology 88, 13811-13820. 
Salvato, M.S., Schweighofer, K.J., Burns, J., and Shimomaye, E.M. (1992). Biochemical 
and immunological evidence that the 11 kDa zinc-binding protein of lymphocytic 
choriomeningitis virus is a structural component of the virus. Virus research 22, 185-198. 
Salvato, M.S., and Shimomaye, E.M. (1989). The completed sequence of lymphocytic 
choriomeningitis virus reveals a unique RNA structure and a gene for a zinc finger protein. 
Virology 173, 1-10. 
Savidis, G., McDougall, W.M., Meraner, P., Perreira, J.M., Portmann, J.M., Trincucci, G., 
John, S.P., Aker, A.M., Renzette, N., Robbins, D.R., Guo, Z., Green, S., Kowalik, T.F., 
and Brass, A.L. (2016). Identification of Zika Virus and Dengue Virus Dependency Factors 
using Functional Genomics. Cell Rep 16, 232-246. 
Schlie, K., Maisa, A., Freiberg, F., Groseth, A., Strecker, T., and Garten, W. (2010). Viral 
protein determinants of Lassa virus entry and release from polarized epithelial cells. 
Journal of virology 84, 3178-3188. 
 256 
 
Schmidt, E.K., Clavarino, G., Ceppi, M., and Pierre, P. (2009). SUnSET, a nonradioactive 
method to monitor protein synthesis. Nature methods 6, 275-277. 
Scott, T.F., and Rivers, T.M. (1936). Meningitis in Man Caused by a Filterable Virus : I. 
Two Cases and the Method of Obtaining a Virus from Their Spinal Fluids. J Exp Med 63, 
397-414. 
Shivaprakash, M., Harnish, D., and Rawls, W. (1988). Characterization of temperature-
sensitive mutants of Pichinde virus. Journal of virology 62, 4037-4043. 
Shtanko, O., Imai, M., Goto, H., Lukashevich, I.S., Neumann, G., Watanabe, T., and 
Kawaoka, Y. (2010). A role for the C terminus of Mopeia virus nucleoprotein in its 
incorporation into Z protein-induced virus-like particles. Journal of virology 84, 5415-
5422. 
Shtanko, O., Watanabe, S., Jasenosky, L.D., Watanabe, T., and Kawaoka, Y. (2011). 
ALIX/AIP1 is required for NP incorporation into Mopeia virus Z-induced virus-like 
particles. Journal of virology 85, 3631-3641. 
Singh, M.K., Fuller-Pace, F.V., Buchmeier, M.J., and Southern, P.J. (1987). Analysis of 
the genomic L RNA segment from lymphocytic choriomeningitis virus. Virology 161, 448-
456. 
Song, T., Zheng, Y., Wang, Y., Katz, Z., Liu, X., Chen, S., Singer, R.H., and Gu, W. 
(2015). Specific interaction of KIF11 with ZBP1 regulates the transport of beta-actin 
mRNA and cell motility. Journal of cell science 128, 1001-1010. 
Southern, P.J., Singh, M.K., Riviere, Y., Jacoby, D.R., Buchmeier, M.J., and Oldstone, 
M.B. (1987). Molecular characterization of the genomic S RNA segment from lymphocytic 
choriomeningitis virus. Virology 157, 145-155. 
Staneck, L.D., Trowbridge, R.S., Welsh, R.M., Wright, E.A., and Pfau, C.J. (1972). 
Arenaviruses: cellular response to long-term in vitro infection with parana and lymphocytic 
choriomeningitis viruses. Infect Immun 6, 444-450. 
Stenglein, M.D., Sanders, C., Kistler, A.L., Ruby, J.G., Franco, J.Y., Reavill, D.R., Dunker, 
F., and Derisi, J.L. (2012). Identification, characterization, and in vitro culture of highly 
divergent arenaviruses from boa constrictors and annulated tree boas: candidate etiological 
agents for snake inclusion body disease. mBio 3, e00180-00112. 
Stenmark, H. (2009). Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell 
Biol 10, 513-525. 
 257 
 
Stephensen, C.B., Blount, S.R., Lanford, R.E., Holmes, K.V., Montali, R.J., Fleenor, M.E., 
and Shaw, J.F. (1992). Prevalence of serum antibodies against lymphocytic 
choriomeningitis virus in selected populations from two U.S. cities. J Med Virol 38, 27-
31. 
Thomas, M.G., Loschi, M., Desbats, M.A., and Boccaccio, G.L. (2011). RNA granules: 
the good, the bad and the ugly. Cellular signalling 23, 324-334. 
Tortorici, M.A., Albarino, C.G., Posik, D.M., Ghiringhelli, P.D., Lozano, M.E., Rivera 
Pomar, R., and Romanowski, V. (2001a). Arenavirus nucleocapsid protein displays a 
transcriptional antitermination activity in vivo. Virus research 73, 41-55. 
Tortorici, M.A., Ghiringhelli, P.D., Lozano, M.E., Albarino, C.G., and Romanowski, V. 
(2001b). Zinc-binding properties of Junin virus nucleocapsid protein. The Journal of 
general virology 82, 121-128. 
Toth, A.M., Devaux, P., Cattaneo, R., and Samuel, C.E. (2009). Protein Kinase PKR 
Mediates the Apoptosis Induction and Growth Restriction Phenotypes of C Protein-
Deficient Measles Virus. Journal of virology 83, 961-968. 
Tourriere, H., Chebli, K., Zekri, L., Courselaud, B., Blanchard, J.M., Bertrand, E., and 
Tazi, J. (2003). The RasGAP-associated endoribonuclease G3BP assembles stress 
granules. The Journal of cell biology 160, 823-831. 
Traub, E. (1935). A Filterable Virus Recovered from White Mice. Science 81, 298-299. 
Tsanov, N., Samacoits, A., Chouaib, R., Traboulsi, A.M., Gostan, T., Weber, C., Zimmer, 
C., Zibara, K., Walter, T., Peter, M., Bertrand, E., and Mueller, F. (2016). smiFISH and 
FISH-quant - a flexible single RNA detection approach with super-resolution capability. 
Nucleic Acids Res 44, e165. 
Urata, S., and Yasuda, J. (2012). Molecular mechanism of arenavirus assembly and 
budding. Viruses 4, 2049-2079. 
Valiente-Echeverria, F., Melnychuk, L., and Mouland, A.J. (2012). Viral modulation of 
stress granules. Virus research 169, 430-437. 
Vela, E. (2012). Animal models, prophylaxis, and therapeutics for arenavirus infections. 
Viruses 4, 1802-1829. 
Viets, H.R., and Watts, J.W. (1929a). Aseptic (Lymphocytic) Meningitis. JAMA 93, 1553-
1555. 
 258 
 
Viets, H.R., and Watts, J.W. (1929b). Three Cases of Aseptic (Lymphocytic) Meningitis. 
N Engl J Med 200, 633-634. 
Weber, E.L., and Buchmeier, M.J. (1988). Fine mapping of a peptide sequence containing 
an antigenic site conserved among arenaviruses. Virology 164, 30-38. 
Welsh, R.M., O'Connell, C.M., and Pfau, C.J. (1972). Properties of defective lymphocytic 
choriomeningitis virus. The Journal of general virology 17, 355-359. 
West, B.R., Hastie, K.M., and Saphire, E.O. (2014). Structure of the LCMV nucleoprotein 
provides a template for understanding arenavirus replication and immunosuppression. Acta 
Crystallogr D Biol Crystallogr 70, 1764-1769. 
White, J.P., and Lloyd, R.E. (2012). Regulation of stress granules in virus systems. Trends 
in microbiology 20, 175-183. 
Wichgers Schreur, P.J., and Kortekaas, J. (2016). Single-Molecule FISH Reveals Non-
selective Packaging of Rift Valley Fever Virus Genome Segments. PLoS pathogens 12, 
e1005800. 
Wildy, P. (1971). Classification and Nomenclature of Viruses. In Monographs in Virology, 
J.L. Melnick, ed. (Basel/New York: S. Karger). 
Wolff, S., Becker, S., and Groseth, A. (2013a). Cleavage of the Junin virus nucleoprotein 
serves a decoy function to inhibit the induction of apoptosis during infection. Journal of 
virology 87, 224-233. 
Wolff, S., Ebihara, H., and Groseth, A. (2013b). Arenavirus budding: a common pathway 
with mechanistic differences. Viruses 5, 528-549. 
Young, P.R., Chanas, A.C., Lee, S.R., Gould, E.A., and Howard, C.R. (1987). Localization 
of an arenavirus protein in the nuclei of infected cells. The Journal of general virology 68 
( Pt 9), 2465-2470. 
Young, P.R., and Howard, C.R. (1983). Fine structure analysis of Pichinde virus 
nucleocapsids. The Journal of general virology 64 (Pt 4), 833-842. 
Yun, N.E., and Walker, D.H. (2012). Pathogenesis of Lassa fever. Viruses 4, 2031-2048. 
Zamanian-Daryoush, M., Mogensen, T.H., DiDonato, J.A., and Williams, B.R. (2000). 
NF-kappaB activation by double-stranded-RNA-activated protein kinase (PKR) is 
mediated through NF-kappaB-inducing kinase and IkappaB kinase. Molecular and cellular 
biology 20, 1278-1290. 
 259 
 
Zenklusen, D., Larson, D.R., and Singer, R.H. (2008). Single-RNA counting reveals 
alternative modes of gene expression in yeast. Nat Struct Mol Biol 15, 1263-1271. 
Zenklusen, D., and Singer, R.H. (2010). Analyzing mRNA expression using single mRNA 
resolution fluorescent in situ hybridization. Methods Enzymol 470, 641-659. 
Zhang, F., Romano, P.R., Nagamura-Inoue, T., Tian, B., Devert, T.E., Mathews, M.B., 
Ozato, K., and Hinnebusch, A.G. (2001). Binding of double-stranded RNA to protein 
kinase PKR is required for dimerization and promotes critical autophosphorylation events 
in the activation loop. Journal of Biological Chemistry 276, 24946-24958. 
Zhang, Y., Li, L., Liu, X., Dong, S., Wang, W., Huo, T., Guo, Y., Rao, Z., and Yang, C. 
(2013). Crystal structure of Junin virus nucleoprotein. The Journal of general virology 94, 
2175-2183. 
Zhou, S., Cerny, A.M., Zacharia, A., Fitzgerald, K.A., Kurt-Jones, E.A., and Finberg, R.W. 
(2010). Induction and inhibition of type I interferon responses by distinct components of 
lymphocytic choriomeningitis virus. Journal of virology 84, 9452-9462. 
Ziegler, C.M., Eisenhauer, P., Bruce, E.A., Beganovic, V., King, B.R., Weir, M.E., Ballif, 
B.A., and Botten, J. (2016a). A novel phosphoserine motif in the LCMV matrix protein Z 
regulates the release of infectious virus and defective interfering particles. The Journal of 
general virology 97, 2084-2089. 
Ziegler, C.M., Eisenhauer, P., Bruce, E.A., Weir, M.E., King, B.R., Klaus, J.P., 
Krementsov, D.N., Shirley, D.J., Ballif, B.A., and Botten, J. (2016b). The Lymphocytic 
Choriomeningitis Virus Matrix Protein PPXY Late Domain Drives the Production of 
Defective Interfering Particles. PLoS pathogens 12, e1005501. 
 
 
